<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">87340</article-id><article-id pub-id-type="doi">10.7554/eLife.87340</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.87340.3</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Advance</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group></article-categories><title-group><article-title>Mitochondrial electron transport chain, ceramide, and coenzyme Q are linked in a pathway that drives insulin resistance in skeletal muscle</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-290313"><name><surname>Diaz-Vegas</surname><given-names>Alexis</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5227-4482</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-307000"><name><surname>Madsen</surname><given-names>Søren</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-224132"><name><surname>Cooke</surname><given-names>Kristen C</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-309069"><name><surname>Carroll</surname><given-names>Luke</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8600-4023</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-309070"><name><surname>Khor</surname><given-names>Jasmine XY</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-278734"><name><surname>Turner</surname><given-names>Nigel</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-309071"><name><surname>Lim</surname><given-names>Xin Y</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-309072"><name><surname>Astore</surname><given-names>Miro A</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-309073"><name><surname>Morris</surname><given-names>Jonathan C</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5109-9069</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-167717"><name><surname>Don</surname><given-names>Anthony S</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-309074"><name><surname>Garfield</surname><given-names>Amanda</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0006-1449-4939</contrib-id><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-309075"><name><surname>Zarini</surname><given-names>Simona</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-309080"><name><surname>Zemski Berry</surname><given-names>Karin A</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7089-691X</contrib-id><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-309077"><name><surname>Ryan</surname><given-names>Andrew P</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8342-3743</contrib-id><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-309078"><name><surname>Bergman</surname><given-names>Bryan C</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-309079"><name><surname>Brozinick</surname><given-names>Joseph T</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7946-3432</contrib-id><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-94836"><name><surname>James</surname><given-names>David E</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5946-5257</contrib-id><email>david.james@sydney.edu.au</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" corresp="yes" id="author-98133"><name><surname>Burchfield</surname><given-names>James G</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6609-6151</contrib-id><email>james.burchfield@sydney.edu.au</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0384j8v12</institution-id><institution>Charles Perkins Centre, School of life and Environmental Sciences, University of Sydney</institution></institution-wrap><addr-line><named-content content-type="city">Sydney</named-content></addr-line><country>Australia</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0384j8v12</institution-id><institution>Charles Perkins Centre and School of Medical Sciences, Faculty of Medicine and Health, University of Sydney</institution></institution-wrap><addr-line><named-content content-type="city">Sydney</named-content></addr-line><country>Australia</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03trvqr13</institution-id><institution>Cellular Bioenergetics Laboratory, Victor Chang Cardiac Research Institute</institution></institution-wrap><addr-line><named-content content-type="city">Sydney</named-content></addr-line><country>Australia</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00sekdz59</institution-id><institution>Center for Computational Biology and Center for Computational Mathematics, Flatiron Institute</institution></institution-wrap><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03r8z3t63</institution-id><institution>School of Chemistry, UNSW Sydney</institution></institution-wrap><addr-line><named-content content-type="city">Sydney</named-content></addr-line><country>Australia</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03wmf1y16</institution-id><institution>Division of Endocrinology, Metabolism, and Diabetes, University of Colorado Anschutz Medical Campus</institution></institution-wrap><addr-line><named-content content-type="city">Aurora</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01qat3289</institution-id><institution>Lilly Research Laboratories, Division of Eli Lilly and Company</institution></institution-wrap><addr-line><named-content content-type="city">Indianapolis</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Czech</surname><given-names>Michael</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0464eyp60</institution-id><institution>University of Massachusetts Medical School</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Kornmann</surname><given-names>Benoît</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/052gg0110</institution-id><institution>University of Oxford</institution></institution-wrap><country>United Kingdom</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>27</day><month>12</month><year>2023</year></pub-date><volume>12</volume><elocation-id>RP87340</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2023-03-10"><day>10</day><month>03</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2023-03-12"><day>12</day><month>03</month><year>2023</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.03.10.532020"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2023-05-04"><day>04</day><month>05</month><year>2023</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.87340.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2023-11-20"><day>20</day><month>11</month><year>2023</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.87340.2"/></event></pub-history><permissions><copyright-statement>© 2023, Diaz-Vegas et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Diaz-Vegas et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-87340-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-87340-figures-v1.pdf"/><related-article related-article-type="article-reference" ext-link-type="doi" xlink:href="10.7554/eLife.32111" id="ra1"/><abstract><p>Insulin resistance (IR) is a complex metabolic disorder that underlies several human diseases, including type 2 diabetes and cardiovascular disease. Despite extensive research, the precise mechanisms underlying IR development remain poorly understood. Previously we showed that deficiency of coenzyme Q (CoQ) is necessary and sufficient for IR in adipocytes and skeletal muscle (Fazakerley et al., 2018). Here, we provide new insights into the mechanistic connections between cellular alterations associated with IR, including increased ceramides, CoQ deficiency, mitochondrial dysfunction, and oxidative stress. We demonstrate that elevated levels of ceramide in the mitochondria of skeletal muscle cells result in CoQ depletion and loss of mitochondrial respiratory chain components, leading to mitochondrial dysfunction and IR. Further, decreasing mitochondrial ceramide levels in vitro and in animal models (mice, C57BL/6J) (under chow and high-fat diet) increased CoQ levels and was protective against IR. CoQ supplementation also rescued ceramide-associated IR. Examination of the mitochondrial proteome from human muscle biopsies revealed a strong correlation between the respirasome system and mitochondrial ceramide as key determinants of insulin sensitivity. Our findings highlight the mitochondrial ceramide–CoQ–respiratory chain nexus as a potential foundation of an IR pathway that may also play a critical role in other conditions associated with ceramide accumulation and mitochondrial dysfunction, such as heart failure, cancer, and aging. These insights may have important clinical implications for the development of novel therapeutic strategies for the treatment of IR and related metabolic disorders.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>muscle</kwd><kwd>insulin resistance</kwd><kwd>ceramides</kwd><kwd>mitochondria</kwd><kwd>coenzyme Q</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd><kwd>Rat</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000925</institution-id><institution>National Health and Medical Research Council</institution></institution-wrap></funding-source><award-id>2013621</award-id><principal-award-recipient><name><surname>Diaz-Vegas</surname><given-names>Alexis</given-names></name><name><surname>Burchfield</surname><given-names>James G</given-names></name><name><surname>James</surname><given-names>David E</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000923</institution-id><institution>Australian Research Council</institution></institution-wrap></funding-source><award-id>DP210102099</award-id><principal-award-recipient><name><surname>Diaz-Vegas</surname><given-names>Alexis</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000923</institution-id><institution>Australian Research Council</institution></institution-wrap></funding-source><award-id>FL200100096</award-id><principal-award-recipient><name><surname>James</surname><given-names>David E</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000925</institution-id><institution>National Health and Medical Research Council</institution></institution-wrap></funding-source><award-id>GNT1120201</award-id><principal-award-recipient><name><surname>James</surname><given-names>David E</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000925</institution-id><institution>National Health and Medical Research Council</institution></institution-wrap></funding-source><award-id>GNT1061122</award-id><principal-award-recipient><name><surname>James</surname><given-names>David E</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000925</institution-id><institution>National Health and Medical Research Council</institution></institution-wrap></funding-source><award-id>GNT112613</award-id><principal-award-recipient><name><surname>Turner</surname><given-names>Nigel</given-names></name><name><surname>Morris</surname><given-names>Jonathan C</given-names></name><name><surname>Don</surname><given-names>Anthony S</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000971</institution-id><institution>Diabetes Australia</institution></institution-wrap></funding-source><award-id>Y22G-DIAA</award-id><principal-award-recipient><name><surname>Burchfield</surname><given-names>James G</given-names></name><name><surname>Diaz-Vegas</surname><given-names>Alexis</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution>Mitochondrial Foundation</institution></institution-wrap></funding-source><award-id>Mitofoundation, G057</award-id><principal-award-recipient><name><surname>Burchfield</surname><given-names>James G</given-names></name><name><surname>Diaz-Vegas</surname><given-names>Alexis</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>In vitro and in vivo studies uncovered a molecular link between elevated mitochondrial ceramide levels, coenzyme Q depletion, and insulin resistance.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Insulin is the primary hormone responsible for lowering blood glucose, in part, by stimulating glucose transport into muscle and adipose tissue. This is mediated by the phosphatidylinositol 3-kinase/Akt-dependent delivery of insulin-sensitive glucose transporters (GLUT4) to the plasma membrane (PM) (<xref ref-type="bibr" rid="bib42">Hill et al., 1999</xref>; <xref ref-type="bibr" rid="bib17">Cong et al., 1997</xref>). This process is defective in insulin resistance, a significant risk factor for cardiometabolic diseases such as type 2 diabetes (<xref ref-type="bibr" rid="bib47">James et al., 2021</xref>), heart failure (<xref ref-type="bibr" rid="bib74">Riehle and Abel, 2016</xref>), and some types of cancer (<xref ref-type="bibr" rid="bib57">Leitner et al., 2022</xref>), and so defective GLUT4 translocation represents one of the hallmarks of insulin resistance.</p><p>The development of insulin resistance in skeletal muscle and adipocytes has been associated with multiple intracellular lesions, including mitochondrial coenzyme Q (CoQ) deficiency (<xref ref-type="bibr" rid="bib26">Fazakerley et al., 2018a</xref>), accumulation of intracellular lipids such as ceramides (<xref ref-type="bibr" rid="bib46">Holland and Summers, 2008</xref>), and increased mitochondrial reactive oxygen species (ROS) (<xref ref-type="bibr" rid="bib1">Anderson et al., 2009</xref>; <xref ref-type="bibr" rid="bib44">Hoehn et al., 2009</xref>; <xref ref-type="bibr" rid="bib27">Fazakerley et al., 2018b</xref>). However, delineating the relative contribution of these lesions to whole-body insulin resistance and their interconnectivity remains a challenge.</p><p>CoQ (CoQ9 in rodents and CoQ10 in humans) is a mitochondrial cofactor and antioxidant synthesized and localized in the inner mitochondrial membrane (IMM). This cofactor is essential for mitochondrial respiration (<xref ref-type="bibr" rid="bib40">Hatefi et al., 1962</xref>), fatty acid oxidation (<xref ref-type="bibr" rid="bib32">Frerman, 1988</xref>), and nucleotide biosynthesis (<xref ref-type="bibr" rid="bib48">Jones, 1980</xref>). We reported that mitochondrial, but not global, CoQ9 depletion is both necessary and sufficient to induce insulin resistance in vitro and in vivo (<xref ref-type="bibr" rid="bib26">Fazakerley et al., 2018a</xref>), suggesting a causal role of CoQ9/10 depletion in insulin resistance. CoQ deficiency can result from primary mutation in the CoQ biosynthetic machinery (named complex Q) (<xref ref-type="bibr" rid="bib64">Montini et al., 2008</xref>) or secondary from other cellular defects such as deletion of the oxidative phosphorylation system (OXPHOS) (<xref ref-type="bibr" rid="bib54">Kühl et al., 2017</xref>; <xref ref-type="bibr" rid="bib13">Calvo et al., 2020</xref>). Low levels of CoQ10 are associated with human metabolic disease, including diabetes (<xref ref-type="bibr" rid="bib2">Ates et al., 2013</xref>; <xref ref-type="bibr" rid="bib23">El-ghoroury et al., 2009</xref>), cardiovascular disease (<xref ref-type="bibr" rid="bib100">Zozina et al., 2018</xref>), and aging (<xref ref-type="bibr" rid="bib19">de Barcelos and Haas, 2019</xref>). Strikingly, many of these conditions are also associated with loss of OXPHOS and mitochondrial dysfunction (<xref ref-type="bibr" rid="bib45">Højlund et al., 2010</xref>; <xref ref-type="bibr" rid="bib20">Diaz-Vegas et al., 2020</xref>). However, it is unclear what causes these mitochondrial defects or if they are mechanistically linked.</p><p>Ceramides belong to the sphingolipid family, and high levels are strongly associated with insulin resistance (<xref ref-type="bibr" rid="bib15">Chaurasia and Summers, 2021</xref>). While it has been proposed that ceramides cause insulin resistance by inhibition of PI3K/Akt signaling (<xref ref-type="bibr" rid="bib84">Summers et al., 1998</xref>; <xref ref-type="bibr" rid="bib79">Schubert et al., 2000</xref>; <xref ref-type="bibr" rid="bib72">Powell et al., 2003</xref>), there is now considerable evidence that does not support this (<xref ref-type="bibr" rid="bib26">Fazakerley et al., 2018a</xref>; <xref ref-type="bibr" rid="bib47">James et al., 2021</xref>; <xref ref-type="bibr" rid="bib50">Kono and Barham, 1971</xref>; <xref ref-type="bibr" rid="bib43">Hoehn et al., 2008</xref>). Hence, ceramides may induce insulin resistance by a non-canonical mechanism. The rapid decline of mitochondrial oxidative phosphorylation in isolated mitochondria in the presence of N-acetylsphingosine (C2-ceramide), a synthetic ceramide analog that can penetrate cells, suggests that ceramides may be responsible for defective mitochondria (<xref ref-type="bibr" rid="bib21">Di Paola et al., 2000</xref>). This effect seems to be ceramide-specific as neither diacylglycerides (DAGs) nor triacylglycerides (TAGs) affect mitochondrial respiration (<xref ref-type="bibr" rid="bib69">Perreault et al., 2018</xref>). Recent evidence suggests a link between mitochondrial ceramides and insulin sensitivity, with the observation that reducing mitochondrial, but not global, ceramide in the liver protects against the development of diet-induced insulin resistance and obesity (<xref ref-type="bibr" rid="bib69">Perreault et al., 2018</xref>; <xref ref-type="bibr" rid="bib39">Hammerschmidt et al., 2019</xref>). Consistent with this, mitochondrial ceramide levels are more strongly associated with insulin resistance than with whole-tissue ceramide in human skeletal muscle (<xref ref-type="bibr" rid="bib69">Perreault et al., 2018</xref>). Despite this association, no direct evidence exists linking mitochondrial ceramides with insulin sensitivity in skeletal muscle.</p><p>Here, we describe the linkage between mitochondrial ceramide, CoQ, OXPHOS, and ROS in the etiology of insulin resistance. We show that a strong inverse relationship between mitochondrial CoQ and ceramide levels is intimately linked to the control of cellular insulin sensitivity. For example, increasing mitochondrial ceramide using either chemical or genetic tools, decreased mitochondrial CoQ levels, and induced insulin resistance. Conversely, genetic or pharmacological manipulations that lowered mitochondrial ceramide levels increased CoQ levels and protected against insulin resistance. Increased mitochondrial ceramides also led to a reduction in several OXPHOS components, hindering mitochondrial respiration and elevating mitochondrial ROS in vitro. This was further supported in human skeletal muscle, where we observed a strong association between insulin sensitivity, abundance of OXPHOS, and mitochondrial ceramides. We propose that increased mitochondrial ceramides cause a depletion in various OXPHOS components, leading to mitochondrial malfunction and deficiency in CoQ, resulting in increased ROS and insulin resistance. This provides a significant advance in our understanding of how ceramide causes mitochondrial dysfunction and insulin resistance in mammals.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Palmitate induces insulin resistance by increasing ceramides and lowering CoQ9 levels in L6 myotubes</title><p>Lipotoxicity plays a major role in insulin resistance and cardiometabolic disease (<xref ref-type="bibr" rid="bib24">Ertunc and Hotamisligil, 2016</xref>). Excess lipids accumulate in insulin target tissues, such as muscle, impairing insulin-stimulated GLUT4 translocation, as well as other metabolic actions of insulin. For this reason, several in vitro models have been employed involving incubation of insulin-sensitive cell types with lipids such as palmitate to mimic lipotoxicity in vivo (<xref ref-type="bibr" rid="bib44">Hoehn et al., 2009</xref>). In this study, we have used cell surface GLUT4-HA abundance as the main readout of insulin response. As shown (<xref ref-type="fig" rid="fig1">Figure 1A</xref>), incubation of L6 myotubes with palmitate (150 μM for 16 hr) reduced the insulin-stimulated translocation of GLUT4 to the cell surface by ~30%, consistent with impaired insulin action. Despite this marked defect in GLUT4 translocation, we did not observe any defect in proximal insulin signaling as measured by phosphorylation of Akt or TBC1D4 (<xref ref-type="fig" rid="fig1">Figure 1C and D</xref> – 100 nM insulin; 20 min). Previous studies linking ceramides to defective insulin signaling have utilized the short-chain ceramide analog (C2-ceramide) (<xref ref-type="bibr" rid="bib84">Summers et al., 1998</xref>; <xref ref-type="bibr" rid="bib79">Schubert et al., 2000</xref>; <xref ref-type="bibr" rid="bib72">Powell et al., 2003</xref>). Intriguingly, we were able to replicate that C2-ceramide inhibited both GLUT4 translocation and Akt phosphorylation in L6 myocytes (<xref ref-type="fig" rid="fig1">Figure 1B–D</xref>). One possibility is that palmitate induces insulin resistance in L6 myotubes via a ceramide-independent pathway. However, this is unlikely as palmitate-induced insulin resistance was prevented by the ceramide biosynthesis inhibitor myriocin (<xref ref-type="fig" rid="fig1">Figure 1A</xref>) and we observed a specific increase in C16-ceramide levels in L6 cells following incubation with palmitate, which was also prevented by myriocin (<xref ref-type="fig" rid="fig1">Figure 1E and F</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). Based on these data, we surmise that C2-ceramide does not faithfully recapitulate physiological insulin resistance, in contrast to that seen with incubation with palmitate.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Palmitate increases ceramides, decreases coenzyme Q (CoQ), and induces insulin resistance in L6 myotubes.</title><p>(<bold>A</bold>) Insulin-induced GLUT4 translocation in L6-HA-GLUT4 myotubes exposed to palmitate (150 μM for 16 hr, Palm) or BSA (Control) in the presence of DMSO (Control), myriocin (10 μM for 16 hr), or CoQ9 (10 μM for 16 hr). Plasma membrane GLUT4 (PM-GLUT4) abundance was normalized to insulin-treated control cells. N = 4 biological replicates, mean ± SEM. *p&lt;0.05 vs Control ins, # p&lt;0.5 vs Palm ins. (<bold>B</bold>) Insulin-induced GLUT4 translocation in L6-HA-GLUT4 myotubes exposed to C2-ceramide, dihydroceramide (100 μM, DHC) or DMSO (Control) for 2 hr. Plasma membrane GLUT4 (PM-GLUT4) abundance was normalized to insulin-treated control cells. N = 5 biological replicates, mean ± SEM. **p&lt;0.01 vs Control ins, # p&lt;0.5 vs 100 μM C2-ceramide ins. (<bold>C, D</bold>) L6-HA-GLUT4 myotubes were serum-starved after BSA (Control for 16 hr), palmitate (Palm for 16 hr), C2-ceramide (100 μM for 2 hr, C2), or DHC (100 μM for 2 hr) treatment and acute insulin (Ins) was added where indicated. Phosphorylation status of indicated sites was assessed by immunoblot (<bold>C</bold>). Immunoblots were quantified by densitometry and normalized to insulin-treated control cells (indicated by dotted line). N = 3 biological replicates, mean ± SEM. **p&lt;0.01, ***p&lt;0.001. (<bold>E, F</bold>) Endogenous ceramides levels in L6-HA-GLUT4 myotubes treated for 16 hr with BSA (control), palmitate (150 μM, Palm), myriocin (10 μM for 16 hr), or CoQ (10 μM for 16 hr) as indicated in the graph. Total (<bold>E</bold>) and specific (<bold>F</bold>) ceramide species were quantified. N = 4 biological replicates, mean ± SEM. **p&lt;0.01, ****p&lt;0.001 vs Control, ###p&lt;0.001 vs Palm, ρp&lt;0.01 vs Palm. (<bold>G</bold>) CoQ9 level in mitochondrial fraction obtained from L6-HA-GLUT4 myotubes. N = 4 biological replicates, mean ± SEM. ***p&lt;0.001 vs Control, ##p&lt;0.01 vs Palm. (<bold>H</bold>) Insulin-induced GLUT4 translocation in L6-HA-GLUT4 myotubes exposed to 4-NB (2.5 mM for 16 hr) or DMSO (Control) in the presence of CoQ9 (10 μM for 16 hr). Plasma membrane GLUT4 (PM-GLUT4) abundance was normalized to insulin-treated control cells. N = 4 biological replicates, mean ± SEM. ***p&lt;0.001 vs Control ins, ##p&lt;0.01, ###p&lt;0.001 vs 4NB. (<bold>I</bold>) CoQ9 level in mitochondrial fraction obtained from L6-HA-GLUT4 myotubes exposed to DMSO (Control) or 4NB for 16 hr. N = 4 biological replicates, mean ± SEM. *p&lt;0.05 (<bold>J, K</bold>) Total (<bold>J</bold>) and specific (<bold>K</bold>) ceramide species quantified in L6-HA-GLUT4 myotubes treated for 16 hr with DMSO (control) or 4NB (2.5 mM for 16 hr). N = 4 biological replicates, mean ± SEM. **p&lt;0.01, ****p&lt;0.0001. (<bold>L</bold>) Insulin-induced GLUT4 translocation in L6-HA-GLUT4 myotubes exposed to Saclac (10 μM for 24 hr) or EtOH (Control) in the presence of DMSO (control), myriocin (10 μM for 16 hr), or CoQ9 (10 μM for 16 hr). Plasma membrane GLUT4 (PM-GLUT4) abundance was normalized to insulin-treated control cells. N = 5 biological replicates, mean ± SEM. ***p&lt;0.001 vs Control Ins, ### p&lt;0.001 vs Saclac Ins.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87340-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Inhibiting ceramidases is sufficient to decrease CoQ levels, leading to insulin resistance.</title><p>(<bold>A</bold>) Mitochondrial-enriched fraction from L6 myotubes. Calnexin was used as a marker of endoplasmic reticulum. OXPHOS: oxidative phosphorylation system. Cholesterol (<bold>B</bold>), diacylglycerol (DAGs) (<bold>C</bold>), sphingosine-1 phosphate (S1P) (<bold>D</bold>), and sphingosine (SPH) (<bold>E</bold>) abundance in L6 myotubes exposed to different compounds (as indicated). Lipid abundance was determined by lipidomics and normalized against protein concentration. N = 4, mean ± SEM. ***p&lt;0.001, ****p&lt;0.0001. (<bold>F</bold>) Concentration of endogenous ceramide in L6-HA-GLUT4 myotubes treated for 24 hr with EtOH (Control) or different concentrations of Saclac. N = 3, mean ± SEM. *p&lt;0.05, **p&lt;0.01, ****p&lt;0.0001. (<bold>G, H</bold>) L6-HA-GLUT4 myotubes were serum-starved after EtOH (Control) or Saclac (10 μM) treatment (for 24 hr) and acute insulin (Ins) was added where indicated. Phosphorylation status of indicated sites was assessed by immunoblot. Immunoblots were quantified by densitometry and normalized to insulin-treated control cells. N = 2, mean ± SEM.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87340-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Inhibtion of ceramidases induces CoQ depletion in human cell line.</title><p>(<bold>A, B</bold>) Total (<bold>A</bold>) and specific (<bold>B</bold>) ceramide species quantified in HeLa cells treated for 24 hr with Saclac (2 uM for 24 hr) or vehicle control (EtOH, Control) as indicated. N = 4, mean ± SEM. **p&lt;0.01, ****p&lt;0.0001 vs Control. (<bold>C</bold>) CoQ10 levels in the mitochondrial fraction obtained from HeLa cells exposed to different concentrations of Saclac or vehicle control. N = 4, mean ± SEM. *p&lt;0.05. (<bold>D</bold>) CoQ10 levels in the mitochondrial fraction obtained from HeLa cells exposed to different concentrations of Saclac (2 μM for 24 hr) or control in the presence or absence of myriocin (10 μM for 16 hr). N = 4, mean ± SEM. *p&lt;0.05. (<bold>E–G</bold>) Mitochondrial abundance markers determined by western blot in HeLA cells exposed to 2 uM of Saclac for 24 hr. (<bold>F, G</bold>) Immunoblots were quantified by densitometry and normalized to control cells. N = 3, mean ± SEM. (<bold>H</bold>) Percentage of nonviable HeLa cells determined by propidium iodide (PI) staining and microscopy, following a 24 hr treatment with Saclac. N = 3, mean ± SEM. **p&lt;0.01. (<bold>I</bold>) Specific diacylglycerol species were quantified in HeLA cells exposed to Saclac vs Control. Lipid abundance was determined by lipidomics and normalized against protein concentration. N = 4, mean ± SEM. *p&lt;0.001, ****p&lt;0.0001. (<bold>J</bold>) L6 myotubes were loaded with TMRE (20 nM) for 20 min in control cells, SMPD5-overexpressing cells, and cells treated with Saclac (50 uM) for 24 hr.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87340-fig1-figsupp2-v1.tif"/></fig></fig-group><p>We previously demonstrated that insulin resistance was associated with CoQ depletion in muscle from high-fat diet (HFD)-fed mice (<xref ref-type="bibr" rid="bib26">Fazakerley et al., 2018a</xref>). To test if CoQ supplementation reversed palmitate-induced insulin resistance, L6 myotubes were co-treated with palmitate plus CoQ9. Addition of CoQ9 had no effect on control cells but overcame insulin resistance in palmitate-treated cells (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Notably, the protective effect of CoQ9 appears to be downstream of ceramide accumulation, as it had no impact on palmitate-induced ceramide accumulation (<xref ref-type="fig" rid="fig1">Figure 1E and F</xref>). Strikingly, both myriocin and CoQ9 reversed insulin resistance, suggesting that there might be an interaction between ceramides and CoQ in the induction of insulin resistance with palmitate in these cells. Moreover, we have previously shown that mitochondrial CoQ is a key determinant of insulin resistance (<xref ref-type="bibr" rid="bib26">Fazakerley et al., 2018a</xref>), suggesting that ceramides and CoQ may interact in mitochondria. To explore this link, we next examined the effect of palmitate on mitochondrial CoQ levels. As shown (<xref ref-type="fig" rid="fig1">Figure 1G</xref>), palmitate lowered mitochondrial CoQ9 abundance by ~40%, and this was prevented with myriocin. To test whether CoQ depletion is downstream of ceramide accumulation, we exposed GLUT4-HA-L6 myotubes to 4-nitrobenzoic acid (4NB) to competitively inhibit 4-hydroxybenzoate:prolyprenyl transferase (Coq2), a limiting step in CoQ9 synthesis (<xref ref-type="bibr" rid="bib31">Forsman et al., 2010</xref>). 4NB (2.5 mM for 16 hr) decreased mitochondrial CoQ9 to a similar extent as observed in palmitate-treated myocytes (<xref ref-type="fig" rid="fig1">Figure 1I</xref>) and generated insulin resistance in GLUT4-HA-L6 myotubes (<xref ref-type="fig" rid="fig1">Figure 1H</xref>). Notably, 4NB-mediated insulin resistance was prevented by provision of CoQ9, as described previously (<xref ref-type="bibr" rid="bib26">Fazakerley et al., 2018a</xref>). Interestingly, total ceramide abundance was increased in 4NB-treated cells, albeit to a lesser extent than observed with palmitate, without affecting other lipid species (<xref ref-type="fig" rid="fig1">Figure 1J and K</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). One possibility is that CoQ directly controls ceramide turnover (<xref ref-type="bibr" rid="bib29">Fernández-Ayala et al., 2000</xref>). An alternate possibility is that CoQ inside mitochondria is necessary for fatty acid oxidation (<xref ref-type="bibr" rid="bib32">Frerman, 1988</xref>) and CoQ depletion triggers lipid overload in the cytoplasm promoting ceramide production (<xref ref-type="bibr" rid="bib52">Koves et al., 2008</xref>). In fact, increased fatty acid oxidation is protective against insulin resistance in several model organisms (<xref ref-type="bibr" rid="bib10">Bruce et al., 2009</xref>; <xref ref-type="bibr" rid="bib81">Sebastián et al., 2007</xref>; <xref ref-type="bibr" rid="bib68">Perdomo et al., 2004</xref>). Future studies are required to determine how CoQ depletion promotes Cer accumulation. Regardless, these data indicate that ceramide and CoQ have a central role in regulating cellular insulin sensitivity.</p><p>Since palmitate treatment can have a number of effects beyond ceramides, we next attempted to increase intracellular ceramides by inhibiting the ceramide degradation pathway. We exposed L6 myotubes to different concentrations of Saclac, an inhibitor of acid ceramidase (<xref ref-type="bibr" rid="bib49">Kao et al., 2019</xref>), for 24 hr. Saclac increases ceramides in L6 cells in a dose-dependent fashion, with the largest effect on C16:0 ceramides (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1F</xref>). Interestingly, Saclac also promoted accumulation of DAGs, sphingosine-1 phosphate (S1P), and sphingosine (SPH), demonstrating the tight interaction between these lipid species (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B, C, and E</xref>). Consistent with a role of ceramide in insulin sensitivity, Saclac (10 μM for 24 hr) reduced insulin-stimulated GLUT4 translocation by 40% (<xref ref-type="fig" rid="fig1">Figure 1L</xref>, vs Control; p&lt;0.001), and this was prevented by myriocin or CoQ9 supplementation (<xref ref-type="fig" rid="fig1">Figure 1L</xref>). Notably, no detectable defects in Akt phosphorylation were observed (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1G and H</xref>).</p><p>To explore if ceramides promote CoQ depletion beyond skeletal muscle, human cervical cancer cells (HeLa) were exposed to Saclac, as described previously (2 μM for 24 hr) (<xref ref-type="bibr" rid="bib30">Fisher-Wellman et al., 2021</xref>). Consistent with our observation in L6 myotubes, Saclac increased total ceramide levels (approximately sixfold over basal) (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1F</xref>) and lowered CoQ levels inside mitochondria (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>). Of interest, myriocin prevented Saclac-induced-CoQ depletion, demonstrating that there is a similar interaction between ceramide and CoQ levels in this human cell line as observed in L6 cells (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D</xref>). Moreover, this was relatively specific to CoQ as we did not observe any change in mitochondrial mass with Saclac (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1E–G</xref>), cell viability (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1H</xref>), or DAG abundance (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1I</xref>). Regardless, these data indicate that there is a strong association between ceramide and CoQ and that this has a central role in regulating cellular insulin sensitivity.</p></sec><sec id="s2-2"><title>Mitochondrial ceramide promotes insulin resistance by lowering CoQ levels</title><p>Although mitochondrial ceramides have been linked with insulin resistance in human skeletal muscle (<xref ref-type="bibr" rid="bib69">Perreault et al., 2018</xref>), to date, there is no direct evidence linking mitochondrial ceramides with insulin sensitivity. We wanted to determine whether ceramide accumulation specifically in mitochondria is associated with altered CoQ levels and insulin resistance. To achieve this, we employed doxycycline-Tet-On-inducible (<xref ref-type="bibr" rid="bib18">Das et al., 2016</xref>) overexpression of a mitochondrial-targeted sphingomyelin phosphodiesterase 5 (mtSMPD5) in GLUT4-HA-L6 cells (GLUT4-HA-L6-mtSMPD5) (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). SMPD5 is a murine mitochondria-associated enzyme (<xref ref-type="bibr" rid="bib92">Wu et al., 2010</xref>) that hydrolyzes sphingomyelin to produce ceramides (<xref ref-type="bibr" rid="bib5">Bienias et al., 2016</xref>). Thus, overexpressing mtSMPD5 should specifically increase ceramides within mitochondria and avoid potential nonspecific effects associated with small-molecule inhibitors. As expected, doxycycline induced mitochondrial expression of mtSMPD5, as demonstrated by enrichment of SMPD5 in mitochondria isolated from L6 cells (<xref ref-type="fig" rid="fig2">Figure 2B</xref>), and this was associated with increased total mitochondrial ceramides to the same extent as observed with palmitate treatment (<xref ref-type="fig" rid="fig2">Figure 2C</xref>), with the largest increase in C16-ceramide (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). Importantly, mtSMPD5 overexpression did not affect ceramide abundance in the whole-cell lysate nor other lipid species inside mitochondria such as cardiolipin, cholesterol, and DAGs (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A and D–J</xref>). Intriguingly, mtSMD5 did not affect sphingomyelin levels in mitochondria (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1G</xref>), consistent with exchange between mitochondrial and extra-mitochondrial sphingomyelin pools to compensate for the degradation induced by SMPD5 overexpression (<xref ref-type="bibr" rid="bib28">Feng et al., 2018</xref>). Consistent with our hypothesis, mtSMPD5 was sufficient to promote insulin resistance in response to submaximal and maximal insulin doses (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). Furthermore, mtSMPD5 overexpression promoted insulin resistance without affecting Akt phosphorylation (<xref ref-type="fig" rid="fig2">Figure 2F–H</xref>), and no differences in total GLUT4 levels were observed across the treatments (<xref ref-type="fig" rid="fig2">Figure 2F</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>). We next explored if mitochondrial ceramide-induced insulin resistance was mediated by lowering CoQ within mitochondria. In line with our previous results, mitochondrial CoQ levels were depleted in both palmitate-treated and mtSMPD5-overexpressing cells without any additive effects. This suggests that these strategies to increase ceramides share a common mechanism for inducing CoQ depletion in L6 myotubes (<xref ref-type="fig" rid="fig2">Figure 2I</xref>). Importantly, CoQ9 supplementation prevented both palmitate- and mtSMPD5-induced insulin resistance (<xref ref-type="fig" rid="fig2">Figure 2J</xref>), suggesting that CoQ depletion is an essential mediator of insulin resistance.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Mitochondrial overexpression of SMPD5 induces insulin resistance by lowering CoQ9 in L6 myotubes.</title><p>(<bold>A</bold>) Schematic representation of doxycycline-inducible overexpression of mitochondrial-targeted sphingomyelinase 5 (SMPD5). L6-HA-GLUT4 myotubes were exposed to 1 μg/mL of doxycycline from day 3 to day 6 of differentiation. Experiments were performed on day 7 of differentiation. (<bold>B</bold>) Determination of SMPD5 expression in mitochondrial fraction obtained from L6-HA-GLUT4. Doxycycline was added where indicated. (<bold>C, D</bold>) Levels of endogenous ceramides in mitochondrial fraction from L6-HA-GLUT4 myotubes treated with BSA (Control), palmitate (150 μM for 16 hr, Palm), or doxycycline. Total (<bold>C</bold>) and specific (<bold>D</bold>) ceramide species were quantified. N = 3 biological replicates, mean ± SEM. *p&lt;0.05, **p&lt;0.01, ****p&lt;0.0001 vs Control. (<bold>E</bold>) Insulin-induced GLUT4 translocation in L6-HA-GLUT4 myotubes exposed to doxycycline (1 μg/mL for 3 d). Plasma membrane GLUT4 (PM-GLUT4) abundance was normalized to 100 nM insulin-treated control cells. N = 6 biological replicates, mean ± SEM. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001 vs Control ins. (<bold>F–H</bold>) L6-HA-GLUT4 myotubes were serum-starved after BSA (Control), palmitate (150 μM for 16 hr, Palm), or doxycycline (1 μg/mL for 3 d) treatment and acute insulin (Ins) was added where indicated. Phosphorylation status of indicated sites was assessed by immunoblot. Immunoblots were quantified by densitometry and normalized to insulin-treated control cells (indicated by dotted line). N = 3 biological replicates, mean ± SEM. * p&lt;0.05, *** p&lt;0.001 vs Basal. (<bold>I</bold>) CoQ9 level in mitochondrial fraction obtained from L6-HA-GLUT4 myotubes exposed to doxycycline (1 μg/mL for 3 d). N = 4 biological replicates, mean ± SEM. **p&lt;0.001. (<bold>J</bold>) Insulin-induced GLUT4 translocation in L6-HA-GLUT4 myotubes exposed to doxycycline (1 μg/mL for 3 d). Control or doxycycline-treated cells were exposed to BSA (Control), palmitate (150 μM for 16 hr, Palm), or CoQ9 (10 μM for 16 hr). Plasma membrane GLUT4 (PM-GLUT4) abundance was normalized to insulin-treated control cells. N = 5 biological replicates, mean ± SEM. **p&lt;0.01 vs Control ins, ## p&lt;0.01 vs Palm ins.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87340-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>The overexpression of mtSMPD5 selectively increases mitochondrial ceramides.</title><p>(<bold>A</bold>) Total ceramide levels extracted from whole lysate of L6 myotubes exposed to different treatments (as indicated). (<bold>B, C</bold>) Densitometric analysis of <xref ref-type="fig" rid="fig3">Figure 3F</xref> of selected proteins (as indicated). Mitochondrial levels of cardiolipin (<bold>D</bold>), cholesterol (<bold>E</bold>), sphingosine (<bold>F</bold>), sphingomyelin (<bold>G</bold>), sphingosine-1 phosphate (<bold>H</bold>), and diacylglycerol (<bold>I, J</bold>) (as indicated) were determined by lipidomics and normalized against mitochondrial protein concentration. Cells were exposed to doxycycline for 3 d for SMPD5 induction. N = 3, mean ± SEM. ****p&lt;0.0001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87340-fig2-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-3"><title>Mitochondrial ceramides are necessary for palmitate-induced CoQ depletion and insulin resistance</title><p>Given that increased mitochondrial ceramides are sufficient to induce CoQ depletion and insulin resistance, we next asked whether increased mitochondrial ceramides are necessary to drive these phenotypes. Using the doxycycline-Tet-On-inducible system (<xref ref-type="bibr" rid="bib18">Das et al., 2016</xref>), we overexpressed a mitochondrial-targeted acid ceramidase 1 (mtASAH1) in GLUT4-HA-L6 cells (GLUT4-HA-L6-mtASAH1) (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). ASAH1 degrades ceramides to fatty acid and sphingosine (<xref ref-type="bibr" rid="bib59">Li et al., 1999</xref>). Hence, mitochondrial overexpression of ASAH1 was expected to selectively lower ceramides inside mitochondria. Doxycycline increased the abundance of mtASAH1 in the mitochondrial fraction, demonstrating the correct localization of this construct (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). Furthermore, mtASAH1 induction prevented palmitate-induced mitochondrial ceramide accumulation (total levels and 18:1\16:0 ceramides) (<xref ref-type="fig" rid="fig3">Figure 3C</xref>), indicating that the enzyme was functioning as expected. Similar to our observations with mtSMD5 overexpression, mtASAH1 did not alter ceramide abundance in the whole-cell lysate or mitochondrial sphingomyelin levels (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A and F</xref>). Notably, mtASAH1 overexpression protected cells from palmitate-induced insulin resistance without affecting basal insulin sensitivity (<xref ref-type="fig" rid="fig3">Figure 3E</xref>). Similar results were observed using insulin-induced glycogen synthesis as an orthologous technique for GLUT4 translocation. These results provide additional evidence highlighting the role of dysfunctional mitochondria in muscle cell glucose metabolism (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1K</xref>). Importantly, mtASAH1 overexpression did not rescue insulin sensitivity in cells depleted of CoQ (2.5 mM 4NB for 24 hr), supporting the notion that mitochondrial ceramides are upstream of CoQ (<xref ref-type="fig" rid="fig3">Figure 3E</xref>). Neither palmitate nor mtASAH1 overexpression attenuated insulin-dependent Akt phosphorylation (<xref ref-type="fig" rid="fig3">Figure 3F–H</xref>) nor total GLUT4 abundance (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>). Finally, mtASAH1 overexpression increased CoQ levels. In both control and mtASAH1 cells, palmitate induced a depletion of CoQ; however, the levels in palmitate-treated mtASAH1 cells remained similar to control untreated cells (<xref ref-type="fig" rid="fig3">Figure 3I</xref>). This suggests that the absolute concentration of CoQ is crucial for insulin sensitivity, rather than the relative depletion compared to basal conditions, thus supporting the causal role of mitochondrial ceramide accumulation in reducing CoQ levels in insulin resistance.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Mitochondrial overexpression of ASAH1 protects against insulin resistance and increases coenzyme Q (CoQ) levels in L6 myotubes.</title><p>(<bold>A</bold>) Schematic representation of doxycycline-inducible overexpression of mitochondrial-targeted acid ceramidase 1 (ASAH1). L6-HA-GLUT4 myotubes were exposed to 1 μg/mL of doxycycline from day 3 to day 6 of differentiation. Experiments were performed on day 7 of differentiation. (<bold>B</bold>) Determination of ASAH1 expression in mitochondrial fraction obtained from L6-HA-GLUT4. Doxycycline was added where indicated. (<bold>C, D</bold>) Endogenous ceramides levels in mitochondrial fraction from L6-HA-GLUT4 myotubes treated with BSA (Control), palmitate (150 μM for 16 hr, Palm), or doxycycline. Total (<bold>C</bold>) and specific (<bold>D</bold>) ceramide species were quantified. N = 3 biological replicates, mean ± SEM. *p&lt;0.05 vs Control, ##p&lt;0.01 vs Palm. (<bold>E</bold>) Insulin-induced GLUT4 translocation in L6-HA-GLUT4 myotubes exposed to doxycycline (1 μg/mL for 3 d). Control or doxycycline-treated cells were exposed to BSA (control), palmitate (150 μM for 16 hr, Palm), or 4NB (2.5 mM for 16 hr). Plasma membrane GLUT4 (PM-GLUT4) abundance was normalized to insulin-treated control cells. N = 6 biological replicates, mean ± SEM. **p&lt;0.01 vs Control ins, ### p&lt;0.001 vs Palm ins. (<bold>F–H</bold>) L6-HA-GLUT4 myotubes were serum-starved after BSA (Control), palmitate (150 μM for 16 hr, Ppalm), or doxycycline (1 μg/mL for 3 d) treatment and acute insulin (Ins) was added where indicated. Phosphorylation status of indicated sites was assessed by immunoblot. Immunoblots were quantified by densitometry and normalized to insulin-treated control cells (indicated by dotted line). N = 3 biological replicates, mean ± SEM. ***p&lt;0.001 vs Basal, # p&lt;0.05 vs Control ins. (<bold>I</bold>) CoQ9 level in mitochondrial fraction obtained from L6-HA-GLUT4 myotubes exposed to doxycycline (1 μg/mL for 3 d). Control or doxycycline treated cells were exposed to BSA (Control) or palmitate (150 μM for 16 hr, Palm) N = 4 biological replicates, mean ± SEM. *p&lt;0.05 vs Control, ## p&lt;0.01 vs Palm. (<bold>J</bold>) Levels of total ceramides in skeletal muscle of mice fed chow with vehicle or 5 mg/kg P053 for 6 wk. N = 7 mice per group, mean ± SEM. ***p&lt;0.001. (<bold>K</bold>) Levels of CoQ in mitochondrial fraction isolated from skeletal muscle of mice fed chow with vehicle or 5 mg/kg P053 for 6 wk. N = 7 mice per group, mean ± SEM. *p&lt;0.05.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87340-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>The overexpression of mtASAH1 decreases DAGs in palmitate-treated cells.</title><p>(<bold>A</bold>) Total ceramide levels extracted from whole lysate of L6 myotubes exposed to different treatments (as indicated). (<bold>B, C</bold>) Densitometric analysis of <xref ref-type="fig" rid="fig3">Figure 3F</xref> of selected proteins (as indicated). Mitochondrial levels of cardiolipin (<bold>D</bold>), cholesterol (<bold>E</bold>), sphingosine (<bold>F</bold>), sphingomyelin (<bold>G</bold>), sphingosine-1 phosphate (<bold>H</bold>), and diacylglycerol (<bold>I, J</bold>) (as indicated) were determined by lipidomics and normalized against mitochondrial protein concentration. Cells were exposed to doxycycline for 3 d for ASAH1 induction. N = 3, mean ± SEM. *p&lt;0.05, **p&lt;0.01, ****p&lt;0.0001. (<bold>K</bold>) Insulin-induced glycogen synthesis. L6 myotubes were exposed to different treatments (as indicated) and glycogen storage was measured by 14C glucose (as indicated in the ‘Materials and methods’ section). Data is expressed as a percentage of increased 14-glycogen after insulin stimulation relative to control cells. N = 4, mean ± SEM. *p&lt;0.05. (<bold>H, I</bold>) Total ceramides (<bold>H</bold>) and mitochondrial coenzyme Q (CoQ) levels (<bold>I</bold>) in skeletal muscle from mice exposed to a high-fat diet and exposed to either vehicle (DMSO) or the inhibitor of CerS1 P053 (5 mg/kg) in drinking water for 6 wk as described in <xref ref-type="bibr" rid="bib88">Turner et al., 2018</xref>. N = 6, mean ± SEM. *p&lt;0.05, *** p&lt;0.001 vs Control.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87340-fig3-figsupp1-v1.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Lipidomic analysis of mice exposed to the CerS1 inhibitor P053.</title><p>(<bold>A</bold>) Body weight of mice exposed to either vehicle (DMSO) or the inhibitor of CerS1 P053 (5 mg/kg) in drinking water for 6 wk. (<bold>B</bold>) Ceramide, (<bold>C</bold>) sphingomyelin, and (<bold>D</bold>) diacylglycerol species were determined in skeletal muscle by lipidomics and normalized against mg of tissue. N = 6, mean ± SEM. *p&lt;0.05, ****p&lt;0.0001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87340-fig3-figsupp2-v1.tif"/></fig></fig-group><p>In order to demonstrate the connection between ceramide and CoQ in vivo, we examined whether a reduction in ceramides in mouse skeletal muscle, using a ceramide synthase 1 (CerS1) inhibitor, would alter mitochondrial CoQ levels. Treatment of adult mice with the CerS1 inhibitor P053 for 6 wk selectively lowered muscle ceramides without affecting other lipid species (<xref ref-type="fig" rid="fig3">Figure 3J</xref>, <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>). Notably, CerS1 inhibition increased CoQ in mitochondrial fractions isolated from skeletal muscle (<xref ref-type="fig" rid="fig3">Figure 3K</xref>), and a similar effect was observed in mice exposed to an HFD for 5 wk (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1H and I</xref>). These animals exhibited an improvement in mitochondrial function and reduced muscle triglycerides and adiposity upon HFD (further phenotypic and metabolic characterization of these animals can be found in <xref ref-type="bibr" rid="bib88">Turner et al., 2018</xref>), demonstrating the existence of the ceramide/CoQ relationship in muscle in vivo.</p></sec><sec id="s2-4"><title>Mitochondrial ceramides induce depletion of the electron transport chain</title><p>We have established that both increased mitochondrial ceramides and a loss of mitochondrial CoQ are necessary for the induction of insulin resistance. As such, these changes are likely to induce other mitochondrial defects. To gain insight into how increased mitochondrial ceramides drive changes in mitochondrial function, we performed MS-based proteomics on L6 cells overexpressing mtSMPD5.</p><p>mtSMPD5-L6 myotubes were treated with doxycycline for various time points (2, 8, 24, 48, and 72 hr) and positive induction was observed after 24 hr of treatment (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>). Subsequently, control, 24, and 72 hr time points were selected for further studies. Mitochondria were purified via gradient separation and analyzed using liquid chromatography-tandem mass spectrometry (LC-MS/MS) in data-independent acquisition (DIA) mode (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). Across control and mtSMPD5 cells, we quantified 2501 proteins where 555 were annotated as mitochondrial proteins (MitoCarta 3.0 and UniProt localization) (<xref ref-type="bibr" rid="bib73">Rath et al., 2021</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Mitochondrial ceramides induce a selective depletion of supercomplexes-associated proteins in L6 myotubes.</title><p>(<bold>A</bold>) Workflow schematics. (<bold>B, C</bold>) Pairwise comparisons of mitochondrial proteome between all four groups. Cutoff for -log10 adjusted p-value (-log10(p-value)) was set at 2 and Log2(FC) at 0.5 (blue). (<bold>D</bold>) Quantification of the OXPHOS protein complexes generated by the summed abundance of all subunits within a given complex. (<bold>E</bold>) Quantification of the complex Q (CoQ) protein complexes generated by the summed abundance of all subunits within the complex. (<bold>F</bold>) Schematics of CoQ distribution between CI-binding and free CoQ (<xref ref-type="bibr" rid="bib41">Hernansanz-Agustín and Enríquez, 2021</xref>). (<bold>G</bold>) Schematics of OXPHOS subunits (top) and assembly factors (bottom) significantly upregulated (light red), downregulated (blue), and no change (gray) after 72 hr of mtSMPD5 overexpression. (<bold>H</bold>) Subunit levels for proteins after mtSMPD5 overexpression mapped to the complex I structure (<xref ref-type="bibr" rid="bib98">Zhu et al., 2016</xref>). The colors were calculated with an in-house Python script, and the resultant model was rendered using ChimeraX. Gray, not detected; purple, below cutoff (Log2FC = 0.4).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87340-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Proteomic analysis of mitochondrial fractions obtained rom L6 myotubes overexpressing mtSMPD5.</title><p>(<bold>A</bold>) L6 myotubes were exposed to doxycycline for different times to promote mtSMPD5 overexpression. The immunoblot of Flag is shown in (<bold>A</bold>). (<bold>B</bold>) Violin plot of proteomic data after median normalized. (<bold>C–I</bold>) Summed intensities of protein and subunits associated with a specific process as denoted on the top of each graph. N = 4 ± SEM. (<bold>J</bold>) L6 myotubes were exposed to doxycycline to promote mtSMPD5 overexpression. The immunoblot of Flag is shown in the left panel. mRNA levels for different complex I subunits were determined by RT-PCR and normalized against beta-actin. N = 4 ± SD.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87340-fig4-figsupp1-v1.tif"/></fig></fig-group><p>Analysis of the proteome revealed that 9 and 19% of mitochondrially annotated proteins were significantly changed at 24 and 72 hr, respectively (adj. p&lt;0.05, absolute log2 FC &gt; 0.4), indicative of a temporal progression of changes following induction of mSMPD5 expression (<xref ref-type="fig" rid="fig4">Figure 4B and C</xref>). Sixty proteins were decreased at 72 hr, and of these 47% were functionally annotated as components of oxidative phosphorylation (OXPHOS; rank 1, 28/135 proteins). Within OXPHOS, we observed a significant depletion of the electron transport chain components (ETC). The ETC is composed of several complexes (complexes I–V, CI–CV). In this dataset, CI (14/15 decreased), CIII (5/6 decreased), and CIV (13/13 decreased) but not CII (0/3 decreased) or CV (3/15 decreased) were depleted after mtSMPD5 overexpression (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). Despite the bulk downregulation of CI, III, and IV, the assembly machinery associated with each complex was either upregulated or unchanged after mtSMPD5 overexpression (<xref ref-type="fig" rid="fig4">Figure 4J</xref>), suggesting that mitochondrial ceramides somehow alter ETC stability. Intriguingly, neither CII nor CV were affected by mtSMPD5, suggesting that ceramides preferentially affect those ETC complexes that are part of structures known as supercomplexes (SCs) (<xref ref-type="bibr" rid="bib58">Letts and Sazanov, 2017</xref>). Importantly, as part of CoQ is found in SCs binding CI (<xref ref-type="fig" rid="fig4">Figure 4F</xref>), we mapped the levels of individual subunits of CI onto the recently solved structure of bovine CI (<xref ref-type="bibr" rid="bib98">Zhu et al., 2016</xref>). This revealed the loss of subunits around the N-module (Ndufs1, Ndufs4, Ndufs6, Ndufv2, and Ndufv3) and Q-module (Ndufa5 and Ndufs2) in CI (<xref ref-type="fig" rid="fig4">Figure 4H</xref>). Importantly, CI downregulation was not associated with reduction in gene expression as shown in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1J</xref>. The N-module is essential for NADH oxidation, and the Q-module is where CoQ binds CI. Hence, loss of the Q-module might trigger a stoichiometric depletion of CoQ upon ceramide accumulation.</p><p>Of note, we observed a heterogeneous response of the mitochondrial proteome after mtSMPD5 overexpression. For instance, proteins associated with glucose oxidation and mitochondrial translation/transcription did not change after mtSMPD5 induction (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1D, F, and G</xref>), proteins involved in fatty acid oxidation and OXPHOS were consistently downregulated after 24 hr treatment (<xref ref-type="fig" rid="fig4">Figure 4B–D</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1E</xref>), proteins related with the mitochondrial import machinery were consistently upregulated (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C</xref>), and proteins associated with CoQ production were transiently downregulated after 24 h induction (<xref ref-type="fig" rid="fig4">Figure 4E</xref>).</p></sec><sec id="s2-5"><title>Mitochondrial ceramides impair mitochondrial function</title><p>Based on the ceramide-dependent depletion of ETC members, we hypothesized that mitochondrial ceramides would impair mitochondrial function. To test this, we evaluated several aspects of mitochondrial function upon mtSMPD5 overexpression. Mitochondrial respiration is broadly considered to be the best measure for describing mitochondrial activity (<xref ref-type="bibr" rid="bib20">Diaz-Vegas et al., 2020</xref>; <xref ref-type="bibr" rid="bib9">Brand and Nicholls, 2011</xref>). Respiration was assessed in intact mtSMPD5-L6 myotubes treated with CoQ9 by Seahorse extracellular flux analysis. mtSMPD5 overexpression decreased basal and ATP-linked mitochondrial respiration (<xref ref-type="fig" rid="fig5">Figure 5A–C</xref>), as well as maximal, proton-leak and non-mitochondrial respiration (<xref ref-type="fig" rid="fig5">Figure 5A, D, E, and F</xref>), suggesting that mitochondrial ceramides induce a generalized attenuation in mitochondrial function. Notably, we did not observe evidence of energy deficiency in our model (data not shown). Interestingly, CoQ9 supplementation partially recovered basal and ATP-linked mitochondrial respiration, suggesting that part of the mitochondrial defects are induced by CoQ9 depletion. The attenuation in mitochondrial respiration is consistent with a depletion of the ETC subunits observed in our proteomic dataset (<xref ref-type="fig" rid="fig4">Figure 4</xref>). Since mitochondrial respiratory activity is limited by several factors, including nutrient supply, bioenergetic demands, among others (<xref ref-type="bibr" rid="bib53">Krycer et al., 2020</xref>), we tested whether the ETC generally or a specific respiratory complex was affected by mtSMPD5 overexpression. We measured the activity of the respiratory chain by providing substrates for each respiratory chain complex to permeabilized cells and analyzed oxygen consumption. mtSMPD5-overexpressing cells exhibited attenuated mitochondrial respiration irrespective of the substrate provided (<xref ref-type="fig" rid="fig5">Figure 5G–L</xref>), supporting the notion that mitochondrial ceramides induce a generalized defect in mitochondrial respiration. In line with defective mitochondrial function, cells with mtSMPD5 overexpression also exhibited increased oxidative stress (<xref ref-type="fig" rid="fig5">Figure 5M</xref>) measured by the redox-sensitive dye MitoSOX. Interestingly, no difference in mitochondrial membrane potential was observed across conditions (<xref ref-type="fig" rid="fig5">Figure 5N</xref>). Collectively, these data suggest that increased mitochondrial ceramides cause a loss of mitochondrial respiratory capacity and an increase in ROS production as a result of ETC depletion in L6 myotubes.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Mitochondrial ceramides impair mitochondrial function.</title><p>(<bold>A</bold>) mtSMPD5 overexpression decreases oxygen consumption rate (<italic>J</italic>O<sub>2</sub>) (means ± SEM; n = 6–8 biological replicates) measured by mitochondrial stress test. After 1 hr no CO<sub>2</sub> environment, cells were stimulated with oligomycin (Oligo), carbonyl cyanide-p-trifluoromethoxyphenylhydrazon (FCCP), and antimycin A (AA) and Rotenote (Rot) at indicated time points (means ± SEM; n = 6–8 biological replicates). (<bold>B–F</bold>) Quantification of <italic>J</italic>O<sub>2</sub> measured by mitochondrial stress test from <xref ref-type="fig" rid="fig6">Figure 6A</xref> as described in the ‘Materials and methods’ section (means ± SEM; n = 6–8 biological replicates). * p&lt;0.05, ** p&lt;0.01, *** p&lt;0.001 vs Control. (<bold>G–L</bold>) mtSMPD5 overexpression diminishes respiratory CI (<bold>G, J</bold>), CII (<bold>H, K</bold>), and CIV (<bold>I, L</bold>). <italic>J</italic>O<sub>2</sub> was performed in permeabilized cells supplemented with adenosine diphosphate (ADP) and CI to IV substrates (means ± SEM; n = 3 biological replicates). Mal, malate; Glut, glutamate; Rot, Rotenone; Succ, succinate; TMPD, tetramethyl-phenylenediamine; Asc, ascorbic acid; Oligo, oligomycin. (<bold>J</bold>), (<bold>K</bold>), and (<bold>L</bold>) are quantifications from graphs (<bold>G</bold>), (<bold>H</bold>), and (<bold>I</bold>), respectively. * p&lt;0.05, ** p&lt;0.01 vs Control. (<bold>M</bold>) mtSMPD5 overexpression increased mitochondrial oxidative stress. Cells were loaded with the redox-sensitive dye MitoSOX and the mitochondrial marker MitoTracker Deep Red for 30 min before imaging in a confocal microscope (see ‘Materials and methods’) (means ± SEM; n = 10 biological replicates). AA, antimycin A. ** p&lt;0.01, *** p&lt;0.001 vs Control. (<bold>N</bold>) mtSMPD5 overexpression does not alter mitochondrial membrane potential. Cells were loaded with the potentiometric dye tetramethylrhodamine, ethyl ester, perchlorate (TMRM<sup>+</sup>) in non-quenching mode and the mitochondrial marker MitoTracker Deep Red for 30 min before imaging in a confocal microscope (see ‘Materials and methods’) (means ± SEM; n &gt; 10 biological replicates).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87340-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Proteomic analysis of mitochondria isolated from human muscle biopsies.</title><p>(<bold>A</bold>) Box plot of all proteomics samples before (top) and after (bottom) median normalization. (<bold>B</bold>) Pairwise comparisons of mitochondrial proteome between all four groups. (<bold>C</bold>) Proteins rank against rate glucose disappearance during clamp (Rd) correlation. Proteins within complex IV and V of the electron transport chain associate with Rd. (<bold>D</bold>) Association of proteins within complex II, III, small and large ribosomal subunits with Rd.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87340-fig5-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-6"><title>Association of mitochondrial proteome with insulin sensitivity and mitochondrial ceramides in human muscle</title><p>To further characterize the effect of mitochondrial ceramides on ETC abundance in a more physiological context, we performed a cross-sectional study assessing the mitochondrial lipid profile and protein abundance in muscle biopsies obtained from four groups of people (athletes, lean, obese, and type 2 diabetics [T2D]). The demographic information and detailed lipidomic analysis of these individuals were reported previously (<xref ref-type="bibr" rid="bib69">Perreault et al., 2018</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>). In line with our in vitro data, long-tail ceramides (C18:0) in the mitochondria/endoplasmic reticulum (ER)-enriched fraction, but not whole tissue, were inversely correlated with muscle insulin sensitivity (<xref ref-type="bibr" rid="bib69">Perreault et al., 2018</xref>). To expand this observation, we employed proteomics analysis of the mitochondrial/ER fraction from the same subjects (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). A total of 2058 unique protein groups were quantified in at least one sample, where 571 were annotated as mitochondrial associated proteins (Human MitoCarta 3.0) (<xref ref-type="bibr" rid="bib73">Rath et al., 2021</xref>). After filtering (proteins in &gt;50% of samples within each group), 492 mitochondrial proteins were reliably quantified across 67 samples (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). We noted that the mitochondrial fraction from athletes were enriched for mitochondrial proteins, and this could be corrected by global median normalization (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1D</xref>). Pairwise comparison of the mitochondrial proteome between all groups revealed differences between groups, although relatively small in effect size (<xref ref-type="fig" rid="fig6">Figure 6C and D</xref>). For instance, 16% of all mitochondrial proteins were significantly different between T2D and athletes (<xref ref-type="fig" rid="fig6">Figure 6C</xref>); however, 56% (45/80) of these proteins were changed by less than 1.5-fold. This trend was even stronger when comparing the obese group to the athletes, where 18% of mitochondrial proteins were changed, but ~80% were changed less than 1.5-fold. Gene set enrichment revealed a highly significant general trend following the difference in insulin sensitivity (measured by the rate of glucose disappearance –Rd- using a stable isotope – [6,6-<sup>2</sup>H<sub>2</sub>]glucose – during a hyperinsulinemic-euglycemic clamp; <xref ref-type="bibr" rid="bib69">Perreault et al., 2018</xref>), where TCA cycle and respiratory electron transport and complex I biogenesis were enriched as follows: athletes &gt; lean &gt; obese &gt; T2D (<xref ref-type="supplementary-material" rid="sdata10">Source data 10</xref>). Of note, the T2D group had an enrichment of mitochondrial translation compared to the obese group.</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Mitochondrial proteome profiling associates complex I with muscle insulin sensitivity.</title><p>(<bold>A</bold>) Quantification of proteins across samples. (<bold>B</bold>) Number of significant deferential regulated (DR) proteins by pairwise comparison. Groups not shown have no significantly regulated proteins after correcting for multiple testing. (<bold>C</bold>) Gene set enrichment between all comparisons. (<bold>D</bold>) Relative protein abundance in isolated mitochondria from human skeletal muscle cells. Comparisons are shown on the top of each graph. Light blue, significantly regulated proteins (-log10(p-val)=2). (<bold>E</bold>) Proteins rank against rate glucose disappearance during clamp (Rd) correlation. Proteins within complex I of the electron transport chain are highly significant with Rd. (<bold>F</bold>) Proteins rank against mitochondrial ceramide (Cer) 18:0 abundance. Proteins within complex I of the electron transport chain are highly significant with Cer18:0. (<bold>G</bold>) Subunit levels associated with mitochondrial ceramides mapped to the complex I structure (<xref ref-type="bibr" rid="bib98">Zhu et al., 2016</xref>). The colors were calculated with an in-house Python script, and the resultant model was rendered using ChimeraX. Gray, no detected; purple, below cutoff (Corr. Coef. = –0.25 to 0.25). (<bold>H</bold>) Quantification of the mitochondrial proteins generated by the summed abundance of all subunits associated with a specific function from mtSMPD5-L6 myotubes after 72 hr vs summed mitochondrial proteins (function) associated with either C18:0 ceramide (left panel) or insulin sensitivity (right panel) from human samples.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87340-fig6-v1.tif"/></fig><p>To further explore the relationship between mitochondria and insulin sensitivity, the mitochondrial proteome was correlated to the muscle insulin sensitivity measured using <sup>2</sup>H<sub>2</sub> glucose Rd. As a group, all detected proteins within CI of the ETC were highly correlated with muscle insulin sensitivity (p=4e-15) (<xref ref-type="fig" rid="fig6">Figure 6E</xref>) and to a lesser extent proteins within CIV (p=0.08) and CV (p=0.09; <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1E</xref>). The abundance of CII and CIII, together with the small and large mitochondrial ribosome subunits, was not associated with insulin sensitivity across all the samples (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1F</xref>). Next, we determined the association between the mitochondrial proteome and the levels of C18:0 ceramide in the mitochondria/ER fraction. In line with our previous observations, as a group, CI proteins were inversely correlated with mitochondrial ceramides (p=8e-14) and no association was observed between CII and C18:0 ceramides across samples (<xref ref-type="fig" rid="fig6">Figure 6F</xref>). Furthermore, components of CIV were also negatively correlated with mitochondrial ceramides although to a lesser extent (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1F</xref>, p=0.026) and CV was not associated with mitochondrial ceramides (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1F</xref>, p=0.737). According to these results, ETC subunits exhibit differential sensitivity to mitochondrial ceramides, with CI subunits being the most sensitive in human muscle. To uncover structural changes in CI that could correlate with increased ceramide, we mapped those proteins significantly associated with mitochondrial ceramides to the bovine CI structure (<xref ref-type="bibr" rid="bib98">Zhu et al., 2016</xref>). Consistent with L6-mtSMPD5 myotubes, the N and Q modules were the regions with the most negative associated subunits with mitochondria ceramides in human muscle (<xref ref-type="fig" rid="fig6">Figure 6G</xref>). To determine the conservation in the changes in the mitochondrial proteome induced by increased ceramides, we compared the proteomes of mtSMPD5-L6 myotubes (72 hr after induction) and human muscle biopsies. We observed that across the two datasets CI and CIV subunits were downregulated after mtSMPD5 overexpression and were negatively associated with C18 ceramides in human samples (<xref ref-type="fig" rid="fig6">Figure 6H</xref>). In turn, CI and CIV were positively associated with muscle insulin sensitivity (<xref ref-type="fig" rid="fig6">Figure 6I</xref>), suggesting that these ETC subunits exhibited a conserved sensitivity to ceramide accumulation with a potential role in insulin sensitivity.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Insulin resistance is characterized by attenuated insulin-dependent glucose uptake in relevant target tissues, such as muscle and fat, and it plays a central role in cardiometabolic diseases (<xref ref-type="bibr" rid="bib47">James et al., 2021</xref>). In skeletal muscle, mitochondrial ceramides have been linked to insulin resistance (<xref ref-type="bibr" rid="bib69">Perreault et al., 2018</xref>); however, to date, no direct link connecting mitochondrial ceramides with insulin resistance has been established. Furthermore, CoQ depletion and defective mitochondria have also been independently associated with insulin resistance (<xref ref-type="bibr" rid="bib26">Fazakerley et al., 2018a</xref>; <xref ref-type="bibr" rid="bib46">Holland and Summers, 2008</xref>). In the current study, we present evidence suggesting that these factors are mechanistically linked inside mitochondria. Our data demonstrate that increased mitochondrial ceramides are both necessary and sufficient to induce insulin resistance in skeletal muscle. This is likely a function of increased ROS production that results from the specific depletion of the OXPHOS subunits and the concomitant loss of CoQ. Analysis of the human muscle mitochondrial proteome strongly supports mitochondrial ceramide-linked changes in the OXPHOS machinery as major drivers of insulin sensitivity. In this study, we mainly utilized L6 myotubes, which share many important characteristics with primary muscle fibers. Both types of cells exhibit high sensitivity to insulin and respond similarly to maximal doses of insulin, with GLUT4 translocation stimulated between 2 and 4 times over basal levels in response to 100 nM insulin (as shown in <xref ref-type="fig" rid="fig1">Figures 1</xref>—<xref ref-type="fig" rid="fig4">4</xref>, <xref ref-type="bibr" rid="bib77">Sánchez-Aguilera et al., 2018</xref>; <xref ref-type="bibr" rid="bib76">Rosales-Soto et al., 2020</xref>). Additionally, mitochondrial respiration in L6 myotubes has a similar sensitivity to mitochondrial poisons, as observed in primary muscle fibers (as shown in <xref ref-type="fig" rid="fig5">Figure 5</xref>, <xref ref-type="bibr" rid="bib90">Valladares et al., 2018</xref>). Finally, inhibiting ceramide production increases CoQ levels in both L6 myotubes and adult muscle tissue (as shown in <xref ref-type="fig" rid="fig2">Figures 2</xref> and <xref ref-type="fig" rid="fig3">3</xref>). Therefore, L6 myotubes possess the necessary metabolic features to investigate the role of mitochondria in insulin resistance, and this relationship is likely applicable to primary muscle fibers.</p><p>Many stressors, including chronic inflammation and anticancer drugs, stimulate endogenous ceramide generation (<xref ref-type="bibr" rid="bib14">Chalfant et al., 2002</xref>) and CoQ depletion in mitochondria (<xref ref-type="bibr" rid="bib87">Tesfay et al., 2019</xref>; <xref ref-type="bibr" rid="bib65">Morad et al., 2012</xref>). Nevertheless, experimental evidence testing the link between these molecules has been lacking. We observed that increased mitochondrial ceramides drive a depletion of mitochondrial CoQ leading to insulin resistance (<xref ref-type="fig" rid="fig1">Figures 1</xref> and <xref ref-type="fig" rid="fig2">2</xref>), and that reducing mitochondrial ceramide protects against the loss of CoQ and IR (<xref ref-type="fig" rid="fig3">Figure 3</xref>). These findings align with our earlier observations demonstrating that mice exposed to HFHSD exhibit mitochondrial CoQ depletion in skeletal muscle (<xref ref-type="bibr" rid="bib26">Fazakerley et al., 2018a</xref>). Given that CoQ supplementation is sufficient to overcome ceramide-induced IR (<xref ref-type="fig" rid="fig1">Figures 1</xref> and <xref ref-type="fig" rid="fig2">2</xref>), but a reduction in mitochondrial ceramide does not overcome a loss of CoQ (<xref ref-type="fig" rid="fig3">Figure 3</xref>), our data support a pathway whereby an increase in mitochondrial ceramides precedes loss of CoQ. Interestingly, inhibition of CoQ synthesis also increased ceramides, suggesting a bidirectionality to the ceramide–CoQ nexus. That said, this effect was modest (<xref ref-type="fig" rid="fig1">Figure 1</xref>) and we cannot exclude off-target effects of the inhibitor. It is possible that CoQ directly controls ceramide turnover (<xref ref-type="bibr" rid="bib29">Fernández-Ayala et al., 2000</xref>) or alternatively that CoQ inside mitochondria is necessary for fatty acid oxidation (<xref ref-type="bibr" rid="bib32">Frerman, 1988</xref>) and CoQ depletion triggers lipid overload in the cytoplasm promoting ceramide production (<xref ref-type="bibr" rid="bib52">Koves et al., 2008</xref>). Further studies will be needed to determine how CoQ depletion promotes ceramide accumulation.</p><p>Our proteomics analysis revealed that the loss of CoQ parallels a loss of mitochondrial ETC complexes CI, CIII, and CIV. These are known to form supercomplexes or respirasomes, where ~25–35% of CoQ are localized in mammals (<xref ref-type="bibr" rid="bib78">Schägger and Pfeiffer, 2000</xref>, <xref ref-type="bibr" rid="bib13">Calvo et al., 2020</xref>). This bulk downregulation of the respirasome induced by ceramides may lead to CoQ depletion. The observation that both palmitate and SMPD5 overexpression trigger CoQ depletion without additive effects supports the notion that ceramides may trigger the depletion of a specific CoQ9 pool localized within the IMM. Despite the significant impact of ceramide on mitochondrial respiration, we did not observe any indications of cell damage in any of the treatments, suggesting that our models are not explained by toxicity and increased cell death (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2H and J</xref>). While the physiological role of respirasomes is still a subject of discussion, it has been suggested that they may enhance energy generation by optimizing electron flow while reducing production of ROS (<xref ref-type="bibr" rid="bib56">Lapuente-Brun et al., 2013</xref>; <xref ref-type="bibr" rid="bib60">Maranzana et al., 2013</xref>), and, therefore, their loss can be predicted to increase ROS generation. The two major mechanisms that might account for the loss of the respirasomes are decreased synthesis or increased degradation. Proteomics data suggests no deficiency in the OXPHOS biosynthetic machinery or assembly proteins and an increase in the machinery for protein import (<xref ref-type="fig" rid="fig4">Figure 4</xref>). In addition, the absence of mRNA downregulation in mtSMPD5-overexpressing cells strongly suggests that at least a portion of the observed protein depletion within CI is attributed to diminished protein stability. It therefore seems reasonable to speculate that the loss of these mitochondrial complexes is driven by increased degradation. Interestingly, pharmacological CIII inhibition leads to respirasome degradation via oxidative stress produced by reverse electron transfer (RET) (<xref ref-type="bibr" rid="bib37">Guarás et al., 2016</xref>). Since ceramides can directly inhibit CIII (<xref ref-type="bibr" rid="bib38">Gudz et al., 1997</xref>), it is possible that a similar mechanism mediates the effect of ceramides on the respirasome (<xref ref-type="fig" rid="fig5">Figure 5</xref>). This suggests that defective respirasome activity (e.g., induced by ceramides) triggers ROS, which over time depletes respirasome subunits and a stoichiometric CoQ depletion, leading to further ROS production as a consequence. Another possibility is that, because of its highly hydrophobic nature, ceramides impact membrane fluidity promoting a gel/fluid phase transition (<xref ref-type="bibr" rid="bib71">Pinto et al., 2011</xref>). These alterations in membrane fluidity could decrease respirasome stability. It is likely that bound lipids stabilize the interactions between the complexes in the respirasome and that this is impaired by ceramides. In fact, bound lipid molecules are observed in the structure of the porcine respirasome (<xref ref-type="bibr" rid="bib93">Wu et al., 2016</xref>) and the isolated bovine CI (<xref ref-type="bibr" rid="bib93">Wu et al., 2016</xref>) but none of the lipids identified thus far directly bridge different complexes. In order to understand the role of lipids in stabilizing respirasomes and the role of ceramides in such stabilization, higher-resolution structures will be required (<xref ref-type="bibr" rid="bib62">Mileykovskaya and Dowhan, 2014</xref>).</p><p>The current studies pose a number of key unanswered questions. First, how does ceramide accumulate in mitochondria in insulin resistance? This could involve transfer from a different subcellular compartment (<xref ref-type="bibr" rid="bib4">Babiychuk et al., 2011</xref>; <xref ref-type="bibr" rid="bib3">Babiychuk et al., 2008</xref>) or in situ mitochondrial ceramide synthesis. Consistent with the latter, previous studies have suggested that various enzymes involved in ceramide metabolism are specifically found in mitochondria (<xref ref-type="bibr" rid="bib92">Wu et al., 2010</xref>; <xref ref-type="bibr" rid="bib6">Bionda et al., 2004</xref>; <xref ref-type="bibr" rid="bib66">Novgorodov et al., 2011</xref>; <xref ref-type="bibr" rid="bib7">Birbes et al., 2001</xref>; <xref ref-type="bibr" rid="bib96">Yu et al., 2007</xref>; <xref ref-type="bibr" rid="bib35">García-Ruiz et al., 1997</xref>). Notably, CerS1-derived ceramide induces insulin resistance in skeletal muscle (<xref ref-type="bibr" rid="bib89">Turpin-Nolan et al., 2019</xref>). Although this enzyme has not been reported as a mitochondrial protein, it can be transferred from the endoplasmic reticulum surface to the mitochondria under cellular stress in metabolically active tissues such as muscle and brain (<xref ref-type="bibr" rid="bib67">Oleinik et al., 2019</xref>). This provides a potential mechanism where cellular stress, like nutrient overload, may induce transfer of CerS1 to mitochondria, increasing mitochondrial ceramide to trigger insulin resistance.</p><p>A further question is how ceramide regulates insulin sensitivity. We present evidence that mitochondrial dysfunction precedes insulin resistance. However, previous studies have failed to observe changes in mitochondrial morphology, respiration, or ETC components during early stages of insulin resistance (<xref ref-type="bibr" rid="bib20">Diaz-Vegas et al., 2020</xref>; <xref ref-type="bibr" rid="bib8">Bonnard et al., 2008</xref>). However, in many cases such studies fail to document changes in insulin-dependent glucose metabolism in the same tissue as was used for assessment of mitochondrial function. This is crucial because we and others do not observe impaired insulin action in all muscles from high-fat fed mice for example (<xref ref-type="bibr" rid="bib26">Fazakerley et al., 2018a</xref>; <xref ref-type="bibr" rid="bib44">Hoehn et al., 2009</xref>). In addition, surrogate measures such as insulin-stimulated Akt phosphorylation may not accurately reflect tissue-specific insulin action as demonstrated in <xref ref-type="fig" rid="fig1">Figure 1C</xref>. Thus, further work is required to clarify some of these inconsistencies. We observed that mitochondrial ceramides were associated with the loss of CoQ, increased production of mitochondrial ROS, and impaired mitochondrial respiration (<xref ref-type="bibr" rid="bib26">Fazakerley et al., 2018a</xref>; <xref ref-type="bibr" rid="bib44">Hoehn et al., 2009</xref>; <xref ref-type="bibr" rid="bib27">Fazakerley et al., 2018b</xref>). As discussed above, this is likely a direct result of respirasome depletion. The molecular linkage between ROS production and IR remains unknown. Early studies suggested that ceramides and ROS impaired canonical insulin signaling (<xref ref-type="bibr" rid="bib84">Summers et al., 1998</xref>; <xref ref-type="bibr" rid="bib79">Schubert et al., 2000</xref>; <xref ref-type="bibr" rid="bib72">Powell et al., 2003</xref>); however, our current data do not support this, with the caveat that these were static signaling measures. One possibility is the release of a signaling molecule from the mitochondria that impairs insulin action (<xref ref-type="bibr" rid="bib70">Picard and Shirihai, 2022</xref>). The mitochondrial permeability transition pore (mPTP) is an attractive candidate for this release since its activity is increased by mitochondrial ROS (<xref ref-type="bibr" rid="bib99">Zorov et al., 2014</xref>) and ceramides (<xref ref-type="bibr" rid="bib82">Siskind et al., 2002</xref>). It has been shown that mPTP inhibition protects against insulin resistance in either palmitate- or ceramide-induced L6 myotubes and mice on an HFD (<xref ref-type="bibr" rid="bib86">Taddeo et al., 2014</xref>). Furthermore, mPTP deletion in the liver protects against liver steatosis and insulin resistance in mice (<xref ref-type="bibr" rid="bib16">Cho et al., 2017</xref>). Strikingly, CoQ is an antioxidant and also an inhibitor of mPTP, suggesting that part of the protective mechanism of CoQ may involve the mPTP (<xref ref-type="bibr" rid="bib91">Walter et al., 2000</xref>). Because CoQ can accumulate in various intracellular compartments, it is important to consider that its impact on insulin resistance might be due to its overall antioxidant properties rather than being limited to a mitochondrial effect. Excitingly, mtSMPD5 increased the abundance of mPTP-associated proteins, suggesting a role of this pore in ceramide-induced insulin resistance (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1I</xref>). It is also possible that ceramides generated within mitochondria in SMPD5 cells leak out from the mitochondria into other membranes (e.g., PM and GLUT4 vesicles) affecting other aspects of GLUT4 trafficking and insulin action. However, the observation that ASAH1 overexpression reversed IR without affecting whole-cell ceramides argues against this possibility.</p><p>Ultimately, the significant challenge for the field is the discovery of the unknown factor(s) released from mitochondria that cause insulin resistance, their molecular target(s), and the transduction mechanism(s).</p><p>The observations described above led us to speculate on whether there is a teleological reason for why these mitochondrial perturbations occur and why they drive insulin resistance. Under conditions of stress, nutrient incorporation into the cell needs to be adjusted to keep the balance between energy supply and utilization. In situations where the mitochondrial respirasome is depleted, the mitochondria’s ability to oxidize nutrients can be easily overwhelmed without a corresponding reduction in nutrient uptake. In this scenario, insulin resistance may be a protective mechanism to prevent mitochondrial nutrient oversupply (<xref ref-type="bibr" rid="bib44">Hoehn et al., 2009</xref>). Beyond nutrient uptake, the respirasome depletion could also affect the ability of the mitochondria to switch between different energy substrates depending on fuel availability, named ‘metabolic inflexibility’ (<xref ref-type="bibr" rid="bib34">Galgani and Fernández-Verdejo, 2021</xref>); this mechanism may potentially play a role in the ectopic lipid accumulation seen in individuals with obesity, a condition linked with cardiometabolic disease.</p><p>In summary, our results provide evidence for the existence of a mechanism inside mitochondria connecting ceramides, mitochondrial respiratory complexes, CoQ, and mitochondrial dysfunction as part of a core pathway leading to insulin resistance. We identified that CoQ depletion links ceramides with insulin resistance and define the respirasome as a critical connection between ceramides and mitochondrial dysfunction. While many pieces of the puzzle remain to be solved, identifying the temporal link between ceramide, mitochondrial dysfunction, and CoQ in mitochondria is an important step forward in understanding insulin resistance and other human diseases affecting mitochondrial function.</p><sec id="s3-1"><title>Lead contact</title><p>Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contacts, David James (David.james@sydney.edu.au) or James Burchfield (James.burchfield@sydney.edu.au).</p></sec><sec id="s3-2"><title>Materials availability</title><p>This study generated two new molecular tools to overexpress mitochondria-targeted SMPD5 and ASAH1. The plasmids are available upon request.</p></sec></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Administration of P053 to mice</title><p>Male mice of the C57BL/6J strain were obtained from the Animal Resources Centre of Perth (WA, Australia). Mice were housed in a controlled 12:12 hr light–dark cycle, and they had ad libitum access to water and food. The oral gavage administration of P053 (5 mg/kg) was performed daily, while the control animals received vehicle (2% DMSO). The experiments were approved by the UNSW animal care and ethics committee (ACEC 15/48B) and followed guidelines issued by the National Health and Medical Research Council of Australia.</p></sec><sec id="s4-2"><title>Cell lines</title><p>Mycoplasma-free L6 myotubes overexpressing HA-GLUT4 and HeLa cell lines were used for all in vitro experiments (detailed below each legend). HA-GLUT4 overexpression is essential for studying insulin sensitivity in vitro as we described previously (<xref ref-type="bibr" rid="bib44">Hoehn et al., 2009</xref>). L6-myoblast and HeLa cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) (Gibco by Life Technologies) supplemented with 10% fetal bovine serum (FBS) (v/v) (Gibco by Life Technologies) and 2 mM GlutaMAX (Gibco by Life Technologies) at 37°C and 10% CO<sub>2</sub>. L6 myoblasts were differentiated in DMEM/GlutaMAX/2% horse serum as described previously (<xref ref-type="bibr" rid="bib44">Hoehn et al., 2009</xref>). The media were replaced every 48 hr for 6 d. For induction of SMPD5 or ASAH1, L6 myotubes were incubated with doxycycline from day 3 until day 6 after the initiation of differentiation. L6 myotubes were used on day 7 after the initiation of differentiation. At least 90% of the cells were differentiated prior to experiments.</p></sec><sec id="s4-3"><title>Method details</title><sec id="s4-3-1"><title>Lentiviral transduction</title><p>Lentivirus was made by transfecting LentiX-293T (Takara Bio) cells with Lenti-X Packaging Single Shot (Takara Bio) with one of the following plasmids pLVX-Tet3G, pLVX-TRE3G-SMPD5-Myc-DDK, or pLVX-TRE3G-ASAH-Myc-DDK according to the manufacturer’s specifications. Virus-containing media were collected from the LentiX-293T cells and concentrated using Lenti-X Concentrator (Takara Bio). pLVX-Tet3G virus and polybrene were added to L6-myoblast cells and cells were positively selected using neomycin to create Tet3G-expressing cells. The Tet3G-expressing L6 cells were then subsequently infected with polybrene and either the pLVX-TRE3G-SMPD5-Myc-DDK or pLVX-TRE3G-ASAH-Myc-DDK virus. Cells were selected using puromycin to create a Tet-inducible SMPD5-Myc-Flag-DDK or ASAH-Myc-Flag-DDK L6 cell line.</p></sec><sec id="s4-3-2"><title>Lipid extraction</title><p>Two-phase extraction of lipids from frozen tissue samples (20 mg) or cells was carried out using the methyl-tert-butyl ether (MTBE)/methanol/water (10:3:2.5, v/v/v) method (<xref ref-type="bibr" rid="bib61">Matyash et al., 2008</xref>). Frozen tissue samples (~20 mg) were homogenized in 0.2 mL methanol (0.01% butylated hydroxytoluene [BHT]) using a Precellys 24 homogenizer and Cryolys cooling unit (Betin Technologies) with CK14 (1.4 mm ceramide) beads. HeLa cells and L6 myotubes were washed with PBS and scraped into 0.6 mL of ice-cold methanol (<xref ref-type="bibr" rid="bib88">Turner et al., 2018</xref>). Mitochondrial pellets were washed twice to remove BSA from the fraction (see below), and 30 ug of mitochondrial protein was used for extraction. The homogenates were spiked with an internal standard mixture (2 nmole of 18:1/15:0 d5-diacylglycerol and 18:1/17:0 SM, 4 nmole 14:0/14:0/14:0/14:0 cardiolipin, 5 nmole d7-cholesterol, 500 pmole 18:1/17:0 ceramide, and 200 pmole d17:1 sphingosine and d17:1 S1P), then transferred to 10 mL screw cap glass tubes. MTBE (1.7 mL) was added and the samples were sonicated for 30 min in an ice-cold sonicating water bath (Thermoline Scientific, Australia). Phase separation was induced by adding 417 µL of mass spectrometry-grade water with vortexing (max speed for 30 s), then centrifugation (1000 × <italic>g</italic> for 10 min). The upper organic phase was transferred into 5 mL glass tubes. The aqueous phase was re-extracted three times (MTBE/methanol/water 10:3:2.5), combining the organic phase in the 5 mL glass tube. The organic phase was dried under vacuum in a Savant SC210 SpeedVac (Thermo Scientific). Dried lipids were resuspended in 500 μL of 80% MeOH/0.2% formic acid/2 mM ammonium formate and stored at –20°C until analysis.</p></sec><sec id="s4-3-3"><title>Lipid quantification</title><p>Lipids were quantified by selected reaction monitoring on a TSQ Altis triple quadrupole mass spectrometer coupled to a Vanquish HPLC system (Thermo Fisher Scientific). Lipids were separated on a 2.1 100 mm Waters Acquity UPLC C18 column (1.7 µM pore size) using a flow rate of 0.28 mL/min. Mobile phase A was 0.1% formic acid and 10 mM ammonium formate in 60% acetonitrile/40% water. Mobile phase B was 0.1% formic acid and 10 mM ammonium formate in 90% isopropanol/10% acetonitrile. Total run time was 25 min, starting at 20% B and holding for 3 min, increasing to 100% B from 3 to 14 min, holding at 100% from 14 to 20 min, returning to 20% B at 20.5 min, and holding at 20% B for a further 4.5 min. Ceramides, sphingomyelin, sphingosine, and sphingosine 1-phosphate were identified as the [M+H]+precursor ion, with m/z 262.3 (sphinganine), 264.3 (sphingosine), or 266.3 (sphinganine) product ion, and m/z 184.1 product ion in the case of sphingomyelin. Diacylglycerols (DAGs) were identified as the [M + NH4]+ precursor ion and product ion corresponding to neutral loss of a fatty acid + NH<sub>3</sub>. Cardiolipins were identified as the [M + H]+ precursor ion and product ion corresponding to neutral loss of a DAG. Cholesterol was detected using precursor m/z 369.4 and product m/z 161.1. TraceFinder software (Thermo Fisher) was used for peak alignment and integration. The amount of each lipid was determined relative to its class-specific internal standard. Lipidomic profiling of skeletal muscle tissue was performed exactly as described (<xref ref-type="bibr" rid="bib88">Turner et al., 2018</xref>).</p></sec><sec id="s4-3-4"><title>Mass spectrometry sample preparation</title><p>Isolated mitochondria were defrosted and centrifuged at 4°C at 4000 × <italic>g</italic> for 15 min, and supernatant was removed. The mitochondrial pellet was resuspended in 100 uL 2% SDC in Tris-HCl buffer (100 mM; pH 8.0) and the protein concentration determined by BCA assay. 10 ug of each sample was aliquoted and volume adjusted to 50 uL with milli-Q water, and samples were reduced and alkylated by addition of TCEP and CAA (10 and 40 mM, respectively) at 60°C for 20 min. Once cooled to room temperature, 0.4 ug MS-grade trypsin and Lys-C were added to each sample, and proteins were digested overnight (16 hr) at 37°C. Peptides were prepared for MS analysis by SDB-RPS stage tips. Two layers of SDB-RPS material were packed into 200 µL tips and washed by centrifugation of StageTips at 1000 × <italic>g</italic> for 2 min in a 96-well adaptor with 50 µL acetonitrile followed by 0.2% TFA in 30% methanol and then 0.2% TFA in water. 50 µL of samples were loaded to StageTips by centrifugation at 1000 × <italic>g</italic> for 3 min. Stage tips were washed with subsequent spins at 1000 × <italic>g</italic> for 3 min with 50 uL 1% TFA in ethyl acetate, then 1% TFA in isopropanol, and 0.2% TFA in 5% ACN. Samples were eluted by addition of 60 µL 60% ACN with 5% NH<sub>4</sub>OH<sub>4</sub>. Samples were dried by vacuum centrifugation and reconstituted in 30 µL 0.1% TFA in 2% ACN.</p></sec><sec id="s4-3-5"><title>Mass spectrometry acquisition and analysis</title><p>Samples were analyzed using a Dionex UltiMate 3000 RSLCnano LC coupled to a Exploris Orbitrap mass spectrometer. 3 µL of peptide sample was injected onto an in-house packed 75 μm × 40 cm column (1.9 μm particle size, ReproSil Pur C18-AQ) and separated using a gradient elution, with buffer A consisting of 0.1% formic acid in water and buffer B consisting of 0.1% formic acid in 80% ACN. Samples were loaded to the column at a flow rate 0.5 µL/min at 3% B for 14 min, before dropping to 0.3 µL/min over 1 min and subsequent ramping to 30% B over 110 min, then to 60% B over 5 min and 98% B over 3 min and held for 6 min, before dropping to 50% and increasing flow rate to 0.5 µL/min over 1 min. Eluting peptides were ionized by electrospray with a spray voltage of 2.3 kV and a transfer capillary temperature of 300°C. Mass spectra were collected using a DIA method with varying isolation width windows (widths of m/z 22–589) between 350 and 1650. MS1 spectra were collected between m/z 350–1650 m/z at a resolution of 60,000. Ions were fragmented with an HCD collision energy at 30% and MS2 spectra collected between m/z 300–2000 at resolution of 30,000, with an AGC target of 3e5 and the maximum injection time set to automatic. Raw data files were searched using DIA-NN using a library generated from a 16-fraction high pH reverse phase library (<xref ref-type="bibr" rid="bib95">Yang et al., 2012</xref>). The protease was set to Trypsin/P with one missed cleavage, N-term M excision, carbamidomethylation, and M oxidation options on. Peptide length was set to 7–30, precursor range 350–1650, and fragment range 300–2000, and FDR set to 1%.</p></sec><sec id="s4-3-6"><title>Statistical analysis of L6 mitochondrial proteome</title><p>Mouse MitoCarta (REF) was mapped to <italic>Rattus norvegicus</italic> proteins using OrthoDB identifiers downloaded from UniProt. The Rat MitoCarta was used to annotate the L6 proteome. Manual scanning of the annotation revealed a number of known mitochondrial proteins not captured using this approach. Proteins were therefore classified as mitochondria if they were annotated by our mouse:rat MitoCarta (380 proteins), contained ‘mitochondrial’ in the protein name (78 additional proteins; 231 overlap with MitoCarta), or if the first entry under UniProt ‘Subcellular location’ was mitochondria (97 additional proteins; 374 overlap with MitoCarta or protein name). LFQ intensities were log 2 transformed and normalized to the median of the mitochondrially annotated proteins. Identification of differentially regulated proteins was performed using moderated <italic>t</italic>-tests (<xref ref-type="bibr" rid="bib83">Smyth, 2004</xref>). Functional enrichment was performed using the STRING web-based platform (<xref ref-type="bibr" rid="bib85">Szklarczyk et al., 2019</xref>).</p></sec><sec id="s4-3-7"><title>Statistical analysis of human proteome and mito-ER lipidome</title><p>Analysis of the human proteome and mito-ER lipidome was performed with R (version 4.2.1). Identification of differentially regulated proteins between each group was performed using the R package limma (<xref ref-type="bibr" rid="bib75">Ritchie et al., 2015</xref>), and p-values were corrected with p.adjust (method = “fdr”) within each comparison. Correlations were calculated with biweight midcorrelations from the R package WGCNA (<xref ref-type="bibr" rid="bib55">Langfelder and Horvath, 2008</xref>). Gene set enrichment was performed with the R package clusterProfiler (<xref ref-type="bibr" rid="bib94">Wu et al., 2021</xref>) utilizing pathways from Reactome for differentially regulated proteins (<xref ref-type="bibr" rid="bib25">Fabregat et al., 2018</xref>). Custom mitochondrial genes were constructed from HGNC Database (<xref ref-type="bibr" rid="bib80">Seal et al., 2023</xref>), and enrichment and enrichment figures were done with the R package fgsa (<ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/060012v3">https://www.biorxiv.org/content/10.1101/060012v3</ext-link>).</p></sec><sec id="s4-3-8"><title>High pH reverse-phase fractionation and library generation</title><p>A pooled sample was made by combining 1 uL of each sample and fractionated by high pH reverse-phase liquid chromatography. 50 uL of pooled sample was injected onto a Waters XBridge Peptide BEH C18 column (4.6 × 250 mm, 130 Å, 3.5 um) using a Thermo Scientific UltiMate 3000 BioRS System and peptides separated using gradient elution at 1 mL/min, with the column oven set to 30°C. Buffer A consisted of 10 mM ammonium formate, and buffer B consisted of 10 mM ammonium formate in 80% acetonitrile, which both adjusted to pH 9.0 with ammonium hydroxide. Initially buffer B was set to 10% and ramped up to 40% over 11 min, before ramping up to 100% B over 1 min and held for 5 min before returning to 10% for re-equilibration. Peptides were separated into 64 fractions collected between 3.45 min and 14.5 min, and samples were concatenated into 16 final fractions. Fractions were dried using a GeneVac 2.0 vacuum centrifuge using the HPLC program, with a maximum temperature of 60°C. Fractions were resuspended in 10 uL 0.1% TFA in 2% ACN and 2 uL was injected and separated as described for the DIA samples above; however, MS was acquired in a DDA manner. An MS1 was collected between m/z 350–1650 with a resolution of 60,000. The top 15 most intense precursors were selected from fragmentation with an isolation window of 1.4 m/z, resolution of 15,000, HCD collision energy of 30%, with an exclusion window of 30 s. Raw files were searched with MaxQuant against a FASTA file containing the reviewed UniProt human proteome (downloaded May 2020).</p></sec><sec id="s4-3-9"><title>Matrigel-coated plates</title><p>Matrigel diluted 1:100 v/v in ice-cold PBS was dispensed into 96-well plates (Eppendorf Cell Imaging plate, UNSPSC 41122107; and Perkin Elmer Cell Carrier Ultra, Cat# 6055300) and incubated for 2 hr at room temperature. Before use, plates were washed twice in PBS at room temperature.</p></sec><sec id="s4-3-10"><title>HA-GLUT4 assay</title><p>HA-GLUT4 levels on the PM were determined as described previously (<xref ref-type="bibr" rid="bib44">Hoehn et al., 2009</xref>; <xref ref-type="bibr" rid="bib36">Govers et al., 2004</xref>). L6 myotubes stably overexpressing HA-Glut4 were washed twice with warm PBS and serum-starved for 2 hr (in DMEM/0.2% BSA/GlutaMAX/with 220 mM bicarbonate [pH 7.4] at 37°C, 10% CO<sub>2</sub>). Cells were then stimulated with insulin for 20 min, after which the cells were placed on ice and washed three times with ice-cold PBS. Cells were blocked with ice-cold 10% horse serum in PBS for 20 min, fixed with 4% paraformaldehyde (PFA) for 5 min on ice and 20 min at room temperature. PFA was quenched with 50 mM glycine in PBS for 5 min at room temperature. We measured the accessibility of the HA epitope to an anti-HA antibody (Covance, 16B12) for 1 hr at room temperature. Cells were then incubated with 20 mg/mL goat anti-mouse Alexa-488-conjugated secondary antibody (Thermo Fisher Scientific) for 45 min at room temperature. The determination of total HA-GLUT4 was performed in a separate set of cells following permeabilization with 0.01% saponin (w/v) and anti-HA staining (as above). Each experimental treatment group had its own total HA-GLUT4. A FLuostar Galaxy microplate reader (BMG LABTECH) was used to measure fluorescence (excitation 485 nm/emission 520 nm). Surface HA-GLUT4 was expressed as a fold over control insulin condition.</p></sec><sec id="s4-3-11"><title>Induction of insulin resistance</title><p>To promote insulin resistance, cells were stimulated for 16 hr with 150 μM palmitate-BSA or EtOH-BSA as control. The palmitate was complexed with BSA as described previously (<xref ref-type="bibr" rid="bib44">Hoehn et al., 2009</xref>). Briefly, fatty acid was dissolved in 50% ethanol and then diluted 25 times in 10.5% fatty acid-free BSA solution. These stock solutions were further diluted in culture media to reach a final concentration of 150 μM (final lipid:BSA ratio 4:1).</p></sec><sec id="s4-3-12"><title>Glycogen synthesis assay</title><p>L6 myotubes overexpressing ASAH were grown and differentiated in 12-well plates, as described in the ‘Cell lines’ section, and stimulated for 16 hr with palmitate-BSA or EtOH-BSA, as detailed in the ‘Induction of insulin resistance’ section.</p><p>On day 7 of differentiation, myotubes were serum-starved in plain DMEM for three and a half hours. After incubation for 1 hr at 37°C with 2 µCi/mL D-[U-14C]-glucose in the presence or absence of 100 nM insulin, glycogen synthesis assay was performed, as described previously (<xref ref-type="bibr" rid="bib97">Zarini et al., 2022</xref>).</p></sec><sec id="s4-3-13"><title>Coenzyme Q determination</title><p>CoQ9 and CoQ10 content in cell lysates and mitochondrial fractions were determined as described previously (<xref ref-type="bibr" rid="bib12">Burger et al., 2020</xref>). Aliquots of 15 µg mitochondrial protein as prepared below were adjusted to a volume of 100 µL with water and subsequently mixed with 250 μL ice-cold methanol containing 0.1% HCl, 20 µL internal standard (CoQ8, 200 pmol in hexane, Avanti Polar Lipids), and 300 μL of hexane. The mixture was vortexed for 30 s, centrifuged (9000 × <italic>g</italic> × 5 min), and the supernatant was transferred into deepwell plate 96/1000 uL (Cat# 951032905). Samples were dried using a rotary evaporator (GeneVac, low BP at 45°C for 40 min). The resulting dried lipids were re-dissolved in 100 uL of 100% EtOH (HPLC grade), transferred into HPLC vials, and stored at –20°C until analysis by LC/MS.</p><p>LC-MS/MS was performed on a Vanquish LC (Thermo Fisher) coupled to a TSQ Altis triple quadrupole mass spectrometer (Thermo Fisher Scientific). Samples were kept in the autosampler at 4°C and 15 µL was injected on onto column (50 × 2.1 mm, Kinetex 2.6 μm XB-X18 100A) at 45°C, and CoQ8, CoQ9, and CoQ10 were separated by gradient elution using mobile phase A (2.5 mM ammonium formate in 95:5 methanol:isopropanol) and mobile phase B (2.5 mM ammonium formate in 100% isopropanol) at 0.8 mL/min. An initial concentration of 0% B was held for 1 min before increasing to 45% B over 1 min and held for 1 min, before decreasing back to 0% B over 0.5 min and column re-equilibrated over 1.5 min. Under these conditions, CoQ8 eluted at 1.0 min, CoQ9 at 1.6 min, and CoQ10 at 2.0 min. Eluent was then directed into the QqQ with a source voltage of 3.5 kV, sheath gas set to 2, auxiliary gas set to 2, and a transfer capillary temperature of 350°C. Ammonium adducts of each of the analytes were detected by SRM with Q1 and Q3 resolution set to 0.7 FWHM with the following parameters: [CoQ8 + NH4]+, m/z 744.9 197.1 with collision energy 32.76; [CoQ9 + NH4]+, m/z 812.9 197.1 with collision energy 32.76; [CoQ9H2 + NH4]+, m/z 814.9 197.1 with collision energy 36.4; and [CoQ10 + NH4]+, m/z 880.9 197.1 with collision energy 32.76. CoQ9 and CoQ10 areas were normalized to the internal standard CoQ8 levels (20 ng/mL). CoQ9 and CoQ10 were quantified against external standard curves generated from authentic commercial standards obtained from Sigma-Aldrich (USA).</p></sec><sec id="s4-3-14"><title>Mitochondrial isolation</title><p>Mitochondrial isolation from cultured L6 myotubes was performed as described elsewhere (<xref ref-type="bibr" rid="bib11">Bui et al., 2010</xref>; <xref ref-type="bibr" rid="bib33">Frezza et al., 2007</xref>). Briefly, cells were homogenized in an ice-cold mitochondrial isolation buffer (5 mM HEPES, 0.5 mM EGTA, 200 mM mannitol, and 0.1% BSA, pH 7.4 containing protease inhibitors) using a Cell Homogenizer with 18 micron ball. Cells were passed through the Cell Homogenizer 10 times using 1 mL syringe. Cell Homogenizer was equilibrated with 1 mL of ice-cold isolation buffer prior to the experiment. Homogenates were centrifuged at 700 × <italic>g</italic> for 10 min and the supernatant centrifuged at 10,300 × <italic>g</italic> for 10 min to generate the crude mitochondrial pellet. The 10,300 × <italic>g</italic> pellet was resuspended in 1 mL of isolation buffer and transferred into a polycarbonate tube containing 7.9 mL of 18% Percoll in the homogenization buffer and centrifuged at 95,000 × <italic>g</italic> at 4°C for 30 min. The mitochondrial pellet was collected and diluted in a homogenization buffer (1 mL) and centrifuged at 10,000 × <italic>g</italic> for 10 min at 4°C. The supernatant was discarded, and the pellet was washed with a homogenization buffer without BSA, followed by protein quantification with BCA protein assay.</p><p>Mitochondria from adult skeletal muscle (from mixed hindlimb muscle) were isolated by differential centrifugation as described previously (<xref ref-type="bibr" rid="bib63">Montgomery et al., 2019</xref>). Briefly, muscle was diced in CP-1 medium (100 mM KCl, 50 mM Tris/HCl, pH 7.4, and 2 mM EGTA), digested on ice for 3 min in CP-2 medium (CP-1, to which was added 0.5% [w/v] BSA, 5 mM MgCl<sub>2</sub>, 1 mM ATP and 2.45 units/mL Protease Type VIII [Sigma P 5380]) and homogenized using an ultra-turrax homogenizer. The homogenate was spun for 5 min at 500 × <italic>g</italic> and 4°C. The resulting supernatant was subjected to a high-speed spin (10,600 × <italic>g</italic>, 10 min, 4°C), and the mitochondrial pellet was resuspended in CP-1. The 10,600 × <italic>g</italic> spin cycle was repeated, the supernatant removed, and the mitochondrial pellet snapped frozen.</p></sec><sec id="s4-3-15"><title>Western blotting</title><p>After insulin stimulation or mitochondrial isolation, samples were tip sonicated in 2% SDS-RIPA. Insoluble material was removed by centrifugation at 21,000 × <italic>g</italic> × 10 min. Protein concentration was determined by bicinchoninic acid method (Thermo Scientific). 10 μg of protein was resolved by SDS-PAGE and transferred to PDVF membranes. Membranes were blocked in Tris-buffered saline (TBS) 4% skim milk for 30 min at room temperature, followed by primary antibody incubation (detailed antibodies are provided in the ‘<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>’). Membranes were washed in TBS 0.1% Tween (TBS-T) and incubated with appropriate secondary antibodies (IRDye700- or IRDye800-conjugated) in TBS-T 2% skim milk for 45 min at room temperature. Images were obtained by using 700 or 800 nm channels using Odyssey IR imager. Densitometry analysis of immunoblots was performed using Image Studio Lite (version 5.2). Uncropped western blots are provided in the supplementary material.</p></sec><sec id="s4-3-16"><title>Seahorse extracellular flux analyses</title><p>Mitochondrial respiration (<italic>J</italic>O<sub>2</sub>) of intact cells were measured using an XF HS mini Analyser Extracellular Flux Analyzer (Seahorse Bioscience, Copenhagen, Denmark). L6 myoblasts were seeded and differentiated in Seahorse XFp culture plates coated with Matrigel and assayed after incubation at 37°C without CO<sub>2</sub> for 1 hr. Prior to the assay, cells were washed three times with PBS, once with bicarbonate-free DMEM buffered with 30 mM Na-HEPES, pH 7.4 (DMEM/HEPES), and then incubated in DMEM/HEPES supplemented with 0.2% (w/v) BSA, 25 mM glucose, 1 mM GlutaMAX, and 1 mM glutamine (Media B), for 1.5 hr in a non-CO<sub>2</sub> incubator at 37°C. During the assay, respiration was assayed with mix/wait/read cycles of 2/0/2 min for L6 myotubes. Following assessment of basal respiration, the following compounds (final concentrations in parentheses) were injected sequentially: oligoymcin (10 μg/mL), BAM15 (10 mM), and rotenone/antimycin A (5 μM/10 μM). All of these reagents were obtained from Sigma-Aldrich. Basal (baseline – Ant./Rot), ATP-linked respiration (determined by basal – oligomycin), maximal respiration (calculated by FCCP – AntA/Rot), and non-mitochondrial respiration (equal to AntA/Rot) were determined as described previously (<xref ref-type="bibr" rid="bib22">Díaz-Vegas et al., 2018</xref>). Protein concentration was determined immediately after the assay and data are presented as O<sub>2</sub>/min. Complex specific activity in permeabilized cells was performed according to <xref ref-type="bibr" rid="bib51">Kory et al., 2020</xref>. The cells were seeded and the media changed to a buffer consisting of 70 mM sucrose, 220 mM mannitol, 10 mM KH<sub>2</sub>PO<sub>4</sub>, 5 mM MgCl<sub>2</sub>, 2 mM HEPES (pH 7.2), 1 mM EGTA, and 0.4% BSA. Then, flux measurements began after taking three baseline measurements. The cells were permeabilized by adding digitonin (1 nM) and 1 mM ADP, followed by injecting respiratory complex substrates or ADP only (complex I, glutamate/malate [5 mM/2.5 mM]; complex II, succinate/rotenone [10 mM/1 μM]; complex III, and complex IV, N,N,N,N-tetramethyl-<italic>p</italic>-phenylenediamine/ascorbate [0.5 mM/2 mM]). Subsequently, oligomycin (1 μg/mL) and respective complex inhibitors were added (complex I, 1 μM rotenone; complexes II and III, 20 μM antimycin A; complex IV, 20 mM sodium azide). Wells where cells detached from the plate during the assay were excluded from the analysis.</p></sec><sec id="s4-3-17"><title>Mitochondrial membrane potential</title><p>Mitochondrial membrane potential was measured by loading cells with 20 nM tetramethylrhodamine, ethyl ester (TMRM+, Life Technologies) for 30 min at 37°C plus MitoTracker Deep Red (MTDR). MTDR was used to normalize the fluorescence among the different mitochondrial populations as reported previously (<xref ref-type="bibr" rid="bib22">Díaz-Vegas et al., 2018</xref>). TMRM+ fluorescence was detected using the excitation-emission λ545–580/590 nm, and MTDR was detected using an ex/em ∼644/665 nm using confocal microscopy. The mitochondrial membrane potential was evaluated as raw fluorescence intensity of background-corrected images.</p></sec><sec id="s4-3-18"><title>Mitochondrial oxidative stress</title><p>MitoSOX Red was administered as described by the manufacturer (Molecular Probes); at the end of the induction period, cells were washed twice with PBS and incubated with 0.5 μM MitoSOX Red for 30 min plus MTDR. MTDR was used to normalize the fluorescence among the different mitochondrial populations as reported previously reported. Cells were cultured in low-absorbance, black-walled 96-well plates. After MitoSOX treatment, cells were quickly washed with PBS and fluorescence was detected on a confocal microscope. MitoSOX fluorescence was detected using the excitation–emission λ396/610 nm, and MTDR was detected using an ex/em ~644/665 nm using confocal microscopy.</p></sec></sec><sec id="s4-4"><title>RT-PCR</title><p>RNA was extracted by addition of TRIzol (Thermo Fisher) followed by addition of 0.1× volume of 1-bromo-3-chloropropane. Samples were centrifuged at 13,000 × <italic>g</italic> for 15 min for phase separation. The clear phase was transferred to a fresh tube and an equal volume of isopropanol was added. Samples were centrifuged at 13,000 × <italic>g</italic> for 10 min to precipitate RNA. RNA was washed three times in 70% ethanol with centrifugation. RNA was resuspended in DEPC-treated water and quantified on a NanoDrop 2000 (Thermo Scientific). RNA was reverse-transcribed to cDNA using PrimeScript Reverse Transcriptase (Takara) as per the manufacturer’s instructions. qPCR was performed using FastStart SYBR Green MasterMix (2x) (Bio-Rad) as per the manufacturer’s instructions. All primer sequences can be found in <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>.</p></sec><sec id="s4-5"><title>Statistical analysis</title><p>Data are presented as mean ± SEM. Statistical tests were performed using GraphPad Prism version 9. We employed Student’s <italic>t</italic>-test and one-way ANOVA followed by Dunnett’s post-test for paired data and multiple comparisons, respectively. HA-GLUT4 and western blot assay was analyzed by using Kruskal–Wallis with Dunn’s multiple-comparison test. CoQ and ceramide abundance were analyzed with ordinary one-way ANOVA and Dunnett’s multiple-comparison test. Finally, for comparison of two groups (CoQ and ceramides levels in mice), we used Student’s <italic>t</italic>-test. Significant effects were defined as p&lt;0.05 by these tests as reported in the figures.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>is an employee of Eli Lilly. The author has no other competing interests to declare</p></fn><fn fn-type="COI-statement" id="conf3"><p>Senior editor, eLife</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Data curation, Formal analysis, Writing – original draft</p></fn><fn fn-type="con" id="con3"><p>Data curation, Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con4"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con5"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con6"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con7"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con8"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con9"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con10"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con11"><p>Investigation</p></fn><fn fn-type="con" id="con12"><p>Conceptualization, Investigation, Methodology</p></fn><fn fn-type="con" id="con13"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con14"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con15"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con16"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con17"><p>Conceptualization, Supervision, Funding acquisition, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con18"><p>Conceptualization, Resources, Formal analysis, Supervision, Funding acquisition, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>This study involving human participants received ethical clearance and authorization from the Colorado Multiple Institution Review Board at the University of Colorado Anschutz Medical Campus. Prior to their involvement in the study, all participants submitted written informed consent. All information regarding this ethic approval can be found in JCI.</p></fn><fn fn-type="other"><p>The experiments obtained approval from the UNSW animal care and ethics committee (ACEC 15/48B) and adhered to the guidelines set forth by the National Health and Medical Research Council of Australia. All information regarding this ethic approval can be found in Nat Commun. 2018; 9: 3165.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-87340-mdarchecklist1-v1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Reagents.</title></caption><media xlink:href="elife-87340-supp1-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Sequences.</title></caption><media xlink:href="elife-87340-supp2-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="sdata1"><label>Source data 1.</label><caption><title>Uncropped gels <xref ref-type="fig" rid="fig2">Figures 2</xref> and <xref ref-type="fig" rid="fig3">3F</xref>.</title></caption><media xlink:href="elife-87340-data1-v1.zip" mimetype="application" mime-subtype="zip"/></supplementary-material><supplementary-material id="sdata2"><label>Source data 2.</label><caption><title>Uncropped gells <xref ref-type="fig" rid="fig2">Figures 2F</xref> and <xref ref-type="fig" rid="fig3">3</xref>.</title></caption><media xlink:href="elife-87340-data2-v1.zip" mimetype="application" mime-subtype="zip"/></supplementary-material><supplementary-material id="sdata3"><label>Source data 3.</label><caption><title>Lipidomic analysis L6.</title></caption><media xlink:href="elife-87340-data3-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="sdata4"><label>Source data 4.</label><caption><title>Lipidomic analysis Hela.</title></caption><media xlink:href="elife-87340-data4-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="sdata5"><label>Source data 5.</label><caption><title>Lipidomic analysis L6s with mtSMPD5 overexpression.</title></caption><media xlink:href="elife-87340-data5-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="sdata6"><label>Source data 6.</label><caption><title>Lipidomic analysis of mice exposed to chow or HFD with or without P051.</title></caption><media xlink:href="elife-87340-data6-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="sdata7"><label>Source data 7.</label><caption><title>Correlation analysis of lipidomics and proteomics in human samples.</title></caption><media xlink:href="elife-87340-data7-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="sdata8"><label>Source data 8.</label><caption><title>Correlation analysis between proteomics and human traits.</title></caption><media xlink:href="elife-87340-data8-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="sdata9"><label>Source data 9.</label><caption><title>Correlation analysis between C18 ceramides and human muscle proteomics.</title></caption><media xlink:href="elife-87340-data9-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="sdata10"><label>Source data 10.</label><caption><title>Human proteomics PairWiseComp.</title></caption><media xlink:href="elife-87340-data10-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="sdata11"><label>Source data 11.</label><caption><title>Human proteomics analysis median normalised.</title></caption><media xlink:href="elife-87340-data11-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="sdata12"><label>Source data 12.</label><caption><title>Human proteomics analysis Rd_clamp_correlation_all_protein.</title></caption><media xlink:href="elife-87340-data12-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All Lipidomic and proteomic analyses are available as supporting files. Uncropped western blotting are found in source data files.</p></sec><ack id="ack"><title>Acknowledgements</title><p>This work was supported by the National Health and Medical Research Council (NHMRC) Project Grants: GNT1120201 and GNT1061122 to DEJ; GNT2013621 to JGB, DEJ, and ADV; and GNT112613 to NT, JM, and AD. BCB received a research grant from Eli Lilly and from NIH R01DK111559. DEJ is an Australian Research Council (ARC) Laureate Fellow. JGB and ADV were supported by the Diabetes Australian Research Program (Y22G-DIAA) and the Mitochondrial Foundation (Mitofoundation, G057). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NHMRC or ARC. The authors also acknowledge the facilities, and the scientific and technical assistance of Sydney Cytometry and the Sydney Mass Spectrometry Facility, at the Charles Perkins Centre, University of Sydney. The authors are extremely grateful to Scott A Summers, William L Holland, and Navdeep S Chandel for their thoughtful discussion of the project.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>EJ</given-names></name><name><surname>Lustig</surname><given-names>ME</given-names></name><name><surname>Boyle</surname><given-names>KE</given-names></name><name><surname>Woodlief</surname><given-names>TL</given-names></name><name><surname>Kane</surname><given-names>DA</given-names></name><name><surname>Lin</surname><given-names>CT</given-names></name><name><surname>Price</surname><given-names>JW</given-names></name><name><surname>Kang</surname><given-names>L</given-names></name><name><surname>Rabinovitch</surname><given-names>PS</given-names></name><name><surname>Szeto</surname><given-names>HH</given-names></name><name><surname>Houmard</surname><given-names>JA</given-names></name><name><surname>Cortright</surname><given-names>RN</given-names></name><name><surname>Wasserman</surname><given-names>DH</given-names></name><name><surname>Neufer</surname><given-names>PD</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Mitochondrial H2O2 emission and cellular redox state link excess fat intake to insulin resistance in both rodents and humans</article-title><source>The Journal of Clinical Investigation</source><volume>119</volume><fpage>573</fpage><lpage>581</lpage><pub-id pub-id-type="doi">10.1172/JCI37048</pub-id><pub-id pub-id-type="pmid">19188683</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ates</surname><given-names>O</given-names></name><name><surname>Bilen</surname><given-names>H</given-names></name><name><surname>Keles</surname><given-names>S</given-names></name><name><surname>Alp</surname><given-names>HH</given-names></name><name><surname>Keleş</surname><given-names>MS</given-names></name><name><surname>Yıldırım</surname><given-names>K</given-names></name><name><surname>Ondaş</surname><given-names>O</given-names></name><name><surname>Pınar</surname><given-names>LC</given-names></name><name><surname>Civelekler</surname><given-names>M</given-names></name><name><surname>Baykal</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Plasma coenzyme Q10 levels in type 2 diabetic patients with retinopathy</article-title><source>International Journal of Ophthalmology</source><volume>6</volume><fpage>675</fpage><lpage>679</lpage><pub-id pub-id-type="doi">10.3980/j.issn.2222-3959.2013.05.24</pub-id><pub-id pub-id-type="pmid">24195048</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Babiychuk</surname><given-names>EB</given-names></name><name><surname>Monastyrskaya</surname><given-names>K</given-names></name><name><surname>Draeger</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Fluorescent annexin A1 reveals dynamics of ceramide platforms in living cells</article-title><source>Traffic</source><volume>9</volume><fpage>1757</fpage><lpage>1775</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0854.2008.00800.x</pub-id><pub-id pub-id-type="pmid">18694456</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Babiychuk</surname><given-names>EB</given-names></name><name><surname>Atanassoff</surname><given-names>AP</given-names></name><name><surname>Monastyrskaya</surname><given-names>K</given-names></name><name><surname>Brandenberger</surname><given-names>C</given-names></name><name><surname>Studer</surname><given-names>D</given-names></name><name><surname>Allemann</surname><given-names>C</given-names></name><name><surname>Draeger</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The targeting of plasmalemmal ceramide to mitochondria during apoptosis</article-title><source>PLOS ONE</source><volume>6</volume><elocation-id>e23706</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0023706</pub-id><pub-id pub-id-type="pmid">21886813</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bienias</surname><given-names>K</given-names></name><name><surname>Fiedorowicz</surname><given-names>A</given-names></name><name><surname>Sadowska</surname><given-names>A</given-names></name><name><surname>Prokopiuk</surname><given-names>S</given-names></name><name><surname>Car</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Regulation of sphingomyelin metabolism</article-title><source>Pharmacological Reports</source><volume>68</volume><fpage>570</fpage><lpage>581</lpage><pub-id pub-id-type="doi">10.1016/j.pharep.2015.12.008</pub-id><pub-id pub-id-type="pmid">26940196</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bionda</surname><given-names>C</given-names></name><name><surname>Portoukalian</surname><given-names>J</given-names></name><name><surname>Schmitt</surname><given-names>D</given-names></name><name><surname>Rodriguez-Lafrasse</surname><given-names>C</given-names></name><name><surname>Ardail</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Subcellular compartmentalization of ceramide metabolism: MAM (mitochondria-associated membrane) and/or mitochondria?</article-title><source>The Biochemical Journal</source><volume>382</volume><fpage>527</fpage><lpage>533</lpage><pub-id pub-id-type="doi">10.1042/BJ20031819</pub-id><pub-id pub-id-type="pmid">15144238</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Birbes</surname><given-names>H</given-names></name><name><surname>El Bawab</surname><given-names>S</given-names></name><name><surname>Hannun</surname><given-names>YA</given-names></name><name><surname>Obeid</surname><given-names>LM</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Selective hydrolysis of a mitochondrial pool of sphingomyelin induces apoptosis</article-title><source>FASEB Journal</source><volume>15</volume><fpage>2669</fpage><lpage>2679</lpage><pub-id pub-id-type="doi">10.1096/fj.01-0539com</pub-id><pub-id pub-id-type="pmid">11726543</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonnard</surname><given-names>C</given-names></name><name><surname>Durand</surname><given-names>A</given-names></name><name><surname>Peyrol</surname><given-names>S</given-names></name><name><surname>Chanseaume</surname><given-names>E</given-names></name><name><surname>Chauvin</surname><given-names>M-A</given-names></name><name><surname>Morio</surname><given-names>B</given-names></name><name><surname>Vidal</surname><given-names>H</given-names></name><name><surname>Rieusset</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Mitochondrial dysfunction results from oxidative stress in the skeletal muscle of diet-induced insulin-resistant mice</article-title><source>The Journal of Clinical Investigation</source><volume>118</volume><fpage>789</fpage><lpage>800</lpage><pub-id pub-id-type="doi">10.1172/JCI32601</pub-id><pub-id pub-id-type="pmid">18188455</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brand</surname><given-names>MD</given-names></name><name><surname>Nicholls</surname><given-names>DG</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Assessing mitochondrial dysfunction in cells</article-title><source>The Biochemical Journal</source><volume>435</volume><fpage>297</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1042/BJ20110162</pub-id><pub-id pub-id-type="pmid">21726199</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruce</surname><given-names>CR</given-names></name><name><surname>Hoy</surname><given-names>AJ</given-names></name><name><surname>Turner</surname><given-names>N</given-names></name><name><surname>Watt</surname><given-names>MJ</given-names></name><name><surname>Allen</surname><given-names>TL</given-names></name><name><surname>Carpenter</surname><given-names>K</given-names></name><name><surname>Cooney</surname><given-names>GJ</given-names></name><name><surname>Febbraio</surname><given-names>MA</given-names></name><name><surname>Kraegen</surname><given-names>EW</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Overexpression of carnitine palmitoyltransferase-1 in skeletal muscle is sufficient to enhance fatty acid oxidation and improve high-fat diet-induced insulin resistance</article-title><source>Diabetes</source><volume>58</volume><fpage>550</fpage><lpage>558</lpage><pub-id pub-id-type="doi">10.2337/db08-1078</pub-id><pub-id pub-id-type="pmid">19073774</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bui</surname><given-names>M</given-names></name><name><surname>Gilady</surname><given-names>SY</given-names></name><name><surname>Fitzsimmons</surname><given-names>REB</given-names></name><name><surname>Benson</surname><given-names>MD</given-names></name><name><surname>Lynes</surname><given-names>EM</given-names></name><name><surname>Gesson</surname><given-names>K</given-names></name><name><surname>Alto</surname><given-names>NM</given-names></name><name><surname>Strack</surname><given-names>S</given-names></name><name><surname>Scott</surname><given-names>JD</given-names></name><name><surname>Simmen</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Rab32 modulates apoptosis onset and mitochondria-associated membrane (MAM) properties</article-title><source>The Journal of Biological Chemistry</source><volume>285</volume><fpage>31590</fpage><lpage>31602</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.101584</pub-id><pub-id pub-id-type="pmid">20670942</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burger</surname><given-names>N</given-names></name><name><surname>Logan</surname><given-names>A</given-names></name><name><surname>Prime</surname><given-names>TA</given-names></name><name><surname>Mottahedin</surname><given-names>A</given-names></name><name><surname>Caldwell</surname><given-names>ST</given-names></name><name><surname>Krieg</surname><given-names>T</given-names></name><name><surname>Hartley</surname><given-names>RC</given-names></name><name><surname>James</surname><given-names>AM</given-names></name><name><surname>Murphy</surname><given-names>MP</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A sensitive mass spectrometric assay for mitochondrial CoQ pool redox state in vivo</article-title><source>Free Radical Biology &amp; Medicine</source><volume>147</volume><fpage>37</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2019.11.028</pub-id><pub-id pub-id-type="pmid">31811922</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calvo</surname><given-names>E</given-names></name><name><surname>Cogliati</surname><given-names>S</given-names></name><name><surname>Hernansanz-Agustín</surname><given-names>P</given-names></name><name><surname>Loureiro-López</surname><given-names>M</given-names></name><name><surname>Guarás</surname><given-names>A</given-names></name><name><surname>Casuso</surname><given-names>RA</given-names></name><name><surname>García-Marqués</surname><given-names>F</given-names></name><name><surname>Acín-Pérez</surname><given-names>R</given-names></name><name><surname>Martí-Mateos</surname><given-names>Y</given-names></name><name><surname>Silla-Castro</surname><given-names>JC</given-names></name><name><surname>Carro-Alvarellos</surname><given-names>M</given-names></name><name><surname>Huertas</surname><given-names>JR</given-names></name><name><surname>Vázquez</surname><given-names>J</given-names></name><name><surname>Enríquez</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Functional role of respiratory supercomplexes in mice: SCAF1 relevance and segmentation of the Q<sub>pool</sub></article-title><source>Science Advances</source><volume>6</volume><elocation-id>eaba7509</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.aba7509</pub-id><pub-id pub-id-type="pmid">32637615</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chalfant</surname><given-names>CE</given-names></name><name><surname>Rathman</surname><given-names>K</given-names></name><name><surname>Pinkerman</surname><given-names>RL</given-names></name><name><surname>Wood</surname><given-names>RE</given-names></name><name><surname>Obeid</surname><given-names>LM</given-names></name><name><surname>Ogretmen</surname><given-names>B</given-names></name><name><surname>Hannun</surname><given-names>YA</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>De Novo Ceramide regulates the alternative splicing of Caspase 9 and Bcl-x in A549 Lung Adenocarcinoma Cells</article-title><source>Journal of Biological Chemistry</source><volume>277</volume><fpage>12587</fpage><lpage>12595</lpage><pub-id pub-id-type="doi">10.1074/jbc.M112010200</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaurasia</surname><given-names>B</given-names></name><name><surname>Summers</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Ceramides in metabolism: key lipotoxic players</article-title><source>Annual Review of Physiology</source><volume>83</volume><fpage>303</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1146/annurev-physiol-031620-093815</pub-id><pub-id pub-id-type="pmid">33158378</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Park</surname><given-names>S-Y</given-names></name><name><surname>Joseph</surname><given-names>A-M</given-names></name><name><surname>Han</surname><given-names>C</given-names></name><name><surname>Park</surname><given-names>H-J</given-names></name><name><surname>Kalavalapalli</surname><given-names>S</given-names></name><name><surname>Chun</surname><given-names>S-K</given-names></name><name><surname>Morgan</surname><given-names>D</given-names></name><name><surname>Kim</surname><given-names>J-S</given-names></name><name><surname>Someya</surname><given-names>S</given-names></name><name><surname>Mathews</surname><given-names>CE</given-names></name><name><surname>Lee</surname><given-names>YJ</given-names></name><name><surname>Wohlgemuth</surname><given-names>SE</given-names></name><name><surname>Sunny</surname><given-names>NE</given-names></name><name><surname>Lee</surname><given-names>H-Y</given-names></name><name><surname>Choi</surname><given-names>CS</given-names></name><name><surname>Shiratsuchi</surname><given-names>T</given-names></name><name><surname>Oh</surname><given-names>SP</given-names></name><name><surname>Terada</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Mitochondrial ATP transporter depletion protects mice against liver steatosis and insulin resistance</article-title><source>Nature Communications</source><volume>8</volume><elocation-id>14477</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms14477</pub-id><pub-id pub-id-type="pmid">28205519</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cong</surname><given-names>LN</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>McGibbon</surname><given-names>MA</given-names></name><name><surname>Taylor</surname><given-names>SI</given-names></name><name><surname>Quon</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Physiological role of Akt in insulin-stimulated translocation of GLUT4 in transfected rat adipose cells</article-title><source>Molecular Endocrinology</source><volume>11</volume><fpage>1881</fpage><lpage>1890</lpage><pub-id pub-id-type="doi">10.1210/mend.11.13.0027</pub-id><pub-id pub-id-type="pmid">9415393</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Das</surname><given-names>AT</given-names></name><name><surname>Tenenbaum</surname><given-names>L</given-names></name><name><surname>Berkhout</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Tet-on systems for doxycycline-inducible gene expression</article-title><source>Current Gene Therapy</source><volume>16</volume><fpage>156</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.2174/1566523216666160524144041</pub-id><pub-id pub-id-type="pmid">27216914</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Barcelos</surname><given-names>I</given-names></name><name><surname>Haas</surname><given-names>RH</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>CoQ10 and Aging</article-title><source>Biology</source><volume>8</volume><elocation-id>28</elocation-id><pub-id pub-id-type="doi">10.3390/biology8020028</pub-id><pub-id pub-id-type="pmid">31083534</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diaz-Vegas</surname><given-names>A</given-names></name><name><surname>Sanchez-Aguilera</surname><given-names>P</given-names></name><name><surname>Krycer</surname><given-names>JR</given-names></name><name><surname>Morales</surname><given-names>PE</given-names></name><name><surname>Monsalves-Alvarez</surname><given-names>M</given-names></name><name><surname>Cifuentes</surname><given-names>M</given-names></name><name><surname>Rothermel</surname><given-names>BA</given-names></name><name><surname>Lavandero</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Is mitochondrial dysfunction a common root of noncommunicable chronic diseases?</article-title><source>Endocrine Reviews</source><volume>41</volume><elocation-id>bnaa005</elocation-id><pub-id pub-id-type="doi">10.1210/endrev/bnaa005</pub-id><pub-id pub-id-type="pmid">32179913</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Paola</surname><given-names>M</given-names></name><name><surname>Cocco</surname><given-names>T</given-names></name><name><surname>Lorusso</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Ceramide interaction with the respiratory chain of heart mitochondria</article-title><source>Biochemistry</source><volume>39</volume><fpage>6660</fpage><lpage>6668</lpage><pub-id pub-id-type="doi">10.1021/bi9924415</pub-id><pub-id pub-id-type="pmid">10828984</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Díaz-Vegas</surname><given-names>AR</given-names></name><name><surname>Cordova</surname><given-names>A</given-names></name><name><surname>Valladares</surname><given-names>D</given-names></name><name><surname>Llanos</surname><given-names>P</given-names></name><name><surname>Hidalgo</surname><given-names>C</given-names></name><name><surname>Gherardi</surname><given-names>G</given-names></name><name><surname>De Stefani</surname><given-names>D</given-names></name><name><surname>Mammucari</surname><given-names>C</given-names></name><name><surname>Rizzuto</surname><given-names>R</given-names></name><name><surname>Contreras-Ferrat</surname><given-names>A</given-names></name><name><surname>Jaimovich</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Mitochondrial calcium increase induced by RyR1 and IP3R channel activation after membrane depolarization regulates skeletal muscle metabolism</article-title><source>Frontiers in Physiology</source><volume>9</volume><elocation-id>791</elocation-id><pub-id pub-id-type="doi">10.3389/fphys.2018.00791</pub-id><pub-id pub-id-type="pmid">29988564</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-ghoroury</surname><given-names>EA</given-names></name><name><surname>Raslan</surname><given-names>HM</given-names></name><name><surname>Badawy</surname><given-names>EA</given-names></name><name><surname>El-Saaid</surname><given-names>GS</given-names></name><name><surname>Agybi</surname><given-names>MH</given-names></name><name><surname>Siam</surname><given-names>I</given-names></name><name><surname>Salem</surname><given-names>SI</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Malondialdehyde and coenzyme Q10 in platelets and serum in type 2 diabetes mellitus: correlation with glycemic control</article-title><source>Blood Coagulation &amp; Fibrinolysis</source><volume>20</volume><fpage>248</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1097/mbc.0b013e3283254549</pub-id><pub-id pub-id-type="pmid">19530339</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ertunc</surname><given-names>ME</given-names></name><name><surname>Hotamisligil</surname><given-names>GS</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Lipid signaling and lipotoxicity in metaflammation: indications for metabolic disease pathogenesis and treatment</article-title><source>Journal of Lipid Research</source><volume>57</volume><fpage>2099</fpage><lpage>2114</lpage><pub-id pub-id-type="doi">10.1194/jlr.R066514</pub-id><pub-id pub-id-type="pmid">27330055</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fabregat</surname><given-names>A</given-names></name><name><surname>Jupe</surname><given-names>S</given-names></name><name><surname>Matthews</surname><given-names>L</given-names></name><name><surname>Sidiropoulos</surname><given-names>K</given-names></name><name><surname>Gillespie</surname><given-names>M</given-names></name><name><surname>Garapati</surname><given-names>P</given-names></name><name><surname>Haw</surname><given-names>R</given-names></name><name><surname>Jassal</surname><given-names>B</given-names></name><name><surname>Korninger</surname><given-names>F</given-names></name><name><surname>May</surname><given-names>B</given-names></name><name><surname>Milacic</surname><given-names>M</given-names></name><name><surname>Roca</surname><given-names>CD</given-names></name><name><surname>Rothfels</surname><given-names>K</given-names></name><name><surname>Sevilla</surname><given-names>C</given-names></name><name><surname>Shamovsky</surname><given-names>V</given-names></name><name><surname>Shorser</surname><given-names>S</given-names></name><name><surname>Varusai</surname><given-names>T</given-names></name><name><surname>Viteri</surname><given-names>G</given-names></name><name><surname>Weiser</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>G</given-names></name><name><surname>Stein</surname><given-names>L</given-names></name><name><surname>Hermjakob</surname><given-names>H</given-names></name><name><surname>D’Eustachio</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The reactome pathway knowledgebase</article-title><source>Nucleic Acids Research</source><volume>46</volume><fpage>D649</fpage><lpage>D655</lpage><pub-id pub-id-type="doi">10.1093/nar/gkx1132</pub-id><pub-id pub-id-type="pmid">29145629</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fazakerley</surname><given-names>DJ</given-names></name><name><surname>Chaudhuri</surname><given-names>R</given-names></name><name><surname>Yang</surname><given-names>P</given-names></name><name><surname>Maghzal</surname><given-names>GJ</given-names></name><name><surname>Thomas</surname><given-names>KC</given-names></name><name><surname>Krycer</surname><given-names>JR</given-names></name><name><surname>Humphrey</surname><given-names>SJ</given-names></name><name><surname>Parker</surname><given-names>BL</given-names></name><name><surname>Fisher-Wellman</surname><given-names>KH</given-names></name><name><surname>Meoli</surname><given-names>CC</given-names></name><name><surname>Hoffman</surname><given-names>NJ</given-names></name><name><surname>Diskin</surname><given-names>C</given-names></name><name><surname>Burchfield</surname><given-names>JG</given-names></name><name><surname>Cowley</surname><given-names>MJ</given-names></name><name><surname>Kaplan</surname><given-names>W</given-names></name><name><surname>Modrusan</surname><given-names>Z</given-names></name><name><surname>Kolumam</surname><given-names>G</given-names></name><name><surname>Yang</surname><given-names>JY</given-names></name><name><surname>Chen</surname><given-names>DL</given-names></name><name><surname>Samocha-Bonet</surname><given-names>D</given-names></name><name><surname>Greenfield</surname><given-names>JR</given-names></name><name><surname>Hoehn</surname><given-names>KL</given-names></name><name><surname>Stocker</surname><given-names>R</given-names></name><name><surname>James</surname><given-names>DE</given-names></name></person-group><year iso-8601-date="2018">2018a</year><article-title>Mitochondrial CoQ deficiency is a common driver of mitochondrial oxidants and insulin resistance</article-title><source>eLife</source><volume>7</volume><elocation-id>e32111</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.32111</pub-id><pub-id pub-id-type="pmid">29402381</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fazakerley</surname><given-names>DJ</given-names></name><name><surname>Minard</surname><given-names>AY</given-names></name><name><surname>Krycer</surname><given-names>JR</given-names></name><name><surname>Thomas</surname><given-names>KC</given-names></name><name><surname>Stöckli</surname><given-names>J</given-names></name><name><surname>Harney</surname><given-names>DJ</given-names></name><name><surname>Burchfield</surname><given-names>JG</given-names></name><name><surname>Maghzal</surname><given-names>GJ</given-names></name><name><surname>Caldwell</surname><given-names>ST</given-names></name><name><surname>Hartley</surname><given-names>RC</given-names></name><name><surname>Stocker</surname><given-names>R</given-names></name><name><surname>Murphy</surname><given-names>MP</given-names></name><name><surname>James</surname><given-names>DE</given-names></name></person-group><year iso-8601-date="2018">2018b</year><article-title>Mitochondrial oxidative stress causes insulin resistance without disrupting oxidative phosphorylation</article-title><source>The Journal of Biological Chemistry</source><volume>293</volume><fpage>7315</fpage><lpage>7328</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA117.001254</pub-id><pub-id pub-id-type="pmid">29599292</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>S</given-names></name><name><surname>Harayama</surname><given-names>T</given-names></name><name><surname>Montessuit</surname><given-names>S</given-names></name><name><surname>David</surname><given-names>FP</given-names></name><name><surname>Winssinger</surname><given-names>N</given-names></name><name><surname>Martinou</surname><given-names>JC</given-names></name><name><surname>Riezman</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Mitochondria-specific photoactivation to monitor local sphingosine metabolism and function</article-title><source>eLife</source><volume>7</volume><elocation-id>e34555</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.34555</pub-id><pub-id pub-id-type="pmid">29376826</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernández-Ayala</surname><given-names>DJ</given-names></name><name><surname>Martín</surname><given-names>SF</given-names></name><name><surname>Barroso</surname><given-names>MP</given-names></name><name><surname>Gómez-Díaz</surname><given-names>C</given-names></name><name><surname>Villalba</surname><given-names>JM</given-names></name><name><surname>Rodríguez-Aguilera</surname><given-names>JC</given-names></name><name><surname>López-Lluch</surname><given-names>G</given-names></name><name><surname>Navas</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Coenzyme Q protects cells against serum withdrawal-induced apoptosis by inhibition of ceramide release and caspase-3 activation</article-title><source>Antioxidants &amp; Redox Signaling</source><volume>2</volume><fpage>263</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1089/ars.2000.2.2-263</pub-id><pub-id pub-id-type="pmid">11229531</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fisher-Wellman</surname><given-names>KH</given-names></name><name><surname>Hagen</surname><given-names>JT</given-names></name><name><surname>Neufer</surname><given-names>PD</given-names></name><name><surname>Kassai</surname><given-names>M</given-names></name><name><surname>Cabot</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>On the nature of ceramide-mitochondria interactions - Dissection using comprehensive mitochondrial phenotyping</article-title><source>Cellular Signalling</source><volume>78</volume><elocation-id>109838</elocation-id><pub-id pub-id-type="doi">10.1016/j.cellsig.2020.109838</pub-id><pub-id pub-id-type="pmid">33212155</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forsman</surname><given-names>U</given-names></name><name><surname>Sjöberg</surname><given-names>M</given-names></name><name><surname>Turunen</surname><given-names>M</given-names></name><name><surname>Sindelar</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>4-Nitrobenzoate inhibits coenzyme Q biosynthesis in mammalian cell cultures</article-title><source>Nature Chemical Biology</source><volume>6</volume><fpage>515</fpage><lpage>517</lpage><pub-id pub-id-type="doi">10.1038/nchembio.372</pub-id><pub-id pub-id-type="pmid">20526342</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frerman</surname><given-names>FE</given-names></name></person-group><year iso-8601-date="1988">1988</year><article-title>Acyl-CoA dehydrogenases, electron transfer flavoprotein and electron transfer flavoprotein dehydrogenase</article-title><source>Biochemical Society Transactions</source><volume>16</volume><fpage>416</fpage><lpage>418</lpage><pub-id pub-id-type="doi">10.1042/bst0160416</pub-id><pub-id pub-id-type="pmid">3053288</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frezza</surname><given-names>C</given-names></name><name><surname>Cipolat</surname><given-names>S</given-names></name><name><surname>Scorrano</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Organelle isolation: functional mitochondria from mouse liver, muscle and cultured fibroblasts</article-title><source>Nature Protocols</source><volume>2</volume><fpage>287</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1038/nprot.2006.478</pub-id><pub-id pub-id-type="pmid">17406588</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galgani</surname><given-names>JE</given-names></name><name><surname>Fernández-Verdejo</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Pathophysiological role of metabolic flexibility on metabolic health</article-title><source>Obesity Reviews</source><volume>22</volume><elocation-id>e13131</elocation-id><pub-id pub-id-type="doi">10.1111/obr.13131</pub-id><pub-id pub-id-type="pmid">32815226</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>García-Ruiz</surname><given-names>C</given-names></name><name><surname>Colell</surname><given-names>A</given-names></name><name><surname>Marí</surname><given-names>M</given-names></name><name><surname>Morales</surname><given-names>A</given-names></name><name><surname>Fernández-Checa</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Direct effect of ceramide on the mitochondrial electron transport chain leads to generation of reactive oxygen species. Role of mitochondrial glutathione</article-title><source>The Journal of Biological Chemistry</source><volume>272</volume><fpage>11369</fpage><lpage>11377</lpage><pub-id pub-id-type="doi">10.1074/jbc.272.17.11369</pub-id><pub-id pub-id-type="pmid">9111045</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Govers</surname><given-names>R</given-names></name><name><surname>Coster</surname><given-names>ACF</given-names></name><name><surname>James</surname><given-names>DE</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Insulin increases cell surface GLUT4 levels by dose dependently discharging GLUT4 into a cell surface recycling pathway</article-title><source>Molecular and Cellular Biology</source><volume>24</volume><fpage>6456</fpage><lpage>6466</lpage><pub-id pub-id-type="doi">10.1128/MCB.24.14.6456-6466.2004</pub-id><pub-id pub-id-type="pmid">15226445</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guarás</surname><given-names>A</given-names></name><name><surname>Perales-Clemente</surname><given-names>E</given-names></name><name><surname>Calvo</surname><given-names>E</given-names></name><name><surname>Acín-Pérez</surname><given-names>R</given-names></name><name><surname>Loureiro-Lopez</surname><given-names>M</given-names></name><name><surname>Pujol</surname><given-names>C</given-names></name><name><surname>Martínez-Carrascoso</surname><given-names>I</given-names></name><name><surname>Nuñez</surname><given-names>E</given-names></name><name><surname>García-Marqués</surname><given-names>F</given-names></name><name><surname>Rodríguez-Hernández</surname><given-names>MA</given-names></name><name><surname>Cortés</surname><given-names>A</given-names></name><name><surname>Diaz</surname><given-names>F</given-names></name><name><surname>Pérez-Martos</surname><given-names>A</given-names></name><name><surname>Moraes</surname><given-names>CT</given-names></name><name><surname>Fernández-Silva</surname><given-names>P</given-names></name><name><surname>Trifunovic</surname><given-names>A</given-names></name><name><surname>Navas</surname><given-names>P</given-names></name><name><surname>Vazquez</surname><given-names>J</given-names></name><name><surname>Enríquez</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The CoQH2/CoQ ratio serves as a sensor of respiratory chain efficiency</article-title><source>Cell Reports</source><volume>15</volume><fpage>197</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.03.009</pub-id><pub-id pub-id-type="pmid">27052170</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gudz</surname><given-names>TI</given-names></name><name><surname>Tserng</surname><given-names>KY</given-names></name><name><surname>Hoppel</surname><given-names>CL</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Direct inhibition of mitochondrial respiratory chain complex III by cell-permeable ceramide</article-title><source>The Journal of Biological Chemistry</source><volume>272</volume><fpage>24154</fpage><lpage>24158</lpage><pub-id pub-id-type="doi">10.1074/jbc.272.39.24154</pub-id><pub-id pub-id-type="pmid">9305864</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hammerschmidt</surname><given-names>P</given-names></name><name><surname>Ostkotte</surname><given-names>D</given-names></name><name><surname>Nolte</surname><given-names>H</given-names></name><name><surname>Gerl</surname><given-names>MJ</given-names></name><name><surname>Jais</surname><given-names>A</given-names></name><name><surname>Brunner</surname><given-names>HL</given-names></name><name><surname>Sprenger</surname><given-names>H-G</given-names></name><name><surname>Awazawa</surname><given-names>M</given-names></name><name><surname>Nicholls</surname><given-names>HT</given-names></name><name><surname>Turpin-Nolan</surname><given-names>SM</given-names></name><name><surname>Langer</surname><given-names>T</given-names></name><name><surname>Krüger</surname><given-names>M</given-names></name><name><surname>Brügger</surname><given-names>B</given-names></name><name><surname>Brüning</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>CerS6-derived sphingolipids interact with Mff and promote mitochondrial fragmentation in obesity</article-title><source>Cell</source><volume>177</volume><fpage>1536</fpage><lpage>1552</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.05.008</pub-id><pub-id pub-id-type="pmid">31150623</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hatefi</surname><given-names>Y</given-names></name><name><surname>Haavik</surname><given-names>AG</given-names></name><name><surname>Fowler</surname><given-names>LR</given-names></name><name><surname>Griffiths</surname><given-names>DE</given-names></name></person-group><year iso-8601-date="1962">1962</year><article-title>Studies on the electron transfer system. XLII. Reconstitution of the electron transfer system</article-title><source>The Journal of Biological Chemistry</source><volume>237</volume><fpage>2661</fpage><lpage>2669</lpage><pub-id pub-id-type="pmid">13905326</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hernansanz-Agustín</surname><given-names>P</given-names></name><name><surname>Enríquez</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Functional segmentation of CoQ and cyt c pools by respiratory complex superassembly</article-title><source>Free Radical Biology &amp; Medicine</source><volume>167</volume><fpage>232</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2021.03.010</pub-id><pub-id pub-id-type="pmid">33722627</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>MM</given-names></name><name><surname>Clark</surname><given-names>SF</given-names></name><name><surname>Tucker</surname><given-names>DF</given-names></name><name><surname>Birnbaum</surname><given-names>MJ</given-names></name><name><surname>James</surname><given-names>DE</given-names></name><name><surname>Macaulay</surname><given-names>SL</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>A role for protein kinase Bbeta/Akt2 in insulin-stimulated GLUT4 translocation in adipocytes</article-title><source>Molecular and Cellular Biology</source><volume>19</volume><fpage>7771</fpage><lpage>7781</lpage><pub-id pub-id-type="doi">10.1128/MCB.19.11.7771</pub-id><pub-id pub-id-type="pmid">10523666</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoehn</surname><given-names>KL</given-names></name><name><surname>Hohnen-Behrens</surname><given-names>C</given-names></name><name><surname>Cederberg</surname><given-names>A</given-names></name><name><surname>Wu</surname><given-names>LE</given-names></name><name><surname>Turner</surname><given-names>N</given-names></name><name><surname>Yuasa</surname><given-names>T</given-names></name><name><surname>Ebina</surname><given-names>Y</given-names></name><name><surname>James</surname><given-names>DE</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>IRS1-independent defects define major nodes of insulin resistance</article-title><source>Cell Metabolism</source><volume>7</volume><fpage>421</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2008.04.005</pub-id><pub-id pub-id-type="pmid">18460333</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoehn</surname><given-names>KL</given-names></name><name><surname>Salmon</surname><given-names>AB</given-names></name><name><surname>Hohnen-Behrens</surname><given-names>C</given-names></name><name><surname>Turner</surname><given-names>N</given-names></name><name><surname>Hoy</surname><given-names>AJ</given-names></name><name><surname>Maghzal</surname><given-names>GJ</given-names></name><name><surname>Stocker</surname><given-names>R</given-names></name><name><surname>Van Remmen</surname><given-names>H</given-names></name><name><surname>Kraegen</surname><given-names>EW</given-names></name><name><surname>Cooney</surname><given-names>GJ</given-names></name><name><surname>Richardson</surname><given-names>AR</given-names></name><name><surname>James</surname><given-names>DE</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Insulin resistance is a cellular antioxidant defense mechanism</article-title><source>PNAS</source><volume>106</volume><fpage>17787</fpage><lpage>17792</lpage><pub-id pub-id-type="doi">10.1073/pnas.0902380106</pub-id><pub-id pub-id-type="pmid">19805130</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Højlund</surname><given-names>K</given-names></name><name><surname>Yi</surname><given-names>Z</given-names></name><name><surname>Lefort</surname><given-names>N</given-names></name><name><surname>Langlais</surname><given-names>P</given-names></name><name><surname>Bowen</surname><given-names>B</given-names></name><name><surname>Levin</surname><given-names>K</given-names></name><name><surname>Beck-Nielsen</surname><given-names>H</given-names></name><name><surname>Mandarino</surname><given-names>LJ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Human ATP synthase beta is phosphorylated at multiple sites and shows abnormal phosphorylation at specific sites in insulin-resistant muscle</article-title><source>Diabetologia</source><volume>53</volume><fpage>541</fpage><lpage>551</lpage><pub-id pub-id-type="doi">10.1007/s00125-009-1624-0</pub-id><pub-id pub-id-type="pmid">20012595</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holland</surname><given-names>WL</given-names></name><name><surname>Summers</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism</article-title><source>Endocrine Reviews</source><volume>29</volume><fpage>381</fpage><lpage>402</lpage><pub-id pub-id-type="doi">10.1210/er.2007-0025</pub-id><pub-id pub-id-type="pmid">18451260</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>James</surname><given-names>DE</given-names></name><name><surname>Stöckli</surname><given-names>J</given-names></name><name><surname>Birnbaum</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The aetiology and molecular landscape of insulin resistance</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>22</volume><fpage>751</fpage><lpage>771</lpage><pub-id pub-id-type="doi">10.1038/s41580-021-00390-6</pub-id><pub-id pub-id-type="pmid">34285405</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>ME</given-names></name></person-group><year iso-8601-date="1980">1980</year><article-title>Pyrimidine nucleotide biosynthesis in animals: genes, enzymes, and regulation of UMP biosynthesis</article-title><source>Annual Review of Biochemistry</source><volume>49</volume><fpage>253</fpage><lpage>279</lpage><pub-id pub-id-type="doi">10.1146/annurev.bi.49.070180.001345</pub-id><pub-id pub-id-type="pmid">6105839</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kao</surname><given-names>LP</given-names></name><name><surname>Morad</surname><given-names>SAF</given-names></name><name><surname>Davis</surname><given-names>TS</given-names></name><name><surname>MacDougall</surname><given-names>MR</given-names></name><name><surname>Kassai</surname><given-names>M</given-names></name><name><surname>Abdelmageed</surname><given-names>N</given-names></name><name><surname>Fox</surname><given-names>TE</given-names></name><name><surname>Kester</surname><given-names>M</given-names></name><name><surname>Loughran</surname><given-names>TP</given-names></name><name><surname>Abad</surname><given-names>JL</given-names></name><name><surname>Fabrias</surname><given-names>G</given-names></name><name><surname>Tan</surname><given-names>SF</given-names></name><name><surname>Feith</surname><given-names>DJ</given-names></name><name><surname>Claxton</surname><given-names>DF</given-names></name><name><surname>Spiegel</surname><given-names>S</given-names></name><name><surname>Fisher-Wellman</surname><given-names>KH</given-names></name><name><surname>Cabot</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Chemotherapy selection pressure alters sphingolipid composition and mitochondrial bioenergetics in resistant HL-60 cells</article-title><source>Journal of Lipid Research</source><volume>60</volume><fpage>1590</fpage><lpage>1602</lpage><pub-id pub-id-type="doi">10.1194/jlr.RA119000251</pub-id><pub-id pub-id-type="pmid">31363040</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kono</surname><given-names>T</given-names></name><name><surname>Barham</surname><given-names>FW</given-names></name></person-group><year iso-8601-date="1971">1971</year><article-title>The relationship between the insulin-binding capacity of fat cells and the cellular response to insulin. Studies with intact and trypsin-treated fat cells</article-title><source>The Journal of Biological Chemistry</source><volume>246</volume><fpage>6210</fpage><lpage>6216</lpage><pub-id pub-id-type="pmid">5127426</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kory</surname><given-names>N</given-names></name><name><surname>Uit de Bos</surname><given-names>J</given-names></name><name><surname>van der Rijt</surname><given-names>S</given-names></name><name><surname>Jankovic</surname><given-names>N</given-names></name><name><surname>Güra</surname><given-names>M</given-names></name><name><surname>Arp</surname><given-names>N</given-names></name><name><surname>Pena</surname><given-names>IA</given-names></name><name><surname>Prakash</surname><given-names>G</given-names></name><name><surname>Chan</surname><given-names>SH</given-names></name><name><surname>Kunchok</surname><given-names>T</given-names></name><name><surname>Lewis</surname><given-names>CA</given-names></name><name><surname>Sabatini</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>MCART1/SLC25A51 is required for mitochondrial NAD transport</article-title><source>Science Advances</source><volume>6</volume><elocation-id>eabe5310</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.abe5310</pub-id><pub-id pub-id-type="pmid">33087354</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koves</surname><given-names>TR</given-names></name><name><surname>Ussher</surname><given-names>JR</given-names></name><name><surname>Noland</surname><given-names>RC</given-names></name><name><surname>Slentz</surname><given-names>D</given-names></name><name><surname>Mosedale</surname><given-names>M</given-names></name><name><surname>Ilkayeva</surname><given-names>O</given-names></name><name><surname>Bain</surname><given-names>J</given-names></name><name><surname>Stevens</surname><given-names>R</given-names></name><name><surname>Dyck</surname><given-names>JRB</given-names></name><name><surname>Newgard</surname><given-names>CB</given-names></name><name><surname>Lopaschuk</surname><given-names>GD</given-names></name><name><surname>Muoio</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance</article-title><source>Cell Metabolism</source><volume>7</volume><fpage>45</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2007.10.013</pub-id><pub-id pub-id-type="pmid">18177724</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krycer</surname><given-names>JR</given-names></name><name><surname>Elkington</surname><given-names>SD</given-names></name><name><surname>Diaz-Vegas</surname><given-names>A</given-names></name><name><surname>Cooke</surname><given-names>KC</given-names></name><name><surname>Burchfield</surname><given-names>JG</given-names></name><name><surname>Fisher-Wellman</surname><given-names>KH</given-names></name><name><surname>Cooney</surname><given-names>GJ</given-names></name><name><surname>Fazakerley</surname><given-names>DJ</given-names></name><name><surname>James</surname><given-names>DE</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Mitochondrial oxidants, but not respiration, are sensitive to glucose in adipocytes</article-title><source>Journal of Biological Chemistry</source><volume>295</volume><fpage>99</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA119.011695</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kühl</surname><given-names>I</given-names></name><name><surname>Miranda</surname><given-names>M</given-names></name><name><surname>Atanassov</surname><given-names>I</given-names></name><name><surname>Kuznetsova</surname><given-names>I</given-names></name><name><surname>Hinze</surname><given-names>Y</given-names></name><name><surname>Mourier</surname><given-names>A</given-names></name><name><surname>Filipovska</surname><given-names>A</given-names></name><name><surname>Larsson</surname><given-names>N-G</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Transcriptomic and proteomic landscape of mitochondrial dysfunction reveals secondary coenzyme Q deficiency in mammals</article-title><source>eLife</source><volume>6</volume><elocation-id>e30952</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.30952</pub-id><pub-id pub-id-type="pmid">29132502</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langfelder</surname><given-names>P</given-names></name><name><surname>Horvath</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>WGCNA: an R package for weighted correlation network analysis</article-title><source>BMC Bioinformatics</source><volume>9</volume><elocation-id>559</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2105-9-559</pub-id><pub-id pub-id-type="pmid">19114008</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lapuente-Brun</surname><given-names>E</given-names></name><name><surname>Moreno-Loshuertos</surname><given-names>R</given-names></name><name><surname>Acín-Pérez</surname><given-names>R</given-names></name><name><surname>Latorre-Pellicer</surname><given-names>A</given-names></name><name><surname>Colás</surname><given-names>C</given-names></name><name><surname>Balsa</surname><given-names>E</given-names></name><name><surname>Perales-Clemente</surname><given-names>E</given-names></name><name><surname>Quirós</surname><given-names>PM</given-names></name><name><surname>Calvo</surname><given-names>E</given-names></name><name><surname>Rodríguez-Hernández</surname><given-names>MA</given-names></name><name><surname>Navas</surname><given-names>P</given-names></name><name><surname>Cruz</surname><given-names>R</given-names></name><name><surname>Carracedo</surname><given-names>Á</given-names></name><name><surname>López-Otín</surname><given-names>C</given-names></name><name><surname>Pérez-Martos</surname><given-names>A</given-names></name><name><surname>Fernández-Silva</surname><given-names>P</given-names></name><name><surname>Fernández-Vizarra</surname><given-names>E</given-names></name><name><surname>Enríquez</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Supercomplex assembly determines electron flux in the mitochondrial electron transport chain</article-title><source>Science</source><volume>340</volume><fpage>1567</fpage><lpage>1570</lpage><pub-id pub-id-type="doi">10.1126/science.1230381</pub-id><pub-id pub-id-type="pmid">23812712</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leitner</surname><given-names>BP</given-names></name><name><surname>Siebel</surname><given-names>S</given-names></name><name><surname>Akingbesote</surname><given-names>ND</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Perry</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Insulin and cancer: a tangled web</article-title><source>The Biochemical Journal</source><volume>479</volume><fpage>583</fpage><lpage>607</lpage><pub-id pub-id-type="doi">10.1042/BCJ20210134</pub-id><pub-id pub-id-type="pmid">35244142</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Letts</surname><given-names>JA</given-names></name><name><surname>Sazanov</surname><given-names>LA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Clarifying the supercomplex: the higher-order organization of the mitochondrial electron transport chain</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>24</volume><fpage>800</fpage><lpage>808</lpage><pub-id pub-id-type="doi">10.1038/nsmb.3460</pub-id><pub-id pub-id-type="pmid">28981073</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>CM</given-names></name><name><surname>Park</surname><given-names>JH</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Levy</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>Arai</surname><given-names>K</given-names></name><name><surname>Adler</surname><given-names>DA</given-names></name><name><surname>Disteche</surname><given-names>CM</given-names></name><name><surname>Koch</surname><given-names>J</given-names></name><name><surname>Sandhoff</surname><given-names>K</given-names></name><name><surname>Schuchman</surname><given-names>EH</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>The human acid ceramidase gene (ASAH): structure, chromosomal location, mutation analysis, and expression</article-title><source>Genomics</source><volume>62</volume><fpage>223</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1006/geno.1999.5940</pub-id><pub-id pub-id-type="pmid">10610716</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maranzana</surname><given-names>E</given-names></name><name><surname>Barbero</surname><given-names>G</given-names></name><name><surname>Falasca</surname><given-names>AI</given-names></name><name><surname>Lenaz</surname><given-names>G</given-names></name><name><surname>Genova</surname><given-names>ML</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Mitochondrial respiratory supercomplex association limits production of reactive oxygen species from complex I</article-title><source>Antioxidants &amp; Redox Signaling</source><volume>19</volume><fpage>1469</fpage><lpage>1480</lpage><pub-id pub-id-type="doi">10.1089/ars.2012.4845</pub-id><pub-id pub-id-type="pmid">23581604</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matyash</surname><given-names>V</given-names></name><name><surname>Liebisch</surname><given-names>G</given-names></name><name><surname>Kurzchalia</surname><given-names>TV</given-names></name><name><surname>Shevchenko</surname><given-names>A</given-names></name><name><surname>Schwudke</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Lipid extraction by methyl-tert-butyl ether for high-throughput lipidomics</article-title><source>Journal of Lipid Research</source><volume>49</volume><fpage>1137</fpage><lpage>1146</lpage><pub-id pub-id-type="doi">10.1194/jlr.D700041-JLR200</pub-id><pub-id pub-id-type="pmid">18281723</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mileykovskaya</surname><given-names>E</given-names></name><name><surname>Dowhan</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Cardiolipin-dependent formation of mitochondrial respiratory supercomplexes</article-title><source>Chemistry and Physics of Lipids</source><volume>179</volume><fpage>42</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.chemphyslip.2013.10.012</pub-id><pub-id pub-id-type="pmid">24220496</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montgomery</surname><given-names>MK</given-names></name><name><surname>Osborne</surname><given-names>B</given-names></name><name><surname>Brandon</surname><given-names>AE</given-names></name><name><surname>O’Reilly</surname><given-names>L</given-names></name><name><surname>Fiveash</surname><given-names>CE</given-names></name><name><surname>Brown</surname><given-names>SHJ</given-names></name><name><surname>Wilkins</surname><given-names>BP</given-names></name><name><surname>Samsudeen</surname><given-names>A</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Devanapalli</surname><given-names>B</given-names></name><name><surname>Hertzog</surname><given-names>A</given-names></name><name><surname>Tolun</surname><given-names>AA</given-names></name><name><surname>Kavanagh</surname><given-names>T</given-names></name><name><surname>Cooper</surname><given-names>AA</given-names></name><name><surname>Mitchell</surname><given-names>TW</given-names></name><name><surname>Biden</surname><given-names>TJ</given-names></name><name><surname>Smith</surname><given-names>NJ</given-names></name><name><surname>Cooney</surname><given-names>GJ</given-names></name><name><surname>Turner</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Regulation of mitochondrial metabolism in murine skeletal muscle by the medium-chain fatty acid receptor Gpr84</article-title><source>FASEB Journal</source><volume>33</volume><fpage>12264</fpage><lpage>12276</lpage><pub-id pub-id-type="doi">10.1096/fj.201900234R</pub-id><pub-id pub-id-type="pmid">31415180</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montini</surname><given-names>G</given-names></name><name><surname>Malaventura</surname><given-names>C</given-names></name><name><surname>Salviati</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Early coenzyme Q10 supplementation in primary coenzyme Q10 deficiency</article-title><source>The New England Journal of Medicine</source><volume>358</volume><fpage>2849</fpage><lpage>2850</lpage><pub-id pub-id-type="doi">10.1056/NEJMc0800582</pub-id><pub-id pub-id-type="pmid">18579827</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morad</surname><given-names>SAF</given-names></name><name><surname>Levin</surname><given-names>JC</given-names></name><name><surname>Shanmugavelandy</surname><given-names>SS</given-names></name><name><surname>Kester</surname><given-names>M</given-names></name><name><surname>Fabrias</surname><given-names>G</given-names></name><name><surname>Bedia</surname><given-names>C</given-names></name><name><surname>Cabot</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Ceramide--antiestrogen nanoliposomal combinations--novel impact of hormonal therapy in hormone-insensitive breast cancer</article-title><source>Molecular Cancer Therapeutics</source><volume>11</volume><fpage>2352</fpage><lpage>2361</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-12-0594</pub-id><pub-id pub-id-type="pmid">22962326</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Novgorodov</surname><given-names>SA</given-names></name><name><surname>Wu</surname><given-names>BX</given-names></name><name><surname>Gudz</surname><given-names>TI</given-names></name><name><surname>Bielawski</surname><given-names>J</given-names></name><name><surname>Ovchinnikova</surname><given-names>TV</given-names></name><name><surname>Hannun</surname><given-names>YA</given-names></name><name><surname>Obeid</surname><given-names>LM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Novel pathway of ceramide production in mitochondria: thioesterase and neutral ceramidase produce ceramide from sphingosine and acyl-CoA</article-title><source>The Journal of Biological Chemistry</source><volume>286</volume><fpage>25352</fpage><lpage>25362</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.214866</pub-id><pub-id pub-id-type="pmid">21613224</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oleinik</surname><given-names>N</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Roth</surname><given-names>BM</given-names></name><name><surname>Selvam</surname><given-names>SP</given-names></name><name><surname>Gooz</surname><given-names>M</given-names></name><name><surname>Johnson</surname><given-names>RH</given-names></name><name><surname>Lemasters</surname><given-names>JJ</given-names></name><name><surname>Ogretmen</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Mitochondrial protein import is regulated by p17/PERMIT to mediate lipid metabolism and cellular stress</article-title><source>Science Advances</source><volume>5</volume><elocation-id>eaax1978</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.aax1978</pub-id><pub-id pub-id-type="pmid">31535025</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perdomo</surname><given-names>G</given-names></name><name><surname>Commerford</surname><given-names>SR</given-names></name><name><surname>Richard</surname><given-names>A-MT</given-names></name><name><surname>Adams</surname><given-names>SH</given-names></name><name><surname>Corkey</surname><given-names>BE</given-names></name><name><surname>O’Doherty</surname><given-names>RM</given-names></name><name><surname>Brown</surname><given-names>NF</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Increased beta-oxidation in muscle cells enhances insulin-stimulated glucose metabolism and protects against fatty acid-induced insulin resistance despite intramyocellular lipid accumulation</article-title><source>The Journal of Biological Chemistry</source><volume>279</volume><fpage>27177</fpage><lpage>27186</lpage><pub-id pub-id-type="doi">10.1074/jbc.M403566200</pub-id><pub-id pub-id-type="pmid">15105415</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perreault</surname><given-names>L</given-names></name><name><surname>Newsom</surname><given-names>SA</given-names></name><name><surname>Strauss</surname><given-names>A</given-names></name><name><surname>Kerege</surname><given-names>A</given-names></name><name><surname>Kahn</surname><given-names>DE</given-names></name><name><surname>Harrison</surname><given-names>KA</given-names></name><name><surname>Snell-Bergeon</surname><given-names>JK</given-names></name><name><surname>Nemkov</surname><given-names>T</given-names></name><name><surname>D’Alessandro</surname><given-names>A</given-names></name><name><surname>Jackman</surname><given-names>MR</given-names></name><name><surname>MacLean</surname><given-names>PS</given-names></name><name><surname>Bergman</surname><given-names>BC</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Intracellular localization of diacylglycerols and sphingolipids influences insulin sensitivity and mitochondrial function in human skeletal muscle</article-title><source>JCI Insight</source><volume>3</volume><elocation-id>e96805</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.96805</pub-id><pub-id pub-id-type="pmid">29415895</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Picard</surname><given-names>M</given-names></name><name><surname>Shirihai</surname><given-names>OS</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Mitochondrial signal transduction</article-title><source>Cell Metabolism</source><volume>34</volume><fpage>1620</fpage><lpage>1653</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2022.10.008</pub-id><pub-id pub-id-type="pmid">36323233</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinto</surname><given-names>SN</given-names></name><name><surname>Silva</surname><given-names>LC</given-names></name><name><surname>Futerman</surname><given-names>AH</given-names></name><name><surname>Prieto</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Effect of ceramide structure on membrane biophysical properties: the role of acyl chain length and unsaturation</article-title><source>Biochimica et Biophysica Acta</source><volume>1808</volume><fpage>2753</fpage><lpage>2760</lpage><pub-id pub-id-type="doi">10.1016/j.bbamem.2011.07.023</pub-id><pub-id pub-id-type="pmid">21835161</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powell</surname><given-names>DJ</given-names></name><name><surname>Hajduch</surname><given-names>E</given-names></name><name><surname>Kular</surname><given-names>G</given-names></name><name><surname>Hundal</surname><given-names>HS</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Ceramide disables 3-phosphoinositide binding to the pleckstrin homology domain of protein kinase B (PKB)/Akt by a PKCzeta-dependent mechanism</article-title><source>Molecular and Cellular Biology</source><volume>23</volume><fpage>7794</fpage><lpage>7808</lpage><pub-id pub-id-type="doi">10.1128/MCB.23.21.7794-7808.2003</pub-id><pub-id pub-id-type="pmid">14560023</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rath</surname><given-names>S</given-names></name><name><surname>Sharma</surname><given-names>R</given-names></name><name><surname>Gupta</surname><given-names>R</given-names></name><name><surname>Ast</surname><given-names>T</given-names></name><name><surname>Chan</surname><given-names>C</given-names></name><name><surname>Durham</surname><given-names>TJ</given-names></name><name><surname>Goodman</surname><given-names>RP</given-names></name><name><surname>Grabarek</surname><given-names>Z</given-names></name><name><surname>Haas</surname><given-names>ME</given-names></name><name><surname>Hung</surname><given-names>WHW</given-names></name><name><surname>Joshi</surname><given-names>PR</given-names></name><name><surname>Jourdain</surname><given-names>AA</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Kotrys</surname><given-names>AV</given-names></name><name><surname>Lam</surname><given-names>SS</given-names></name><name><surname>McCoy</surname><given-names>JG</given-names></name><name><surname>Meisel</surname><given-names>JD</given-names></name><name><surname>Miranda</surname><given-names>M</given-names></name><name><surname>Panda</surname><given-names>A</given-names></name><name><surname>Patgiri</surname><given-names>A</given-names></name><name><surname>Rogers</surname><given-names>R</given-names></name><name><surname>Sadre</surname><given-names>S</given-names></name><name><surname>Shah</surname><given-names>H</given-names></name><name><surname>Skinner</surname><given-names>OS</given-names></name><name><surname>To</surname><given-names>T-L</given-names></name><name><surname>Walker</surname><given-names>MA</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Ward</surname><given-names>PS</given-names></name><name><surname>Wengrod</surname><given-names>J</given-names></name><name><surname>Yuan</surname><given-names>C-C</given-names></name><name><surname>Calvo</surname><given-names>SE</given-names></name><name><surname>Mootha</surname><given-names>VK</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>MitoCarta3.0: an updated mitochondrial proteome now with sub-organelle localization and pathway annotations</article-title><source>Nucleic Acids Research</source><volume>49</volume><fpage>D1541</fpage><lpage>D1547</lpage><pub-id pub-id-type="doi">10.1093/nar/gkaa1011</pub-id><pub-id pub-id-type="pmid">33174596</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riehle</surname><given-names>C</given-names></name><name><surname>Abel</surname><given-names>ED</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Insulin signaling and Heart Failure</article-title><source>Circulation Research</source><volume>118</volume><fpage>1151</fpage><lpage>1169</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.116.306206</pub-id><pub-id pub-id-type="pmid">27034277</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ritchie</surname><given-names>ME</given-names></name><name><surname>Phipson</surname><given-names>B</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Law</surname><given-names>CW</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>Smyth</surname><given-names>GK</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>limma powers differential expression analyses for RNA-sequencing and microarray studies</article-title><source>Nucleic Acids Research</source><volume>43</volume><elocation-id>e47</elocation-id><pub-id pub-id-type="doi">10.1093/nar/gkv007</pub-id><pub-id pub-id-type="pmid">25605792</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosales-Soto</surname><given-names>G</given-names></name><name><surname>Diaz-Vegas</surname><given-names>A</given-names></name><name><surname>Casas</surname><given-names>M</given-names></name><name><surname>Contreras-Ferrat</surname><given-names>A</given-names></name><name><surname>Jaimovich</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Fibroblast growth factor-21 potentiates glucose transport in skeletal muscle fibers</article-title><source>Journal of Molecular Endocrinology</source><volume>65</volume><fpage>85</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1530/JME-19-0210</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sánchez-Aguilera</surname><given-names>P</given-names></name><name><surname>Diaz-Vegas</surname><given-names>A</given-names></name><name><surname>Campos</surname><given-names>C</given-names></name><name><surname>Quinteros-Waltemath</surname><given-names>O</given-names></name><name><surname>Cerda-Kohler</surname><given-names>H</given-names></name><name><surname>Barrientos</surname><given-names>G</given-names></name><name><surname>Contreras-Ferrat</surname><given-names>A</given-names></name><name><surname>Llanos</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Role of ABCA1 on membrane cholesterol content, insulin-dependent Akt phosphorylation and glucose uptake in adult skeletal muscle fibers from mice</article-title><source>Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids</source><volume>1863</volume><fpage>1469</fpage><lpage>1477</lpage><pub-id pub-id-type="doi">10.1016/j.bbalip.2018.09.005</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schägger</surname><given-names>H</given-names></name><name><surname>Pfeiffer</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Supercomplexes in the respiratory chains of yeast and mammalian mitochondria</article-title><source>The EMBO Journal</source><volume>19</volume><fpage>1777</fpage><lpage>1783</lpage><pub-id pub-id-type="doi">10.1093/emboj/19.8.1777</pub-id><pub-id pub-id-type="pmid">10775262</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schubert</surname><given-names>KM</given-names></name><name><surname>Scheid</surname><given-names>MP</given-names></name><name><surname>Duronio</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Ceramide inhibits protein kinase B/Akt by promoting dephosphorylation of serine 473</article-title><source>The Journal of Biological Chemistry</source><volume>275</volume><fpage>13330</fpage><lpage>13335</lpage><pub-id pub-id-type="doi">10.1074/jbc.275.18.13330</pub-id><pub-id pub-id-type="pmid">10788440</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seal</surname><given-names>RL</given-names></name><name><surname>Braschi</surname><given-names>B</given-names></name><name><surname>Gray</surname><given-names>K</given-names></name><name><surname>Jones</surname><given-names>TEM</given-names></name><name><surname>Tweedie</surname><given-names>S</given-names></name><name><surname>Haim-Vilmovsky</surname><given-names>L</given-names></name><name><surname>Bruford</surname><given-names>EA</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Genenames.org: the HGNC resources in 2023</article-title><source>Nucleic Acids Research</source><volume>51</volume><fpage>D1003</fpage><lpage>D1009</lpage><pub-id pub-id-type="doi">10.1093/nar/gkac888</pub-id><pub-id pub-id-type="pmid">36243972</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sebastián</surname><given-names>D</given-names></name><name><surname>Herrero</surname><given-names>L</given-names></name><name><surname>Serra</surname><given-names>D</given-names></name><name><surname>Asins</surname><given-names>G</given-names></name><name><surname>Hegardt</surname><given-names>FG</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>CPT I overexpression protects L6E9 muscle cells from fatty acid-induced insulin resistance</article-title><source>American Journal of Physiology. Endocrinology and Metabolism</source><volume>292</volume><fpage>E677</fpage><lpage>E686</lpage><pub-id pub-id-type="doi">10.1152/ajpendo.00360.2006</pub-id><pub-id pub-id-type="pmid">17062841</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siskind</surname><given-names>LJ</given-names></name><name><surname>Kolesnick</surname><given-names>RN</given-names></name><name><surname>Colombini</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Ceramide channels increase the permeability of the mitochondrial outer membrane to small proteins</article-title><source>The Journal of Biological Chemistry</source><volume>277</volume><fpage>26796</fpage><lpage>26803</lpage><pub-id pub-id-type="doi">10.1074/jbc.M200754200</pub-id><pub-id pub-id-type="pmid">12006562</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smyth</surname><given-names>GK</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Linear models and empirical bayes methods for assessing differential expression in microarray experiments</article-title><source>Statistical Applications in Genetics and Molecular Biology</source><volume>3</volume><elocation-id>Article3</elocation-id><pub-id pub-id-type="doi">10.2202/1544-6115.1027</pub-id><pub-id pub-id-type="pmid">16646809</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Summers</surname><given-names>SA</given-names></name><name><surname>Garza</surname><given-names>LA</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Birnbaum</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Regulation of insulin-stimulated glucose transporter GLUT4 translocation and Akt kinase activity by ceramide</article-title><source>Molecular and Cellular Biology</source><volume>18</volume><fpage>5457</fpage><lpage>5464</lpage><pub-id pub-id-type="doi">10.1128/MCB.18.9.5457</pub-id><pub-id pub-id-type="pmid">9710629</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szklarczyk</surname><given-names>D</given-names></name><name><surname>Gable</surname><given-names>AL</given-names></name><name><surname>Lyon</surname><given-names>D</given-names></name><name><surname>Junge</surname><given-names>A</given-names></name><name><surname>Wyder</surname><given-names>S</given-names></name><name><surname>Huerta-Cepas</surname><given-names>J</given-names></name><name><surname>Simonovic</surname><given-names>M</given-names></name><name><surname>Doncheva</surname><given-names>NT</given-names></name><name><surname>Morris</surname><given-names>JH</given-names></name><name><surname>Bork</surname><given-names>P</given-names></name><name><surname>Jensen</surname><given-names>LJ</given-names></name><name><surname>von Mering</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets</article-title><source>Nucleic Acids Research</source><volume>47</volume><fpage>D607</fpage><lpage>D613</lpage><pub-id pub-id-type="doi">10.1093/nar/gky1131</pub-id><pub-id pub-id-type="pmid">30476243</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taddeo</surname><given-names>EP</given-names></name><name><surname>Laker</surname><given-names>RC</given-names></name><name><surname>Breen</surname><given-names>DS</given-names></name><name><surname>Akhtar</surname><given-names>YN</given-names></name><name><surname>Kenwood</surname><given-names>BM</given-names></name><name><surname>Liao</surname><given-names>JA</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Fazakerley</surname><given-names>DJ</given-names></name><name><surname>Tomsig</surname><given-names>JL</given-names></name><name><surname>Harris</surname><given-names>TE</given-names></name><name><surname>Keller</surname><given-names>SR</given-names></name><name><surname>Chow</surname><given-names>JD</given-names></name><name><surname>Lynch</surname><given-names>KR</given-names></name><name><surname>Chokki</surname><given-names>M</given-names></name><name><surname>Molkentin</surname><given-names>JD</given-names></name><name><surname>Turner</surname><given-names>N</given-names></name><name><surname>James</surname><given-names>DE</given-names></name><name><surname>Yan</surname><given-names>Z</given-names></name><name><surname>Hoehn</surname><given-names>KL</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Opening of the mitochondrial permeability transition pore links mitochondrial dysfunction to insulin resistance in skeletal muscle</article-title><source>Molecular Metabolism</source><volume>3</volume><fpage>124</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1016/j.molmet.2013.11.003</pub-id><pub-id pub-id-type="pmid">24634818</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tesfay</surname><given-names>L</given-names></name><name><surname>Paul</surname><given-names>BT</given-names></name><name><surname>Konstorum</surname><given-names>A</given-names></name><name><surname>Deng</surname><given-names>Z</given-names></name><name><surname>Cox</surname><given-names>AO</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Furdui</surname><given-names>CM</given-names></name><name><surname>Hegde</surname><given-names>P</given-names></name><name><surname>Torti</surname><given-names>FM</given-names></name><name><surname>Torti</surname><given-names>SV</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Stearoyl-CoA desaturase 1 protects ovarian cancer cells from ferroptotic cell death</article-title><source>Cancer Research</source><volume>79</volume><fpage>5355</fpage><lpage>5366</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-19-0369</pub-id><pub-id pub-id-type="pmid">31270077</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>N</given-names></name><name><surname>Lim</surname><given-names>XY</given-names></name><name><surname>Toop</surname><given-names>HD</given-names></name><name><surname>Osborne</surname><given-names>B</given-names></name><name><surname>Brandon</surname><given-names>AE</given-names></name><name><surname>Taylor</surname><given-names>EN</given-names></name><name><surname>Fiveash</surname><given-names>CE</given-names></name><name><surname>Govindaraju</surname><given-names>H</given-names></name><name><surname>Teo</surname><given-names>JD</given-names></name><name><surname>McEwen</surname><given-names>HP</given-names></name><name><surname>Couttas</surname><given-names>TA</given-names></name><name><surname>Butler</surname><given-names>SM</given-names></name><name><surname>Das</surname><given-names>A</given-names></name><name><surname>Kowalski</surname><given-names>GM</given-names></name><name><surname>Bruce</surname><given-names>CR</given-names></name><name><surname>Hoehn</surname><given-names>KL</given-names></name><name><surname>Fath</surname><given-names>T</given-names></name><name><surname>Schmitz-Peiffer</surname><given-names>C</given-names></name><name><surname>Cooney</surname><given-names>GJ</given-names></name><name><surname>Montgomery</surname><given-names>MK</given-names></name><name><surname>Morris</surname><given-names>JC</given-names></name><name><surname>Don</surname><given-names>AS</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A selective inhibitor of ceramide synthase 1 reveals A novel role in fat metabolism</article-title><source>Nature Communications</source><volume>9</volume><elocation-id>3165</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-05613-7</pub-id><pub-id pub-id-type="pmid">30131496</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turpin-Nolan</surname><given-names>SM</given-names></name><name><surname>Hammerschmidt</surname><given-names>P</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Jais</surname><given-names>A</given-names></name><name><surname>Timper</surname><given-names>K</given-names></name><name><surname>Awazawa</surname><given-names>M</given-names></name><name><surname>Brodesser</surname><given-names>S</given-names></name><name><surname>Brüning</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>CerS1-Derived C<sub>18:0</sub> ceramide in skeletal muscle promotes obesity-induced insulin resistance</article-title><source>Cell Reports</source><volume>26</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2018.12.031</pub-id><pub-id pub-id-type="pmid">30605666</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valladares</surname><given-names>D</given-names></name><name><surname>Utreras-Mendoza</surname><given-names>Y</given-names></name><name><surname>Campos</surname><given-names>C</given-names></name><name><surname>Morales</surname><given-names>C</given-names></name><name><surname>Diaz-Vegas</surname><given-names>A</given-names></name><name><surname>Contreras-Ferrat</surname><given-names>A</given-names></name><name><surname>Westermeier</surname><given-names>F</given-names></name><name><surname>Jaimovich</surname><given-names>E</given-names></name><name><surname>Marchi</surname><given-names>S</given-names></name><name><surname>Pinton</surname><given-names>P</given-names></name><name><surname>Lavandero</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>IP3 receptor blockade restores autophagy and mitochondrial function in skeletal muscle fibers of dystrophic mice</article-title><source>Biochimica et Biophysica Acta - Molecular Basis of Disease</source><volume>1864</volume><fpage>3685</fpage><lpage>3695</lpage><pub-id pub-id-type="doi">10.1016/j.bbadis.2018.08.042</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walter</surname><given-names>L</given-names></name><name><surname>Nogueira</surname><given-names>V</given-names></name><name><surname>Leverve</surname><given-names>X</given-names></name><name><surname>Heitz</surname><given-names>MP</given-names></name><name><surname>Bernardi</surname><given-names>P</given-names></name><name><surname>Fontaine</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Three classes of ubiquinone analogs regulate the mitochondrial permeability transition pore through a common site</article-title><source>The Journal of Biological Chemistry</source><volume>275</volume><fpage>29521</fpage><lpage>29527</lpage><pub-id pub-id-type="doi">10.1074/jbc.M004128200</pub-id><pub-id pub-id-type="pmid">10889201</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>BX</given-names></name><name><surname>Rajagopalan</surname><given-names>V</given-names></name><name><surname>Roddy</surname><given-names>PL</given-names></name><name><surname>Clarke</surname><given-names>CJ</given-names></name><name><surname>Hannun</surname><given-names>YA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Identification and characterization of murine mitochondria-associated neutral sphingomyelinase (MA-nSMase), the mammalian sphingomyelin phosphodiesterase 5</article-title><source>The Journal of Biological Chemistry</source><volume>285</volume><fpage>17993</fpage><lpage>18002</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.102988</pub-id><pub-id pub-id-type="pmid">20378533</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>M</given-names></name><name><surname>Gu</surname><given-names>J</given-names></name><name><surname>Guo</surname><given-names>R</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Structure of mammalian respiratory supercomplex I 1 III 2 IV 1</article-title><source>Cell</source><volume>167</volume><fpage>1598</fpage><lpage>1609</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.11.012</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>T</given-names></name><name><surname>Hu</surname><given-names>E</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Guo</surname><given-names>P</given-names></name><name><surname>Dai</surname><given-names>Z</given-names></name><name><surname>Feng</surname><given-names>T</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Tang</surname><given-names>W</given-names></name><name><surname>Zhan</surname><given-names>L</given-names></name><name><surname>Fu</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Bo</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>clusterProfiler 4.0: A universal enrichment tool for interpreting omics data</article-title><source>Innovation</source><volume>2</volume><elocation-id>100141</elocation-id><pub-id pub-id-type="doi">10.1016/j.xinn.2021.100141</pub-id><pub-id pub-id-type="pmid">34557778</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Camp</surname><given-names>DG</given-names></name><name><surname>Smith</surname><given-names>RD</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>High-pH reversed-phase chromatography with fraction concatenation for 2D proteomic analysis</article-title><source>Expert Review of Proteomics</source><volume>9</volume><fpage>129</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1586/epr.12.15</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Novgorodov</surname><given-names>SA</given-names></name><name><surname>Chudakova</surname><given-names>D</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Bielawska</surname><given-names>A</given-names></name><name><surname>Bielawski</surname><given-names>J</given-names></name><name><surname>Obeid</surname><given-names>LM</given-names></name><name><surname>Kindy</surname><given-names>MS</given-names></name><name><surname>Gudz</surname><given-names>TI</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>JNK3 signaling pathway activates ceramide synthase leading to mitochondrial dysfunction</article-title><source>The Journal of Biological Chemistry</source><volume>282</volume><fpage>25940</fpage><lpage>25949</lpage><pub-id pub-id-type="doi">10.1074/jbc.M701812200</pub-id><pub-id pub-id-type="pmid">17609208</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zarini</surname><given-names>S</given-names></name><name><surname>Brozinick</surname><given-names>JT</given-names></name><name><surname>Zemski Berry</surname><given-names>KA</given-names></name><name><surname>Garfield</surname><given-names>A</given-names></name><name><surname>Perreault</surname><given-names>L</given-names></name><name><surname>Kerege</surname><given-names>A</given-names></name><name><surname>Bui</surname><given-names>HH</given-names></name><name><surname>Sanders</surname><given-names>P</given-names></name><name><surname>Siddall</surname><given-names>P</given-names></name><name><surname>Kuo</surname><given-names>MS</given-names></name><name><surname>Bergman</surname><given-names>BC</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Serum dihydroceramides correlate with insulin sensitivity in humans and decrease insulin sensitivity in vitro</article-title><source>Journal of Lipid Research</source><volume>63</volume><elocation-id>100270</elocation-id><pub-id pub-id-type="doi">10.1016/j.jlr.2022.100270</pub-id><pub-id pub-id-type="pmid">36030929</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Vinothkumar</surname><given-names>KR</given-names></name><name><surname>Hirst</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Structure of mammalian respiratory complex I</article-title><source>Nature</source><volume>536</volume><fpage>354</fpage><lpage>358</lpage><pub-id pub-id-type="doi">10.1038/nature19095</pub-id><pub-id pub-id-type="pmid">27509854</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zorov</surname><given-names>DB</given-names></name><name><surname>Juhaszova</surname><given-names>M</given-names></name><name><surname>Sollott</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release</article-title><source>Physiological Reviews</source><volume>94</volume><fpage>909</fpage><lpage>950</lpage><pub-id pub-id-type="doi">10.1152/physrev.00026.2013</pub-id><pub-id pub-id-type="pmid">24987008</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zozina</surname><given-names>VI</given-names></name><name><surname>Covantev</surname><given-names>S</given-names></name><name><surname>Goroshko</surname><given-names>OA</given-names></name><name><surname>Krasnykh</surname><given-names>LM</given-names></name><name><surname>Kukes</surname><given-names>VG</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Coenzyme Q10 in cardiovascular and metabolic diseases: current state of the problem</article-title><source>Current Cardiology Reviews</source><volume>14</volume><fpage>164</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.2174/1573403X14666180416115428</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.87340.3.sa0</article-id><title-group><article-title>eLife assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Czech</surname><given-names>Michael</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>University of Massachusetts Medical School</institution><country>United States</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Compelling</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Important</kwd></kwd-group></front-stub><body><p>This <bold>important</bold> study highlights a potential connection between fatty acid intrusion into myocytes and increases in mitochondrial ceramide that cause deficits in coenzyme Q and consequent insulin resistance. The authors primarily use the L6 myocyte model, which may not fully recapitulate in vivo conditions; however, the article shows <bold>compelling</bold> data in mice that substantially supports the L6 cell results. Overall, this study provides a strong framework for a <bold>compelling</bold> pathway of myocyte dysfunction and for continued efforts to test the <bold>important</bold> hypotheses that are presented.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.87340.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public Review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Previous reports suggested an association between ceramide accumulation in skeletal muscle and disruption of insulin signaling and metabolic dysregulation. Mechanistically, however, how intracellular ceramide attenuates insulin action and reduces metabolism is not fully understood. It was suggested that insulin receptor (IR) signaling to PI3-K/AKT is inhibited by elevated intracellular ceramide. However, other studies failed to demonstrate an inhibitory effect of ceramide on PI3K/AKT. More recently, a study was published describing that intracellular localization of diacylglycerols and sphingolipids influences insulin sensitivity and mitochondrial function in human skeletal muscle (PMID: 29415895). In the present study, Diaz-Vegas and colleagues used an in vitro system to investigate this topic further and better understand how intracellular ceramide accumulation causes cellular insulin resistance and metabolic dysregulations in cultured myocytes.</p><p>The authors applied multiple methods to achieve this goal. Among these procedures are:</p><p>1. The overexpression of enzymes involved in mitochondrial ceramide synthesis and degradation;</p><p>2. Treatments of myocytes with different pharmacological tools to validate their findings;</p><p>3. Mitochondrial proteomics and lipidomics analyses.</p><p>The effects of these experimental conditions and treatment on intracellular lipids contents, mitochondrial functions, and insulin signaling in myocytes were then evaluated.</p><p>Findings:</p><p>The author's findings indicate that incubation of myocytes with palmitate increases mitochondrial ceramide and reduces the insulin-stimulated GLUT4-HA translocation to the myocyte surface without affecting AKT activation. The elevation in mitochondrial ceramide lowers the coenzyme Q levels e depletes the electron transport chain (ETC) components, impairing mitochondrial respiration. Such mitochondrial dysfunction appears to attenuate the translocation of GLUT4-HA to the plasma membrane of the L6-myotubule. Also, mitochondrial proteomic analysis revealed an association of insulin sensitivity with mitochondrial ceramide and ETC expression levels in human muscle.</p><p>Based on these findings, the authors propose a mechanism whereby the building up of ceramide inside mitochondria depletes CoQ and compromises mitochondrial respiratory complexes, raising ROS. The resulting mitochondrial dysfunction causes insulin resistance in cultured myocytes. They postulate that CoQ depletion links ceramides with insulin resistance and define the respirasome as a critical connection between ceramides and mitochondrial dysfunction.</p><p>Relevance and critiques:</p><p>This original study provides direct evidence that mitochondrial ceramide accumulation depletes CoQ and downregulates multiple ETC components in myocytes. Consequently, elevation in the levels of reactive oxygen species (ROS) and mitochondrial dysfunctions occur. The authors proposed that such mitochondrial dysregulation attenuates insulin-stimulated GLUT4 translocation to the plasma membrane of L6-myotubules. Moreover, mitochondrial ceramide accumulation does not affect insulin action on AKT activation.</p><p>Overall, this is a well-done study, showing that in obesity, elevated mitochondrial ceramide suppresses mitochondrial function and attenuates insulin action on glucose transporter GLUT4 translocation into the myocyte surface. The main conclusion is supported by the results presented. The study also applied multiple methods and described several experiments designed to test the author's central hypothesis.</p><p>Importantly, these new findings shed light on possible cellular mechanisms whereby ectopic fat deposition in skeletal muscle drives insulin resistance and metabolism dysregulation. The results demonstrating that alterations in mitochondrial ceramide are sufficient to attenuate insulin-stimulated GLUT4 trafficking in cultured myocytes are very interesting. Well-done.</p><p>Comments for further discussion and suggestions:</p><p>Although the author's results suggest that higher mitochondrial ceramide levels suppress cellular insulin sensitivity, they rely solely on a partial inhibition (i.e., 30%) of insulin-stimulated GLUT4-HA translocation in L6 myocytes. It would be critical to examine how much the increased mitochondrial ceramide would inhibit insulin-induced glucose uptake in myocytes using radiolabel deoxy-glucose.</p><p>Another important question to be addressed is whether glycogen synthesis is affected in myocytes under these experimental conditions. Results demonstrating reductions in insulin-stimulated glucose transport and glycogen synthesis in myocytes with dysfunctional mitochondria due to ceramide accumulation would further support the author's claim.</p><p>In addition, it would be critical to assess whether the increased mitochondrial ceramide and consequent lowering of energy levels affect all exocytic pathways in L6 myoblasts or just the GLUT4 trafficking. Is the secretory pathway also disrupted under these conditions?</p><p>Additional suggestions:</p><p>• Figure 1: How does increased mitochondrial ceramide affect fatty acid oxidation (FAO) in L6-myocytes? As the accumulation of mitochondrial ceramide inhibits respirasome and mitochondrial activity in vitro, can reduced FAO in vivo, due to high mitochondrial ceramide, accounts for ectopic lipid deposition in skeletal muscle of obese subjects?</p><p>• Figure 2: Although the authors show that mtSMPD5 overexpression does not affect ceramide abundance in whole cell lysate, it would be critical to examine the abundance of this lipid in other cellular membranes and organelles, particularly plasma membrane. What is the effect of mtSMPD5 overexpression on plasma membrane lipids composition? Does that affect GLUT4-containing vesicles fusion into the plasma membrane, possibly due to depletion of v-SNARE or tSNARE?</p><p>• Figure 4: One critical piece of information missing is the effect (if any) of mitochondrial ceramide accumulation on the mRNAs encoding the ETC components affected by this lipid. Although the ETC protein's lower stability may account for the effect of increased ceramide, transcriptional inhibition can't be ruled out without checking the mRNA expression levels for these ETC components.</p><p>In the revised version of their study, the authors nicely addressed all concerns previously raised. The amount of work that went into the revisions is appreciated. All weak points have been properly addressed, and the manuscript has improved substantially.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.87340.3.sa2</article-id><title-group><article-title>Reviewer #2 (Public Review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary</p><p>The findings reported by Diaz-Vegas et al. extend those described in a previous paper from the same group establishing a role for mitochondrial CoQ depletion in the development of insulin resistance in muscle and adipose tissue (Fazakerley, 2018). In this new report, investigators sought to determine whether CoQ depletion contributes to insulin resistance caused by palmitate exposure and/or intracellular ceramide accumulation. To this end, researchers employed a widely used in vitro model of insulin resistance wherein L6 myocytes develop impaired Glut4 translocation upon exposure to palmitate (in this case, 150 uM for 16 hours). This model was combined with a variety of pharmacologic and genetic manipulations aimed at augmenting or inhibiting CoQ biosynthesis and/or ceramide biosynthesis, specifically in mitochondria. This series of experiments produced a valuable and provocative body of evidence positioning CoQ depletion downstream of mitochondrial ceramide accumulation and necessary for both palmitate- and ceramide-induced insulin resistance in L6 myocytes. Investigators concluded that mitochondrial ceramides, CoQ depletion and respiratory dysfunction are part of a core pathway leading to insulin resistance.</p><p>Strengths</p><p>The study provides exciting, first-time evidence linking palmitate-induced insulin resistance to ceramide accumulation within the mitochondria and subsequent depletion of CoQ. Ceramide accumulation specifically in mitochondria was found to be necessary and sufficient to cause insulin resistance in cultured L6 myocytes.</p><p>The in vitro experiments featured a set of mitochondrial-targeted genetic manipulations that permitted up/down-regulation of ceramide levels specifically in the mitochondrial compartment. Genetically induced mitochondrial ceramide accumulation led to CoQ depletion, which was accompanied by increased ROS production and diminution of ETC proteins and OXPHOS capacity and impaired insulin action, thereby establishing cause/effect.</p><p>Analysis of mitochondria isolated from human muscle biopsies obtained from individuals with disparate metabolic phenotypes revealed a positive correlation between complex I proteins and insulin sensitivity and a negative correlation with mitochondrial ceramide content. While it is likely that many factors contribute to these correlations, the results support the possibility that the ceramide/CoQ mechanism might be relevant to glucose control in humans.</p><p>Investigators were responsive to the reviewers' queries and critiques and performed additional experiments to bolster the interpretations and conclusions put forth in the manuscript. These included experiments to confirm that mito-targeted SMPD5 does not cause toxicity in L6 myocytes, and further studies using targeted metabolomic and lipidomic analyses to investigate the impact of ceramide depletion on CoQ levels in mice fed a high-fat diet and treated with P053 (a selective inhibitor of CerS1). The results were consistent with the in vitro findings.</p><p>Overall, these important findings offer valuable new insights into mechanisms that connect ceramides to insulin resistance and mitochondrial dysfunction, and could inform new therapeutic approaches towards improved glucose control.</p><p>Weaknesses</p><p>The mechanistic aspect of the work and conclusions put forth rely heavily on studies performed in cultured myocytes, which are highly glycolytic and generally viewed as an imperfect model for studying muscle metabolism and insulin action. Nonetheless, results from the cell culture model are generally convincing and align with the descriptive data from studies in animal models. Overall, the findings provide a strong rationale for moving this line of investigation into mouse gain/loss of function models.</p><p>One caveat of the approach taken is that exposure of cells to palmitate alone is not reflective of in vivo physiology. It would be interesting to know if similar effects on CoQ are observed when cells are exposed to a more physiological mixture of fatty acids that includes a high ratio of palmitate, but better mimics in vivo nutrition.</p></body></sub-article><sub-article article-type="author-comment" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.87340.3.sa3</article-id><title-group><article-title>Author Response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Vegas</surname><given-names>Alexis Diaz</given-names></name><role specific-use="author">Author</role><aff><institution>University of Sydney</institution><addr-line><named-content content-type="city">Sydney</named-content></addr-line><country>Australia</country></aff></contrib><contrib contrib-type="author"><name><surname>Madsen</surname><given-names>Søren</given-names></name><role specific-use="author">Author</role><aff><institution>University of Sydney</institution><addr-line><named-content content-type="city">Sydney</named-content></addr-line><country>Australia</country></aff></contrib><contrib contrib-type="author"><name><surname>Cooke</surname><given-names>Kristen C</given-names></name><role specific-use="author">Author</role><aff><institution>University of Sydney</institution><addr-line><named-content content-type="city">Sydney</named-content></addr-line><country>Australia</country></aff></contrib><contrib contrib-type="author"><name><surname>Carroll</surname><given-names>Luke</given-names></name><role specific-use="author">Author</role><aff><institution>University of Sydney</institution><addr-line><named-content content-type="city">Sydney</named-content></addr-line><country>Australia</country></aff></contrib><contrib contrib-type="author"><name><surname>Khor</surname><given-names>Jasmine XY</given-names></name><role specific-use="author">Author</role><aff><institution>University of Sydney</institution><addr-line><named-content content-type="city">Sydney</named-content></addr-line><country>Australia</country></aff></contrib><contrib contrib-type="author"><name><surname>Turner</surname><given-names>Nigel</given-names></name><role specific-use="author">Author</role><aff><institution>University of New South Wales</institution><addr-line><named-content content-type="city">Sydney</named-content></addr-line><country>Australia</country></aff></contrib><contrib contrib-type="author"><name><surname>Lim</surname><given-names>Xin Ying</given-names></name><role specific-use="author">Author</role><aff><institution>University of Sydney</institution><addr-line><named-content content-type="city">Sydney</named-content></addr-line><country>Australia</country></aff></contrib><contrib contrib-type="author"><name><surname>Astore</surname><given-names>Miro A</given-names></name><role specific-use="author">Author</role><aff><institution>Flatiron Health</institution><addr-line><named-content content-type="city">Flatiron</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Morris</surname><given-names>Jonathan C</given-names></name><role specific-use="author">Author</role><aff><institution>UNSW Sydney</institution><addr-line><named-content content-type="city">Sydney</named-content></addr-line><country>Australia</country></aff></contrib><contrib contrib-type="author"><name><surname>Don</surname><given-names>Anthony S</given-names></name><role specific-use="author">Author</role><aff><institution>University of Sydney</institution><addr-line><named-content content-type="city">Sydney</named-content></addr-line><country>Australia</country></aff></contrib><contrib contrib-type="author"><name><surname>Garfield</surname><given-names>Amanda</given-names></name><role specific-use="author">Author</role><aff><institution>University of Colorado Anschutz Medical Campus</institution><addr-line><named-content content-type="city">Aurora</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Zarini</surname><given-names>Simona</given-names></name><role specific-use="author">Author</role><aff><institution>University of Colorado Anschutz Medical Campus</institution><addr-line><named-content content-type="city">Aurora</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Zemski Berry</surname><given-names>Karin A</given-names></name><role specific-use="author">Author</role><aff><institution>University of Colorado Anschutz Medical Campus</institution><addr-line><named-content content-type="city">Aurora</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Ryan</surname><given-names>Andrew P</given-names></name><role specific-use="author">Author</role><aff><institution>Eli Lilly</institution><addr-line><named-content content-type="city">Indianapolis</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Bergman</surname><given-names>Bryan C</given-names></name><role specific-use="author">Author</role><aff><institution>University of Colorado Anschutz Medical Campus</institution><addr-line><named-content content-type="city">Aurora</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Brozinick</surname><given-names>Joseph T</given-names></name><role specific-use="author">Author</role><aff><institution>Eli Lilly</institution><addr-line><named-content content-type="city">Indianapolis</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>James</surname><given-names>David E</given-names></name><role specific-use="author">Author</role><aff><institution>University of Sydney</institution><addr-line><named-content content-type="city">Sydney</named-content></addr-line><country>Australia</country></aff></contrib><contrib contrib-type="author"><name><surname>Burchfield</surname><given-names>James G</given-names></name><role specific-use="author">Author</role><aff><institution>University of Sydney</institution><addr-line><named-content content-type="city">The University of Sydney</named-content></addr-line><country>Australia</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews.</p><disp-quote content-type="editor-comment"><p>Assessment note: “Whereas the results and interpretations are generally solid, the mechanistic aspect of the work and conclusions put forth rely heavily on in vitro studies performed in cultured L6 myocytes, which are highly glycolytic and generally not viewed as a good model for studying muscle metabolism and insulin action.”</p></disp-quote><p>While we acknowledge that in vitro models may not fully recapitulate the complexity of in vivo systems, we believe L6 myotubes are appropriate for studying the mechanisms underlying muscle metabolism and insulin action. L6 myotubes possess many important characteristics relevant to our research, including high insulin sensitivity and a similar mitochondrial respiration sensitivity compared to primary muscle fibres. Furthermore, several studies have demonstrated the utility of L6 myotubes as a model for studying insulin sensitivity and metabolism, including our own previous work (PMID: 19805130, 31693893, 19915010) and work of others (PMID:12086937, 29486284, 15193147).</p><p>Importantly, our observations from the L6 myotube model are supported by in vivo data from both mice and humans. Chow (Figure 3J, K) and high-fat fed mice (new data - Supplementary Figure 4 H-I) demonstrated a reduction in mitochondrial Ceramide and an increase in CoQ9. Muscle biopsies from humans showed a strong negative correlation between mitochondrial C18:0 ceramide levels and insulin sensitivity (PMID: 29415895). Further, complex I and IV abundance was strongly correlated with both muscle insulin sensitivity and mitochondrial ceramide (CerC18:0) (Figure 6E, F). This is consistent with our observations in L6 myotubes (Figure 6H, I). These findings support the relevance of our in vitro results to in vivo muscle metabolism.</p><disp-quote content-type="editor-comment"><p><bold>Points from reviewer 1</bold></p><p>1. Although the authors' results suggest that higher mitochondrial ceramide levels suppress cellular insulin sensitivity, they rely solely on a partial inhibition (i.e., 30%) of insulin-stimulated GLUT4-HA translocation in L6 myocytes. It would be critical to examine how much the increased mitochondrial ceramide would inhibit insulin-induced glucose uptake in myocytes using radiolabeled deoxy-glucose.Another important question to be addressed is whether glycogen synthesis is affected in myocytes under these experimental conditions. Results demonstrating reductions in insulin-stimulated glucose transport and glycogen synthesis in myocytes with dysfunctional mitochondria due to ceramide accumulation would further support the authors' claim.</p></disp-quote><p>Response: We have now conducted additional experiments focusing on glycogen synthesis as a readout of insulin sensitivity, as it offers an orthogonal method for assessing GLUT4 translocation and glucose uptake. L6-myotubes overexpressing the mitochondrial-targeted ASAH1 construct (as described in Fig. 3) were challenged with palmitate and insulin stimulated glycogen synthesis was measured using 14C radiolabeled glucose. As shown below, palmitate suppressed insulin-induced glycogen synthesis, which was effectively prevented by overexpression of ASAH1 (N = 5, * p&lt;0.05) supporting our previous observation using GLUT4 translocation as a readout of insulin sensitivity (Fig. 3). These results provide additional evidence highlighting the role of dysfunctional mitochondria in muscle cell glucose metabolism.</p><p>These data have now been added to Supplementary Figure 4K and the results modified as follows:</p><p>“...For this reason, several in vitro models have been employed involving incubation of insulin sensitive cell types with lipids such as palmitate to mimic lipotoxicity in vivo. In this study we have used cell surface GLUT4-HA abundance as the main readout of insulin response...”</p><p>“Notably, mtASAH1 overexpression protected cells from palmitate-induced insulin resistance without affecting basal insulin sensitivity (Fig. 3E). Similar results were observed using insulin-induced glycogen synthesis as an orthologous technique for Glut4 translocation. These results provide additional evidence highlighting the role of dysfunctional mitochondria in muscle cell glucose metabolism (Sup. Fig. 5K). Importantly, mtASAH1 overexpression did not rescue insulin sensitivity in cells depleted…”</p><p>Additionally, the following text was added to the method section:</p><p>“L6 myotubes overexpressing ASAH were grown and differentiated in 12-well plates, as described in the Cell lines section, and stimulated for 16 h with palmitate-BSA or EtOH-BSA, as detailed in the Induction of insulin resistance section.</p><p>On day seven of differentiation, myotubes were serum starved in DMEM for 3.5 h. After incubation for 1 h at 37 °C with 2 µCi/ml D-[U-14C]-glucose in the presence or absence of 100 nM insulin, glycogen synthesis assay was performed, as previously described (Zarini S. et al., JLipid Res, 63(10): 100270, 2022).”</p><disp-quote content-type="editor-comment"><p>2. In addition, it would be critical to assess whether the increased mitochondrial ceramide and consequent lowering of energy levels affect all exocytic pathways in L6 myoblasts or just the GLUT4 trafficking. Is the secretory pathway also disrupted under these conditions?</p></disp-quote><p>Response: This is an interesting point raised by the reviewer that is aimed at the next phase of this work, to identify how ceramide induced mitochondrial dysfunction drives insulin resistance. Looking at energy deficiency in more detail as well as general trafficking is part of ongoing work, but given the complexity of this question, it is beyond the scope of the current study.</p><disp-quote content-type="editor-comment"><p><bold>Points from reviewer 2</bold></p><p>1. The mechanistic aspect of the work and conclusions put forth rely heavily on studies performed in cultured myocytes, which are highly glycolytic and generally viewed as a poor model for studying muscle metabolism and insulin action. Nonetheless, the findings provide a strong rationale for moving this line of investigation into mouse gain/loss of function models.</p></disp-quote><p>Response: We acknowledge that in vitro models may not fully mimic in vivo complexity as described above in the response to the “Assessment note”. We have now added to theDiscussion:</p><p>“In this study, we mainly utilised L6-myotubes, which share many important characteristics with primary muscle fibres. Both types of cells exhibit high sensitivity to insulin and respond similarly to maximal doses of insulin, with GLUT4 translocation stimulated between 2 to 4 times over basal levels in response to 100 nM insulin (as shown in Fig. 1-4 and (46,47)). Additionally, mitochondrial respiration in L6-myotubes has a similar sensitivity to mitochondrial poisons, as observed in primary muscle fibres (as shown in Fig. 5 (48)). Finally, inhibiting ceramide production increases CoQ levels in both L6-myotubes and adult muscle tissue (as shown in Fig. 2-3). Therefore, L6-myotubes possess the necessary metabolic features to investigate the role of mitochondria in insulin resistance, and this relationship is likely applicable to primary muscle fibres”.</p><disp-quote content-type="editor-comment"><p>2. One caveat of the approach taken is that exposure of cells to palmitate alone is not reflective of in vivo physiology. It would be interesting to know if similar effects on CoQ are observed when cells are exposed to a more physiological mixture of fatty acids that includes a high ratio of palmitate, but better mimics in vivo nutrition.</p></disp-quote><p>Response: We appreciate the reviewer's comment. Previously, we reported that mitochondrial CoQ depletion occurs in skeletal muscle after 14 and 42 days of HFHSD feeding, coinciding with the onset of insulin resistance (PMID: 29402381, see Author response image 1).</p><fig id="sa3fig1" position="float"><label>Author response image 1.</label><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87340-sa3-fig1-v1.tif"/></fig><p>These data demonstrated that our in vitro model recapitulates the loss of CoQ in insulin resistance observed in muscle tissue in response to a more physiological mixture of fatty acids. Further, it has been reported that different fatty acids can induce insulin resistance via different mechanisms (PMID:20609972), which would complicate interpretation of the data. Saturated fatty acids such as palmitate increase ceramides in cell-lines and humans, but unsaturated FAs generally do not (PMID: 10446195,14592453,34704121). As such we conclude that palmitate is a cleaner model for studying the effects of ceramide on skeletal muscle function.</p><p>We have added to discussion:</p><p>“…These findings align with our earlier observations demonstrating that mice exposed to HFHSD exhibit mitochondrial CoQ depletion in skeletal muscle (Fazakerley et al. 2018).”</p><disp-quote content-type="editor-comment"><p>3. While the utility of targeting SMPD5 to the mitochondria is appreciated, the results in Figure 5 suggest that this manoeuvre caused a rather severe form of mitochondrial dysfunction. This could be more representative of toxicity rather than pathophysiology. It would be helpful to know if these same effects are observed with other manipulations that lower CoQ to a similar degree. If not, the discrepancies should be discussed.</p></disp-quote><p>Response: As the reviewer suggests many of these lipids can cause cell death (toxicity) if the dose is too high. We have previously found that low levels (0.15 mM) of palmitate were sufficient to trigger insulin resistance without any signs of toxicity (Hoehn, K, PNAS, 19805130). Using a similar approach, we show that mitochondrial membrane potential is maintained in SMPD5 overexpressing cells (Sup. Fig. 2J - and Author response image 2). Given that toxicity is associated with a loss of mitochondrial membrane potential (eg., 50uM Saclac; RH panel), these data suggest SMPD5 overexpression is not causing overt toxicity.</p><fig id="sa3fig2" position="float"><label>Author response image 2.</label><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87340-sa3-fig2-v1.tif"/></fig><p>Furthermore, we conducted an overrepresentation analysis of molecular processes within our proteomic data from SMPD5-overexpressing cells. As depicted below, no signs of cell toxicity were observed in our model at the protein level. This data is now available in supplementary table 1.</p><fig id="sa3fig3" position="float"><label>Author response image 3</label><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87340-sa3-fig3-v1.tif"/></fig><fig id="sa3fig4" position="float"><label>Author response image 4.</label><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87340-sa3-fig4-v1.tif"/></fig><p>Our results are therefore consistent with a pathological condition induced by elevated levels of ceramides independently of cellular toxicity. The following text has been added to the discussion:“...downregulation of the respirasome induced by ceramides may lead to CoQ depletion.Despite the significant impact of ceramide on mitochondrial respiration, we did not observe anyindications of cell damage in any of the treatments, suggesting that our models are not explained by toxicity and increased cell death (Sup. Fig. 2H &amp; J).”</p><disp-quote content-type="editor-comment"><p>4. The conclusions could be strengthened by more extensive studies in mice to assess the interplay between mitochondrial ceramides, CoQ depletion and ETC/mitochondrial dysfunction in the context of a standard diet versus HF diet-induced insulin resistance. Does P053 affect mitochondrial ceramide, ETC protein abundance, mitochondrial function, and muscle insulin sensitivity in the predicted directions?</p></disp-quote><p>Response: We agree with the referee about the importance of performing in vivo studies to corroborate our in vitro data. We have now conducted extensive new studies in mice skeletal muscle using targeted metabolomic and lipidomic analyses to investigate the impact of ceramide depletion in CoQ levels in HF-fed mice. Mice were exposed to a HF-fed diet with or without the administration of P053 (selective inhibitor of CerS1) for 5 weeks. As illustrated in Author response image 3, the administration of P053 led to a reduction in ceramide levels (left panel), increase in CoQ levels (middle panel) and a negative correlation between these molecules (right panel), which is consistent with our in vitro findings.</p><disp-quote content-type="editor-comment"><p>Additional suggestions:</p><p>1. Figure 1: How does increased mitochondrial ceramide affect fatty acid oxidation (FAO) in L6-myocytes? As the accumulation of mitochondrial ceramide inhibits respirasome and mitochondrial activity in vitro, can reduce FAO in vivo, due to high mitochondrial ceramide, accounts for ectopic lipid deposition in skeletal muscle of obese subjects?</p></disp-quote><p>Response: We appreciate the reviewer for bringing up this intriguing point. We would like to emphasise that Complex II activity is vital for fatty acid oxidation. As shown in Fig. 5H, our results indicate that specifically Complex II mediated respiration was diminished in cells with SMPD5 overexpression, suggesting that ceramides hinder the mitochondria's capability to oxidise lipids. We agree that this mechanism may potentially play a role in the ectopic lipid accumulation seen in individuals with obesity.</p><p>We have added the following text to discussion:</p><p>“...the mitochondria to switch between different energy substrates depending on fuel availability, named “metabolic Inflexibility”...this mechanism may potentially play a role in the ectopic lipid accumulation seen in individuals with obesity, a condition linked with cardio-metabolic disease.”</p><disp-quote content-type="editor-comment"><p>2. Figure 2: Although the authors show that mtSMPD5 overexpression does not affect ceramide abundance in whole cell lysate, it would be critical to examine the abundance of this lipid in other cellular membranes and organelles, particularly plasma membrane. What is the effect of mtSMPD5 overexpression on plasma membrane lipids composition? Does that affect GLUT4-containing vesicles fusion into the plasma membrane, possibly due to depletion of v-SNARE or tSNARE?Response: While we acknowledge the importance of this point we strongly feel that measuring lipids in purified membranes has its limitations because it is impossible to purify specific membranes without contamination from other kinds of membranes. For example, we have done proteomics on purified plasma membranes from different cell types and we always observe considerable mitochondrial contamination with these membranes (e.g. PMID 21928809). This was the main factor that led us to use the mitochondrial targeting approach.</p></disp-quote><p>Nevertheless we do acknowledge that there is a possibility that ceramides that are produced in the mitochondria in SMPD5 cells could leak out of mitochondria into other membranes and this could influence other aspects of GLUT4 trafficking and insulin action. However, we believe that the studies using mito targeted ASAH mitigate against this problem. Thus, we have now included a statement in the revised manuscript as follows: “It is also possible that ceramides generated within mitochondria in SMPD5 cells leak out from the mitochondria into other membranes (e.g. PM and Glut4 vesicles) affecting other aspects of Glut4 trafficking and insulin action. However, the observation that ASAH1 overexpression reversed IR without affecting whole cell ceramides argues against this possibility.”.</p><disp-quote content-type="editor-comment"><p>3. Figure 4: One critical piece of information missing is the effect (if any) of mitochondrial ceramide accumulation on the mRNAs encoding the ETC components affected by this lipid. Although the ETC protein's lower stability may account for the effect of increased ceramide, transcriptional inhibition can't be ruled out without checking the mRNA expression levels for these ETC components.Response: To address this point, we have quantified the mRNA abundance of nine complex I subunits that exhibit downregulation in our proteomic dataset subsequent to mtSMPD5 overexpression (as depicted in Figure 4G).</p></disp-quote><p>Induction of mtSMPD5 expression with doxycycline (Author response image 4 - Left hand panel) had no effect on the mRNA levels of the Complex I subunits (Author response image 4 - right hand panel).. This is consistent with our initial hypothesis that the reduction in electron transport chain (ETC) components, caused by heightened ceramide levels, primarily arises from alterations in protein stability rather than gene expression. While we acknowledge the possibility that certain subunits might be regulated at the transcriptional level, the absence of mRNA downregulation across our data strongly suggests that, at the very least, a portion of the observed protein depletion is attributed to diminished protein stability. We have incorporated this dataset into Supplementary Figure 6J and added the following text to the results:</p><fig id="sa3fig5" position="float"><label>Author response image 5.</label><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87340-sa3-fig5-v1.tif"/></fig><p>“Importantly, CI downregulation was not associated with reduction in gene expression as shown in Sup. Fig. 6J.”</p><p>Additionally, we have added the following text to discussion:</p><p>“In addition, the absence of mRNA downregulation in mtSMPD5 overexpressing cells strongly suggests that at least a portion of the observed protein depletion within CI is attributed to diminished protein stability.”</p><disp-quote content-type="editor-comment"><p>4. Figure 3: The authors state that neither palmitate nor mtASAH1 overexpression affected insulin-dependent Akt phosphorylation. However, the results in Figure 3F-G do not support this conclusion, as the overexpression of mtASAH1 does enhance the insulin-stimulated AKT (thr-308) phosphorylation. They need to clarify this issue.</p></disp-quote><p>Response: We have now analysed these data in a manner that preserves the control variance, consistent with the other figures in the manuscript and there is no significant change in Akt phosphorylation in ASAH over-expressing cells.</p><fig id="sa3fig6" position="float"><label>Author response image 6.</label><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87340-sa3-fig6-v1.tif"/></fig><disp-quote content-type="editor-comment"><p>5. Figure S2: A functional assessment of mitochondrial function in HeLa cells would be helpful to validate the small effect of Saclac treatment on CI NDUFB8.</p></disp-quote><p>Response: Mitochondrial respiration was conducted in cells treated with Saclac (2 µM and 10 µM) for 24 hours. As shown in Author response image 6, in Hela cells, we did not detect any mitochondrial respiratory impairments at low doses, but only at high doses of Saclac. This suggests that the minor effect of Saclac on CI NDUFB8 is insufficient to alter mitochondrial function.</p><fig id="sa3fig7" position="float"><label>Author response image 7.</label><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87340-sa3-fig7-v1.tif"/></fig><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations For The Authors):</bold></p><p>Additional questions and comments for consideration:</p><p>1. The working model links ceramide-induced CoQ depletion to a reduction in ETC proteins and accompanying deficits in OxPhos capacity. The idea that mitochondrial dysfunction necessarily precedes and causes insulin resistance has been heavily debated for years because many animal and human studies have found no overt changes in ETC proteins and/or mitochondrial respiratory capacity during the early phases of insulin resistance. How do the investigators reconcile their work in the context of this controversy?</p></disp-quote><p>Response: We acknowledge this controversy in our revised manuscript more clearly now as follows on page 21: “We present evidence that mitochondrial dysfunction precedes insulin resistance. However, previous studies have failed to observe changes in mitochondrial morphology, respiration or ETC components during early stages of insulin resistance (72). However, in many cases such studies fail to document changes in insulin-dependent glucose metabolism in the same tissue as was used for assessment of mitochondrial function. This is crucial because we and others do not observe impaired insulin action in all muscles from high fat fed mice for example. In addition, surrogate measures such as insulin-stimulated Akt phosphorylation may not accurately reflect tissue specific insulin action as demonstrated in figure 1C. Thus, further work is required to clarify some of these inconsistencies''.</p><disp-quote content-type="editor-comment"><p>2. While the utility of targeting SMPD5 to the mitochondria is appreciated, the results in Figure 5 suggest that this manoeuvre caused a rather severe form of mitochondrial dysfunction. Is this representative of pathophysiology or toxicity?</p></disp-quote><p>Response: We believe we have addressed this in point 3 above (Principal comments, reviewer 1, point 3)</p><disp-quote content-type="editor-comment"><p>3. How did this affect other mitochondrial lipids (e.g. cardiolipin)?</p></disp-quote><p>Response: As shown in the supplementary figure 3, SMPD5 overexpression did not affect other lipids species such as cardiolipin (D-J). We have added to results:</p><p>“Importantly, mtSMPD5 overexpression did not affect ceramide abundance in the whole cell lysate nor other lipid species inside mitochondria such as cardiolipin, cholesterol and DAGs (Sup. Fig. 3 A, D-J)”</p><disp-quote content-type="editor-comment"><p>4. Are these severe effects rescued by CoQ supplementation?</p></disp-quote><p>Response: We have performed additional experiments to address this point. As shown below, mitochondrial ceramide accumulation induced by palmitate was not reversed by CoQ supplementation, as demonstrated in Figure 1F. We have added to results:</p><p>“Addition of CoQ9 had no effect on control cells but overcame insulin resistance in palmitate treated cells (Fig. 1A). Notably, the protective effect of CoQ9 appears to be downstream of ceramide accumulation, as it had no impact on palmitate-induced ceramide accumulation (Fig. 1E-F). Strikingly, both myriocin and CoQ9…”</p><p>Additionally, we assessed mitochondrial respiration by using SeaHorse in cells with SMPD5 overexpression treated with or without CoQ supplementation. Our results, depicted below, indicate that CoQ supplementation reversed the ceramide-induced decrease in basal and ATP linked mitochondrial respiration. We have modified Fig.5.</p><fig id="sa3fig8" position="float"><label>Author response image 8.</label><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87340-sa3-fig8-v1.tif"/></fig><p>We have added to results:</p><p>“Respiration was assessed in intact mtSMPD5-L6 myotubes treated with CoQ9 by Seahorse extracellular flux analysis. mtSMPD5 overexpression decreased basal and ATP-linked mitochondrial respiration (Fig. 5 A, B &amp;C), as well as maximal, proton-leak and non-mitochondrial respiration (Fig. 5 A, D, E &amp; F) suggesting that mitochondrial ceramides induce a generalised attenuation in mitochondrial function. Interestingly, CoQ9 supplementation partially recovered basal and ATP-linked mitochondrial respiration, suggesting that part of the mitochondrial defects are induced by CoQ9 depletion. The attenuation in mitochondrial respiration is consistent with a depletion of the ETC subunits observed in our proteomic dataset (Fig. 4)...”</p><disp-quote content-type="editor-comment"><p>5. Are these same effects observed with other manipulations that lower CoQ to a similar degree?</p></disp-quote><p>Response: As mentioned in point 5 (additional suggestions from Reviewer 1), we conducted mitochondrial respiration measurements on HeLa cells treated with Saclac (2 µM and 10 µM) for 24 hours. Our findings showed no signs of mitochondrial respiratory impairments at low doses of Saclac in HeLa cells, despite observing CoQ depletion at this dose (Fig. Sup. 2C). We believe that this variation could be due to the varying sensitivity of mitochondrial respiration/ETC abundance to ceramide-induced CoQ depletion in different cell lines. Alternatively, it is possible that reduced mitochondrial respiration is a secondary event to other mitochondrial/cellular defects such as mitochondrial fragmentation or deficient nutrient transport inside mitochondria.</p><disp-quote content-type="editor-comment"><p>6. The mitochondrial concentrations of CoQ required to maintain insulin sensitivity in L6 myocytes seem to vary from experiment to experiment. Is it the absolute concentration that matters and/or the change relative to a baseline condition?</p></disp-quote><p>Response: This is an excellent observation. The findings indicate that the absolute concentration of CoQ is the determining factor for insulin sensitivity, rather than the relative depletion of CoQ compared to basal conditions. We have added to discussion:“Finally, mtASAH1 overexpression increased CoQ levels. In both control and mtASAH1 cells, palmitate induced a depletion of CoQ, however the levels in palmitate treated mtASAH1 cells remained similar to control untreated cells (Fig. 3I). This suggests that the absolute concentration of CoQ is crucial for insulin sensitivity, rather than the relative depletion compared to basal conditions, thus supporting the causal role of mitochondrial ceramide accumulation in reducing CoQ levels in insulin resistance”</p><disp-quote content-type="editor-comment"><p>7. Considering that CoQ has been shown to have antioxidant properties, does the rescue observed after a 16 h treatment require the prolonged exposure, or alternatively, are similar effects observed during short-term exposures (~1-2 h), which might imply a different or additional mechanism.</p></disp-quote><p>Response: This is an excellent point that we have long considered. The problem is how to address the question in a way that will be definitive and we are concerned that the experiment suggested by the referee will not generate definitive data. A major issue is that CoQ has low solubility and needs to reach the right compartment. As such if short term treatment (as suggested) does not rescue, it would be difficult to make any definite conclusions as this might just be because insufficient CoQ is delivered to mitochondria. Conversely, if short term treatment does rescue this could be either because CoQ does get into mitochondria and regulate ETC or because of its general antioxidant function. So, even if we observe a rescue after 1 hour of incubation with CoQ, it will not clarify whether this is due to the antioxidant effect or simply because 1 hour is adequate to boost mitoCoQ levels. Thus, in our view this experiment might not get us any closer to the answer. Nevertheless, we do feel this is an important point and we have added the following statement to our revised manuscript to acknowledge this: “Because CoQ can accumulate in various intracellular compartments, it's important to consider that its impact on insulin resistance might be due to its overall antioxidant properties rather than being limited to a mitochondrial effect”</p><disp-quote content-type="editor-comment"><p>8. In Figure 1, CoQ depletion due to 4NB treatment resulted in increased ceramide levels. Could this be due to impaired palmitate oxidation leading to rerouting of intracellular palmitate to the ceramide pathway? This could be tested using stable isotope tracers.</p></disp-quote><p>Response: We have added the statement below to the manuscript to address this point. We feel that while an interesting experiment to perform it is somewhat outside of the major focus of this study.</p><p>“One possibility is that CoQ directly controls ceramide turnover (35). An alternate possibility is that CoQ inside mitochondria is necessary for fatty acid oxidation (12) and CoQ depletion triggers lipid overload in the cytoplasm promoting ceramide production (36). Future studies are required to determine how CoQ depletion promotes Cer accumulation. Regardless, these data indicate that ceramide and CoQ have a central role in regulating cellular insulin sensitivity.”</p><disp-quote content-type="editor-comment"><p>9. To a similar point, it would be helpful to know if the C2 ceramide analog is sufficient to cause elevated mito-ceramide and/or CoQ depletion. If not, the results might imply mitochondrial uptake of palmitate is required.</p></disp-quote><p>Response: We feel this point is analogous to Point 7 above in that this experiment is not definitive enough to make any clear conclusions as it may or may not work for many different reasons. For example, C2 ceramide may not work simply because it has the wrong chain length.Moreover, it is clear that C2 ceramide has effects that clearly differ from those observed with palmitate most notably the inhibitory effect on Akt signalling. For these reasons we do not agree with the logic of this experiment.</p><p>We have mentioned in the results section:</p><p>“Based on these data we surmise that C2-ceramide does not faithfully recapitulate physiological insulin resistance, in contrast to that seen with incubation with palmitate”.</p><disp-quote content-type="editor-comment"><p>10. Likewise, does inhibition of CPT1 ameliorate or exacerbate palmitate-induced insulin resistance?</p></disp-quote><p>Response: This experiment has been performed by a number of different labs. For instance, muscle specific CPT1 overexpression is protective against high fat diet induced insulin resistance in mice (Bruce C, PMID19073774), CPT1 overexpression protects L6E9 muscle cells from fatty acid-induced insulin resistance (Sebastian D, PMID17062841) and increased beta-oxidation in muscle cells enhances insulin stimulated glucose metabolism and is protective against lipid induced insulin resistance (Perdomo G, PMID15105415). We have now cited all of these studies in our revised manuscript in the discussion: “In fact, increased fatty acid oxidation is protective against insulin resistance in several model organisms (37–39)”</p><disp-quote content-type="editor-comment"><p>11. Does the addition of palmitate to the cells treated with mtSMPD5 further reduce CoQ9 (Figure 2I and 2J)?</p></disp-quote><p>Response: This intriguing observation, as highlighted by the referee, has prompted us to conduct additional experiments to investigate the effects of palmitate and SMPD5 overexpression on Coenzyme Q (CoQ) levels in L6 myotubes. As demonstrated in the figures presented below, both palmitate and SMPD5 overexpression independently resulted in the depletion of CoQ9, with no observed additive effects suggesting that they shared a common pathway driving CoQ9 deficiency. One plausible hypothesis is that ceramides may trigger the depletion of a specific CoQ9 pool localised within the inner mitochondrial membrane, likely the pool associated with Complex I (CI) in the Electron Transport Chain (ETC). This hypothesis is supported by previous studies indicating that approximately ~25 - 35 % of CoQ binds to CI (PMID: 33722627) and our data demonstrating that ceramide induces a selective depletion of CI in L6 myotubes (Fig. 4).</p><p>We have added this result to Fig. 2I in the main section.</p><p>We have added to the result section:</p><p>“Mitochondrial CoQ levels were depleted in both palmitate-treated and mtSMPD5-overexpressing cells without any additive effects. This suggests that these strategies to increase ceramides share a common mechanism for inducing CoQ depletion in L6 myotubes (Fig. 2I).”</p><p>We have added to the discussion section:</p><p>“...These are known to form supercomplexes or respirasomes where ~25 - 35 % of CoQ is localised in mammals (58,16).…The observation that both palmitate and SMPD5 overexpression trigger CoQ depletion without additive effects support the notion that ceramides may trigger the depletion of a specific CoQ9 pool localised within the inner mitochondrial membrane.”</p><disp-quote content-type="editor-comment"><p>12. Some of the cell-based experiments appear to be underpowered and therefore confidence in the interpretations might benefit from additional repeats. For example, in Figure 3i, it appears that palmitate still causes a substantial reduction of CoQ in the cells treated with mtASAH1, even though mito-ceramide levels are restored to baseline. Please specify if these and other results are representative of multiple cell culture experiments or a single experiment.</p></disp-quote><p>Response: <xref ref-type="fig" rid="sa3fig9">Author response image 9</xref> All data were derived from a minimum of 3-4 independent experiments from at least two separate cultures of L6 cells. Separate batches of drug treatments were prepared for each experiment. We have previously compared metabolic parameters between batches of cells differentiated at different times (i.e. at least weeks apart) in a previous study (Krycer PMID 31744882) and found variations of &lt;20% for insulin-stimulated glucose oxidation. With an expected variance of 20% and a type I error rate of 0.05, this is sufficient to detect a 40% difference with a power of 0.8. As the reviewer has indicated this is likely underpowered in situations where variance is unexpectedly high or if a small difference needs to be detected.</p><fig id="sa3fig9" position="float"><label>Author response image 9.</label><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87340-sa3-fig9-v1.tif"/></fig><p>In terms of Fig3, the reviewer raises an interesting point. As discussed in point 6, the fact that palmitate still appears to cause a depletion of CoQ in mtASAH1 cells likely indicates that the absolute concentration of CoQ is the determining factor for insulin sensitivity, rather than the relative depletion of CoQ compared to basal conditions. We have added to the discussion:</p><p>“Finally, mtASAH1 overexpression increased CoQ levels. In both control and mtASAH1 cells, palmitate induced a depletion of CoQ, but this effect was less pronounced in the mtASAH1 cell line (Fig. 3I). Our results suggest that the absolute concentration of CoQ is crucial for insulin sensitivity, rather than the relative depletion compared to basal conditions, thus supporting the causal role of mitochondrial ceramide accumulation in reducing CoQ levels in insulin resistance”</p><disp-quote content-type="editor-comment"><p>13. The color scheme of 2E is inconsistent with other panels in the figure.</p></disp-quote><p>Response: Corrected</p><disp-quote content-type="editor-comment"><p>14. It would be helpful if the axis labels for CoQ graphs were labeled as &quot;Mito-CoQ&quot; for clarity.</p></disp-quote><p>Response: Corrected</p></body></sub-article></article>